molecular_profile_id,molecular_profile_name,summary,molecular_profile_score
1,BCR::ABL1 Fusion,"The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.",353.5
2,ABL1 T315I,"While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.",0.0
3,ABL1 E255K,"While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.",0.0
4,AKT1 E17K,"AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.",33.5
5,EML4::ALK Fusion,"The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.",48.0
8,ALK F1174L,"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.",33.5
9,ALK R1275Q,"ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.",23.0
10,ARAF S214C,"ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.",14.0
11,BRAF V600D,"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.",47.0
12,BRAF V600E,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1433.5
16,BRAF V600R,"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.",0.0
17,BRAF V600,"BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.",460.0
18,CCND1 Amplification,CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.,47.0
19,CCND1 Expression,"CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.",30.0
20,CCND1 Overexpression,"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.",116.0
21,CCND2 OVEREXPRESSION,"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.",16.0
22,CCND2 PROMOTER DEMETHYLATION,"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.",3.0
23,CCND3 Loss,"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.",3.0
24,CCNE1 Overexpression,"Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.",42.0
25,CDK4 EXPRESSION,"CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.",10.0
26,CDK6 EXPRESSION,"CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.",0.0
27,CDKN2A Promoter Hypermethylation,"CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.",30.0
28,CEBPA N-TERMINAL FRAME SHIFT,"CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity.",18.0
29,CEBPA Mutation,"CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.",163.0
30,MEF2D::CSF1R Fusion,"MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.",10.5
31,DNAJB1::PRKACA Fusion,"This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.",75.0
32,DNMT3A R882,"DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.",510.0
33,EGFR L858R,"EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.",379.0
34,EGFR T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",406.25
35,ERBB2 D769H,"ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines were shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",4.0
36,ERBB2 D769Y,"ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",11.5
37,ERBB2 L755_T759del,"ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",5.0
38,ERBB2 G309A,"ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",5.0
39,ERBB2 L755S,"ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.",23.5
40,ERBB2 L755W,"ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",5.0
42,ERBB2 R678Q,"ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.",5.0
43,ERBB2 R896C,"ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",5.0
44,ERBB2 V777L,"ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",11.0
45,ERBB2 V842I,"ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",9.0
46,ESR1 L536Q,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",8.0
47,ESR1 D538G,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",18.0
48,ESR1 Y537C,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",8.0
49,ESR1 Y537N,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",8.0
50,ESR1 Y537S,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",8.0
51,FGFR2 P235R,,0.0
52,FGFR2::OGA Fusion,"In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.",5.0
53,FGFR3::BAIAP2L1 Fusion,"In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.",3.0
54,FGFR2::TACC3 Fusion,"In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.",7.5
55,FLT3 ITD,"FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.",448.5
56,FLT3 TKD MUTATION,"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.",120.0
57,GATA2 EXPRESSION,"GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer.",4.0
58,IDH1 R132,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",199.0
59,IDH1 R132C,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",56.0
62,IDH2 R140,"IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.",60.0
63,IDH2 R172K,"IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.",35.0
64,JAK2 V617F,"JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.",103.0
65,KIT D816V,KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.,67.0
66,KIT Exon 11 Mutation,"c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.",197.5
67,KIT Internal Duplication,"c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.",7.5
69,KIT Exon 14 Mutation,"c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.",15.0
70,KIT EXON 17 MUTATIONS,"c-KIT exon 17 mutations lie within the TK2 domain, containing the activation loop of the protein. In cell lines, mutations within this domain have been shown to be sensitive to imatinib. However, in double KIT mutants in which the exon 17 mutation is a secondary mutation, cell lines have shown resistance to both imatinib and sunitinib.",0.0
72,KIT L576P,"KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.",16.0
73,KIT V654A,"KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.",18.0
74,KRAS EXON 2 Mutations,A study by Li√®vre et al in 2006 showed that colorectal cancer patients with KRAS exon 1 mutations had low cetuximab response rates.,0.0
75,KRAS Exon 2 Mutation,Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.,168.0
76,KRAS G12,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",115.0
77,KRAS G12/G13,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",191.0
78,KRAS G12C,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",256.5
79,KRAS G12D,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0
80,KRAS G13,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",20.0
81,KRAS G13D,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",108.5
82,MAP2K1 P124S,"MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.",3.0
83,MAP2K1 Q56P,MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.,3.0
85,MGMT Promoter Methylation,"MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.",136.0
86,NPM1 EXON 11 MUTATION,"NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.",454.0
87,NPM1 W288FS,"NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).",13.75
88,NRAS EXON 2-3 MUTATION,NRAS exon 2 and 3 mutations were studied by Jakob et al in 2012 and were shown to be correlated with poorer overall survival relative to wild-type NRAS in melanoma patients.,0.0
89,NRAS EXON 2 MUTATIONS,"NRAS exon 2 mutations have been shown to be correlated with poorer overall survival in melanoma patients and colorectal cancer patients, however no prognostic impact was seen in acute myeloid leukemia patients.",0.0
90,NRAS EXON 3 MUTATIONS,"In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS exon 3 and 4 mutations were correlated with poorer overall survival.",0.0
91,NRAS EXON 4 MUTATIONS,"In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS exon 3 and 4 mutations were correlated with poorer overall survival.",0.0
92,NRAS G12,"While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.",15.0
93,NRAS G13D,"While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.",5.0
94,NRAS Q61,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",100.0
95,NRAS Q61L,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5
96,NRAS Q61R,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",10.0
97,PDGFRA V536E,,0.0
98,PDGFRA D842I,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",4.0
99,PDGFRA D842V,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",100.5
100,PDGFRA D842Y,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",4.0
101,PDGFRA I843DEL,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",5.0
102,PDGFRA D842_I843delinsVM,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",4.0
103,PIK3CA E542K,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",75.5
104,PIK3CA E545K,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",77.5
105,PIK3CA Exon 21 Mutation,"PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",45.0
106,PIK3CA Exon 10 Mutation,"PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",45.0
107,PIK3CA H1047R,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5
108,PML::RARA Fusion,"The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.",192.5
110,PTEN R233*,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.",19.0
112,RET C634W,"RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.",3.0
113,RET M918T,"RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.",86.0
114,SF3B1 K666N,"SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.",2.0
115,SF3B1 K700E,"SF3B1 K700E is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients. Additionally, these mutations are the most common SF3B1 mutation observed in MDS and highly associated with subtypes of MDS that are defined by ringed sideroblasts.",0.0
116,TP53 R175H,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",25.0
117,TP53 R248Q,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0
118,TP53 R248W,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",22.0
119,TP53 R249,"This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",30.0
120,TP53 R249W,"This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",0.0
121,TP53 R273C,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",44.5
122,TP53 R273H,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0
123,TP53 r249,"While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",0.0
124,TSC1 Frameshift Truncation,"In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.",18.0
125,TSC1 Loss-of-function,"In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.",15.0
127,U2AF1 Q157P/R,"U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.",50.0
128,U2AF1 S34Y/F,"U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.",25.0
129,WT1 Exon 7 Mutation,"WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.",130.0
130,WT1 Exon 9 Mutation,"WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.",35.0
131,BRCA1 Loss-of-function,BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.,254.0
132,BRCA2 Loss-of-function,BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.,261.0
133,EGFR Exon 19 Deletion,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.",318.0
134,EGFR G719S,"While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.",23.0
135,NOTCH1 D1642H,"Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer.",20.0
136,NOTCH1 R2327W,"Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer.",20.0
137,NOTCH1 V2444FS,"Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer.",20.0
138,NOTCH1 S2275FS,"Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer.",20.0
139,DDR2 L63V,"Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.",4.0
140,DDR2 L239R,"Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.",4.0
141,DDR2 G253C,"Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.",4.0
142,DDR2 G505S,"Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.",4.0
143,DDR2 I638F,"DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.",4.0
144,DDR2 G774V,"Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.",4.0
145,DDR2 S768R,"Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines.",7.5
147,KRAS G12V,"KRAS G12V, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",0.0
148,KRAS G12A,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0
151,BCL2 reg_e@[IGH]::BCL2,"The typically reciprocal t(14;18)(q32;q21) translocation involves rearrangement between the immunoglobulin heavy chain locus on chromosome 14 and the 3' UTR of BCL2 on chromosome 18, leading to the overexpression of BCL2. This rearrangment is observed in >80% of patients with follicular lymphoma.",20.0
152,BCL2 Overexpression,,20.0
153,FOXP1 AMPLIFICATION,Amplication in FOXP1 has been shown to be associated with the ABC subtype of DLBCL.,15.0
154,REL AMPLIFICATION,,20.0
155,RUNX1 Mutation,"RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.",110.0
156,IGF2 Overexpression,,6.0
157,TET2 Mutation,"TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving ""CN AML"" and ""de novo AML"" however have been unable to elucidate a clinical impact.",120.0
158,AURKA EXPRESSION,,30.0
159,VHL Loss-of-function,,15.0
160,VHL Mutation,,85.0
161,PBRM1 Mutation,,30.0
162,REL EXPRESSION,,0.0
163,EZH2 Mutation,,35.0
164,EWSR1::FLI1 e7::e6,"Although multiple fusion transcripts have been described, type 1 consists of EWSR1 exon 7 fused to FLI1 exon 6, the most common arrangement in Ewings Sarcoma.",20.0
165,EZH2 Y646,"Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010).",45.0
166,BCL2 LOSS-OF-FUNCTION,,0.0
167,KMT2D Loss-of-function,,15.0
168,BTK C481S,,40.0
169,AKT1 Q79K,,16.0
171,ALK G1202R,"ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor 17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.",0.0
172,ALK S1206Y,,0.0
174,APC Mutation,,7.0
175,AR F877L,,4.0
176,AR W742,,4.0
177,ASXL1 Mutation,ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.,100.0
178,ATM Mutation,,130.5
179,ATM Underexpression,,39.0
180,AURKA Amplification,,0.75
181,AURKA Overexpression,,38.0
182,BAP1 EXPRESSION,,15.0
183,BAP1 Mutation,"BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and Œ≤-amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of ""atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC"".",98.5
184,AKAP9::BRAF Fusion,,20.0
185,BRCA1 Mutation,,455.0
186,BRCA2 Mutation,,462.5
187,CCNE1 Amplification,,27.0
188,CEBPA Mutation,,0.0
189,DNMT3A Mutation,"DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.",115.0
190,EGFR Amplification,,173.0
191,EGFR Copy Number Variation,,20.0
192,EGFR INCREASED COPY NUMBER,,0.0
193,EGFR Overexpression,,145.0
195,TMPRSS2::ERG Fusion,"TMPRSS2 fusions are prevalent in Prostate Cancer. TMPRSS2 fusion with ETS family members such as ERG are among the most common. Fusion of TMPRSS2 with ERG may result in overexpression of ERG driven by the TMPRSS2 androgen-responsive promoter elements. Due to the high prevalence of this fusion, it may have diagnostic utility for prostate cancer, especially ERG expression positive prostate cancer.",15.0
198,FOXL2 C134W,"The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.",70.0
199,IDH2 R172,"IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation ""catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate"" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140).",105.0
200,IKZF1 Deletion,"IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for ""normal hematopoiesis"". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease. Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.",240.0
201,KIT M541L,,25.5
202,KIT V560DEL,V560 Resides within the Juxtamembrane domain on exon 11 of KIT. In melanoma this region is one 4 hotspots and is the 3rd highest recurrently mutated region. Mouse models have shown that mutations in this hotspot lead to  constitutive phosphorylation of KIT which will induce a stronger activation of the PI3K pathway however it is currently unknown if deletions follow the same model. Case studies in Gastrointestinal Stromal Tumors with V560DEL have reported a sensitivity when treated with imatinib and regorafenib.,12.5
203,KRAS Q61,,40.0
204,NCOA3 AMPLIFICATION,,15.0
205,NCOA3 OVEREXPRESSION,,15.0
206,NOTCH1 Mutation,,100.0
207,NOTCH1 P2514FS,"This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling.",35.0
208,NRAS Mutation,,213.0
209,PAX8::PPARG Fusion,PAX8-PPAR gamma is a oncogene caused by a translocation between 2q13 and 3p25 resulting in an in-frame fusion between the two genes. It has been observed in Follicular Thyroid Cancer (FTC) and is one of two known fusion products involving PPAR gamma in FTC indicating this region may be a breakpoint hotspot. Studies have indicated that the fusion product increases cell viability and proliferation and decreases apoptosis.,15.0
210,PGR Expression,,60.0
211,PGR LOW EXPRESSION,,0.0
212,PIK3CA Amplification,,45.0
213,PTEN Deletion,,55.0
214,PTEN Loss,,272.0
215,SF3B1 Mutation,,130.0
216,SMAD4 Mutation,,25.0
217,SMARCA4 Mutation,,25.0
218,SMARCA4 INACTIVATING MUTATION,,20.75
219,TERT Amplification,,15.0
220,TERT Promoter Mutation,"TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.",105.0
221,TP53 Deleterious Mutation,Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.,78.0
222,TP53 Mutation,,457.0
223,TP53 Truncating Mutation,,40.0
224,TTF1 AMPLIFICATION,,15.0
227,CHEK2 Loss-of-function,,25.0
228,ERBB2 OVEREXPRESSION,,0.0
229,KRAS EXON 1 MUTATIONS,,0.0
230,AR F876L,,0.0
231,AR W741,,0.0
232,CDK12 Loss-of-function,,4.0
233,AKT1 Gain-of-function,,0.0
234,NT5C2 R367Q,,21.0
235,NT5C2 K359Q,,28.0
236,NT5C2 D407A,,8.0
238,TP53 DNA Binding Domain Mutation,,35.0
239,ATM S2289*,A frameshift mutation at the DNA level predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain at amino acid 2289.,7.5
240,ATM N2875H,A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain,7.5
241,NF2 Y177fs,,7.5
243,PDGFRA V561A,,3.0
244,TERT C228T,"Two TERT promotor mutations -124 (C228T, most common) and -146 (C250T) occur in up to 83% of primary glioblastomas,   71% of melanomas, 66% of urothelial carcinomas of the bladder, 47% of hapatocellular carcinomas, 21% of medulloblastomas and up to 40% of thyroid cancers. These promoter mutations reactivate TERT expression by recruitment of the GABP transcription factor.",40.0
245,XRCC1 R194W,,20.0
246,GSTP1 Deletion,,4.0
247,BIRC7 Amplification,,4.0
248,EGFR Exon 4 Deletion,,4.0
249,EGFR 3' UTR MUTATION,,0.0
250,KRAS RS61764370,Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy.,30.0
251,ERCC5 RS751402,,15.0
252,KIT rs17084733,,15.0
253,EZH2 Intron 6 Mutation,,20.0
254,MTHFR A222V,,55.0
255,GSTP1 I105V,,20.0
256,ABCG2 Q141K,,15.0
257,XRCC1 Q399R,XRCC1 Q399R germline polymorphism (NM_006297.2:c.1196A>G) is associated with better outcome for patients with NSCLC and increased response to chemotherapy for patients with cervical cancer.,40.0
258,ABCB1 S893T,,15.0
259,ABCB1 I1145I,"ABCB1 I1145I is a germline polymorphism that has improved responses in cancer. Specifically, it can indicate sensitivity to platinum-based chemotherapies for patients with NSCLC or better outcome for HER2-positive metastatic breast cancer patients.",25.0
260,ERCC2 K751Q,,35.0
261,TYMS 5' TANDEM REPEAT,,15.0
262,LRP1B EXON 12-22 DELETION,,3.0
263,FGFR1 Amplification,"FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).",185.5
264,FGFR1 Expression,"FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (G√∂ke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (G√∂ke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (G√∂ke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).",46.0
266,MET Amplification,,81.5
267,ATR I774FS,"Single A insertion or deletion in the 10 A mononucleotide run in exon 10 of ATR results in a frameshift of codon I774. In patients with endometrial cancer, this mutation has only been observed in patients with microsatellite instability.",20.0
268,CDKN2A p16 Expression,"CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.",180.0
269,KIF5B::RET Fusion,"In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., 2012)",10.0
270,HRAS G13D,,7.5
271,HRAS Mutation,,23.0
272,CD274 Expression,,330.0
273,MTOR Mutation,,22.5
274,AKT2 EXPRESSION,,15.0
275,NF2 K159fs,,7.5
276,EGFR S249R,,0.0
277,FBXW7 Mutation,,20.0
278,SMAD4 Underexpression,,3.0
279,MTOR H1968Y,,3.0
280,MTOR P2213S,,3.0
281,AGK::BRAF Fusion,,7.0
282,PAPSS1::BRAF Fusion,,6.0
283,TRIM24::BRAF Fusion,,6.0
284,BRAF L597R,,12.0
285,ERBB3 Overexpression,,37.0
286,NT5E Overexpression,,15.0
287,EZH2 Overexpression,,20.0
288,MYD88 Overexpression,,2.0
290,PIK3CA P471L,,7.5
291,RET EXPRESSION,,0.0
292,RIT1 OVEREXPRESSION,,15.0
293,RIT1 Mutation,,3.0
294,MYCN Amplification,,46.0
295,SMO D473H,,13.5
296,SMO Mutation,,44.0
297,PTCH1 Mutation,,25.0
298,PTCH1 LOH,,10.0
299,STK11 EXON 1-2 MUTATION,,20.0
300,STK11 Underexpression,,2.0
301,SYK OVEREXPRESSION,,3.0
302,ERBB2 Amplification,"Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy. These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors. Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC. Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC. The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases. In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely. Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy. Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.",891.0
303,ALK L1152R,,0.0
304,ALK G1269A,,0.0
305,EGFR AUTOCRINE ACTIVATION,,0.0
306,ERBB4 Mutation,"ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib.",4.0
307,PIK3CA Mutation,"PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer, colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.",446.5
308,EGFR VIII,"The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)",69.0
309,PTEN Expression,,54.5
310,NRG1 Expression,,37.0
311,AREG Expression,,58.0
312,TGFA EXPRESSION,,15.0
313,EGFR G724S,,4.0
314,EREG EXPRESSION,,35.5
315,EFNA2 EXPRESSION,,0.0
316,MAPK1 E322K,,10.0
317,MAPK1 Amplification,,4.0
318,KRAS A146V,,8.0
319,MET Mutation,,15.0
320,MET Exon 14 Skipping Mutation,"Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).",108.5
321,FGFR3 Overexpression,,6.0
322,CBLC EXPRESSION,,2.0
323,PTPRD Mutation,,3.0
324,DEFA1 EXPRESSION,,10.0
325,ERCC1 Expression,,30.0
326,NOTCH1 Amplification,,12.0
327,WEE1 RS3910384,,15.0
328,FNTB RS11623866,,10.0
329,PTPRT Promoter Hypermethylation,,2.0
330,VEGFA Decreased Peri-therapeutic Expression,,10.0
331,DNMT1 EXPRESSION,,18.0
332,KRAS Mutation,,545.5
333,PDCD4 EXPRESSION,"A new study, a retrospective analysis of 77 patients, has implicated PDCD4 expression in the sensitivity to paclitaxel. However, this finding came from a large proteome screen and has not yet been replicated in independent patient sets.",20.0
334,MGMT RS16906252,,15.0
335,TFF3 EXPRESSION,,15.0
336,DKK1 NUCLEAR EXPRESSION,,15.0
337,CD44 CD44s Expression,,3.0
338,EGF EXPRESSION,,3.0
339,MDM2 EXPRESSION,,20.0
340,HMOX1 EXPRESSION,,15.0
341,SPHK1 OVEREXPRESSION,,10.0
342,CASP8 Overexpression,,3.0
343,TYMS Overexpression,,40.0
344,PBK OVEREXPRESSION,,3.0
345,SMARCA4 Underexpression,,30.0
346,SETBP1 Exon 4 Mutation,,15.0
347,SETBP1 G870S,,3.0
349,BRCA1 LOSS,,0.0
350,EGFR Expression,,60.0
351,CDKN1A EXPRESSION,,15.0
352,ALCAM EXPRESSION,,15.0
353,STMN1 EXPRESSION,,15.0
354,RSF1 Amplification,,10.0
355,AR OVEREXPRESSION,,3.0
356,CDKN1B CYTOPLASMIC MISLOCALIZATION,,3.0
357,ERBB3 EXPRESSION,,6.0
358,AR V7 EXPRESSION,,15.0
359,UGT1A EXPRESSION,,3.0
360,ERBB4 NUCLEAR TRANSLOCATION,,2.0
361,ERBB4 EXPRESSION,,5.0
362,SLFN11 EXPRESSION,,2.0
363,RAC1 P29S,,4.0
364,BIRC5 NUCLEAR EXPRESSION,,15.0
365,TP53 Wildtype,,68.0
366,MRE11 Loss,,2.0
367,TOP1 Amplification,,5.0
368,CDKN1B EXPRESSION,,10.0
369,AGR2 EXPRESSION,,5.0
370,NAPRT Promoter Hypermethylation,,3.0
371,EGFR Exon 18 Overexpression,,10.0
372,ZEB1 Expression,,5.0
373,TIMP1 Overexpression,,12.0
374,PTP4A3 OVEREXPRESSION,,3.0
375,TYMS Amplification,,15.0
376,IGF1R EXPRESSION,,2.0
377,EPHB4 EXPRESSION,,10.0
378,TYMS Underexpression,,20.0
379,TOP2A EXPRESSION,,10.0
380,TOP1 EXPRESSION,,25.0
381,PRKAA2 T172 PHOSPHORYLATION,,0.5
382,HSPA5 EXPRESSION,,20.0
383,EIF4EBP1 PHOSPHORYLATION,,4.0
384,KIT Mutation,,17.0
385,TUBB3 EXPRESSION,,12.0
386,EGFR Y1092 PHOSPHORYLATION,"Although referred to as Y1068 in the literature, based on the recognition peptide described, this tyrosine occurs at Y1039 (ENST00000454757.2 v75) or Y1092 (ENST00000275493.2 v75).",15.0
387,IGF1R NUCLEAR EXPRESSION,,10.0
388,CFLAR EXPRESSION,,3.0
389,PROM1 EXPRESSION,,10.0
390,FOXP3 EXPRESSION,,20.0
391,RPS6 PHOSPHORYLATION,,2.0
392,JAK1 OVEREXPRESSION,,11.5
393,BRCA1 Expression,,2.0
394,DUSP6 EXPRESSION,,3.0
395,BRAF Mutation,,166.0
396,HSPB1 EXPRESSION,,2.0
397,NQO1 EXPRESSION,,2.0
398,NQO1 P187S,,2.0
399,BRCA1 Underexpression,,15.0
400,ABCB1 EXPRESSION,,0.0
401,CXCR4 EXPRESSION,,10.0
402,MAGEH1 EXPRESSION,,2.0
403,ABCC3 Amplification,,3.0
404,ABCC10 Overexpression,,3.0
405,ASNS Amplification,,2.0
406,CDX2 EXPRESSION,,20.0
407,STAT3 SH2 DOMAIN MUTATION,,20.0
408,POU5F1 EXPRESSION,,2.0
409,ERBB2 Kinase Domain Mutation,,17.5
410,ERBB2 Y772_A775DUP,"Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.",42.0
411,EGFR C797S,,17.5
412,ERBB2 SERUM LEVELS,,35.0
413,THBS2 UNDEREXPRESSION,,15.0
414,TERT MUTATION,,0.0
415,v::NTRK1 Fusion,,135.0
416,IDH1 R132H,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",9.0
417,TERT RS2736100,,10.0
418,STAG2 Underexpression,,14.0
419,HLA-DRA EXPRESSION,,15.0
420,MYD88 L265P,,31.0
421,KRAS G12V,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5
422,BRAF Wildtype,,10.0
423,NRAS Q61K,,24.5
424,MRE11 Frameshift,,10.0
425,KIT EXPRESSION,,35.0
427,CBFB::MYH11 Fusion,"CBFB-MYH11 is the result of inv(16)(p13q22) or t(16;16)(p13;q22) and is sufficient for the diagnosis of acute myeloid leukemia (in the correct setting) according to WHO criteria, even when blast counts are <20% (Vardiman et al, Blood 2008). This fusion is typically associated with favorable prognosis relative to other AML subtypes (including cytogenetically normal); however, the impact of additional mutations in the context of this fusion is incompletely understood. AMLs with this fusion are often grouped with other rearrangements affecting genes encoding core binding factor subunits, referred to as CBF AMLs.",35.0
428,KMT2A::MLLT3 Fusion,,40.0
429,HIF1A 3' UTR Polymorphism,,10.0
430,HIF1A OVEREXPRESSION,,25.0
431,EPAS1 Overexpression,,25.0
432,VHL Loss,,3.0
433,FLT3 D835,,46.0
434,PSMB8 NUCLEAR EXPRESSION,,10.0
435,PBK NUCLEAR EXPRESSION,,10.0
436,PTTG1 OVEREXPRESSION,,10.0
437,LEPR UNDEREXPRESSION,,10.0
438,EGFR Mutation,,260.0
439,EGFR G465R,,20.0
440,NEDD9 EXPRESSION,,15.0
441,ETS2 RS461155,,10.0
442,KRT18 UNDEREXPRESSION,,2.0
443,FGF13 CYTOPLASMIC EXPRESSION,,15.0
444,SS18::SSX1 Fusion,,145.0
445,SS18::SSX2 Fusion,,85.0
446,SS18::SSX4 Fusion,,5.0
447,ABCB1 S893A/T,"Refer to 
https://www.pharmgkb.org/rsid/rs2032582 
for more information.",15.0
448,EGFR S2492R,,0.0
449,EGFR S492R,,23.0
450,EGFR R451C,,2.0
451,EGFR K467T,,6.0
452,FCGR2A H167R,,35.0
453,FCGR3A F212V,,35.0
454,FCGR2B I232T,,20.0
455,FCGR2A R131H,,0.0
456,EGFR P753S,,7.5
457,PML B2 DOMAIN MUTATION,The B2 domain in PML is the binding site for ATRA. Point mutations in this region have been associated with ATRA resistance in patients with APL.,20.0
458,PML A216V,A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.,30.0
459,PML L218P,L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.,7.5
463,KDR A1065T,,3.0
464,KDR D717V,,3.0
465,TSC2 Q1178*,,12.5
466,MTOR F2108L,,16.5
467,RAD51D R186*,,5.0
468,ALDH1A2 Overexpression,,30.0
469,ALDH1A2 Underexpression,,2.0
470,CIP2A EXPRESSION,,15.0
471,CIP2A Underexpression,,3.0
472,MIR218-1 EXPRESSION,,30.0
473,BRCA1 P968FS,,20.0
474,AR SPLICE VARIANT 7,,0.0
475,KRAS Q22*,,5.0
476,DNMT3A P904L,,0.0
477,DDX43 Overexpression,,4.0
478,KIT RS3733542,,5.0
479,TBK1 Overexpression,,2.0
481,STK11 Loss,,23.0
482,HAVCR2 Overexpression,,10.5
483,MMP2 SERUM LEVELS,,25.0
484,MMP9 SERUM LEVELS,,15.0
485,FST SERUM LEVELS,,0.0
486,HSPH1 NUCLEAR EXPRESSION,,11.0
487,HSPH1 T17 DELETION,,10.0
488,ECSCR EXPRESSION,,5.0
489,ROBO4 EXPRESSION,,5.0
490,PIM1 NUCLEAR EXPRESSION,,10.0
491,MDM2 SNP309,,10.0
492,ERBB2 L866M,This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.,4.0
493,ERBB2 S310F/Y,"ERBB2 S310F/Y was one of the first ERBB2 variants to be functionally classified (Greulich et al. 2012). This mutation was shown to be an activating mutation (through hyperphosphorylation) in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in murine Ba/F3 cells have been shown to be sensitive to the ERBB2 inhibitors (afatinib, lapatinib and neratinib). More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",4.0
494,MIR218-1 UNDEREXPRESSION,,3.0
495,v::ALK Fusion,"Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer. In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response. Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets. ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib ‚Äì a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC. ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC. Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.",798.0
496,EML4::ALK e20::e20,"EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.",16.5
497,EML4::ALK e2::e20,,1.75
498,KDR R961W,,2.5
499,EML4::ALK e6::e20,"The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.",25.0
500,TP53 P47S,,0.5
501,GNAQ Mutation,,26.0
502,GNA11 Mutation,,24.0
503,GNAQ Q209,,20.0
504,PMS2 K706FS*19,,10.0
505,KIT Exon 9 Mutation,"In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.",122.5
506,PTEN Mutation,,31.0
507,FGFR2 Mutation,,28.0
508,ALK Mutation,,20.0
509,NPM1::ALK Fusion,,27.0
510,RANBP2::ALK Fusion,,10.0
511,FGFR1 N546K,,8.0
512,ROS1 L2026M,"The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.",9.0
513,ROS1 L2155S,,3.0
514,ROS1 G2101A,,4.0
515,FLT3 Mutation,,85.0
516,CLTC::ALK Fusion,"The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).",19.0
517,U2AF1 MUTATION,,20.0
518,BRAF DEL 485-490,,3.0
520,DUX4::v Fusion,,11.5
521,B4GALT1 Overexpression,,15.0
522,BCL2L11 Deletion Polymorphism,,40.0
523,ALK I1171,Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.,42.5
524,ALK V1180L,"The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.",0.0
525,SIRT1 Overexpression,,16.0
526,KRAS G12R,,32.5
527,TP53 P72R,"This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.",45.0
528,PALB2 Biallelic Inactivation,,17.5
529,SMAD4 Expression,,15.0
530,FANCC Loss-of-function,,3.0
531,EBF1::PDGFRB Fusion,EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.,32.5
532,SULT1E1 SNP,,0.0
533,RB1 EXPRESSION,,10.0
534,MLH1 METHYLATION,,10.0
535,PTPN11 Overexpression,,10.0
536,FLT3 T227M,"FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.",15.0
537,PALB2 L531FS*30,,15.0
538,MTOR S2215Y,,2.0
539,MTOR C1483Y,,2.0
540,MTOR E1799K,,2.0
541,FGFR2 N550K,,3.0
542,ACTA1 EXPRESSION,,10.0
543,RB1 Overexpression,,2.0
544,PPP1R15A RS557806,,5.0
545,ALK F1245C,,10.5
546,ALK Exon 4-11 Deletion,,3.0
549,CDK4 Amplification,,30.0
550,CDKN2A Loss,,52.5
551,CDKN2B Loss,,5.0
552,CDK4 R24C,,1.0
553,ASXL1 EXON 12 MUTATION,,20.0
554,GNA11 Q209,,15.0
555,CALR EXON 9 FRAMESHIFT,"Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52‚Äâbp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival.",80.0
556,CSF3R Mutation,,30.0
558,EGFR S768I,,20.5
559,BRAF V600K,,107.5
560,SMAD4 LOSS,,15.0
561,SF3B1 K700E,,5.0
562,MAP2K7 E116K,,25.0
563,v::PDGFRA Fusion,,100.0
564,v::PDGFRB Fusion,,140.0
565,v::FGFR1 Fusion,,103.0
566,IDH2 Mutation,,101.5
567,PCM1::JAK2 Fusion,,57.5
568,MTOR E2014K,,0.0
569,RICTOR Amplification,,12.5
570,FIP1L1::PDGFRA Fusion,"Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRŒ± fusion kinase&quot; (NDA021588).",63.5
572,TFG::ROS1 Fusion,,7.5
573,PDGFRA T674I,A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib.,15.5
574,BIRC5 Overexpression,,20.0
575,BRAF D594A,,0.75
576,BRAF D594V,,0.75
577,BRAF K483M,The K483M variant is a kinase dead loss-of-function variant in the catalytic site of BRAF. This engineered variant is often used as a control when evaluating other BRAF variants.,0.75
578,BRAF L597S,,9.5
579,BRAF L597Q,,14.5
580,BRAF K601E,,3.0
581,BRAF L597V,,7.5
582,KIT Amplification,,15.0
583,NF1 Mutation,,62.0
584,ALK I1171N,,0.0
585,ALK I1171S,,0.0
586,BIRC3 TRUNCATING MUTATION,,10.0
587,RAF1 Amplification,,10.0
588,KRAS Amplification,,27.0
590,CEBPA BIALLELIC INACTIVATION,,25.0
591,SRSF2 MUTATION,,25.0
592,NRAS G12/G13,,20.0
593,RET Overexpression,,24.5
595,CTLA4::CD28 Fusion,"A survey of 115 T-cell lymphoma samples of diverse subtypes identified this fusion in 26 of 45 cases of angioimmunoblastic T-cell lymphomas (58%), nine of 39 peripheral T-cell lymphomas, not otherwise specified (23%), and nine of 31 extranodal NK/T cell lymphomas (29%).",5.0
596,AR Mutation,,20.0
597,NOTCH1 Loss-of-function,,2.0
598,CDK6 Overexpression,,24.0
599,FLT3 Overexpression,,7.5
600,GNAQ Q209P,,8.0
601,PTEN V317FS,,3.0
602,RB1 Loss-of-function,,6.0
603,ESR1 Overexpression,,20.0
605,MTOR M2327I,,7.0
606,MTOR A2034V,,8.0
607,BRAF D594G,This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.,43.5
608,FLT3 D835H,,9.5
609,FLT3 D835H/Y,,1.0
610,JAK1 Q503*,,10.0
611,JAK2 c.1641+1dup,,10.0
612,B2M S14FS,,7.5
613,PPFIBP2::BRAF Fusion,,5.0
614,KIAA1549::BRAF Fusion,,109.5
615,PTGS2 Overexpression,,0.0
617,MET Overexpression,,64.0
619,POT1 MUTATION,,15.0
620,MKI67 EXPRESSION,,35.0
621,RAD23B EXPRESSION,,2.0
622,CCDC6::RET Fusion,,12.5
623,MAP2K1 C121S,,10.0
624,FGFR3 S249C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,21.0
625,FGFR2 Amplification,,25.0
626,FGF3 Amplification,,10.0
627,VHL R200W (c.598C>T),,10.0
628,RB1 PHOSPHORYLATION,,15.0
629,PIK3R1 Mutation,,2.0
630,STK11 D194E,,5.0
631,AKT2 Amplification,,2.5
632,PTEN R130*,,2.0
633,FBXW7 Loss-of-function,,4.5
634,RB1 M695FS*26,,2.0
635,JUN Overexpression,,5.0
636,FOS Overexpression,,5.0
637,CDKN2A RS3814960,,15.0
638,MDM2 RS34886328,,10.0
639,CBLB RS2305035,,10.0
640,PRDM1 MUTATION,,20.0
641,IDH1 Mutation,,90.5
642,SMAD4 Deletion,,15.0
643,LRP1B DELETION,,20.0
644,ATRX Underexpression,,39.0
645,MET D1228N,,5.0
646,CASP8 D302H,,15.0
647,AXL EXPRESSION,,20.0
648,GAS6 EXPRESSION,,23.0
649,ETV4 Overexpression,,15.0
650,STAG3 Underexpression,,4.0
651,MAP2K1 Q56_V60del,,10.0
652,BRAF::CUL1 Fusion,,5.0
653,ZKSCAN1::BRAF Fusion,,7.5
654,BRAF L505H,,19.0
655,NF2 Mutation,,0.0
656,HIF1A EXPRESSION,,10.0
657,BRCA2 D3095E,,7.5
658,MLH1 EXPRESSION,,15.0
659,BCOR Mutation,,15.0
660,CDH1 MUTATION,,0.5
661,RHOA MUTATION,,0.5
662,ERBB2 Mutation,,37.5
663,MEN1 FRAMESHIFT TRUNCATION,,5.0
664,KMT2C Mutation,,15.0
665,STAG2 MUTATION,,30.0
666,MYCL EXPRESSION,,1.0
667,HGF EXPRESSION,,2.0
668,SOX10 Loss,,4.0
669,FGF2 EXPRESSION,,4.0
670,EIF1AX MUTATION,,10.0
671,PAX8 Expression,,40.0
672,ERRFI1 E384*,,5.0
673,ESR1 S463P,,2.0
674,SGK1 Overexpression,,24.0
675,BRAF G596C,,2.0
676,SMARCB1 Underexpression,,2.0
677,SMARCB1 Deletion,,3.0
678,NF2 Loss,,4.0
679,NF1 Loss,,3.0
680,SH2B3 RS3184504,,10.0
681,KIF23 EXPRESSION,,15.0
682,ERBB3 V104M,,15.0
683,ERBB3 R103G,,15.0
684,ERBB3 G284R,,15.0
685,BRAF V600E+V600K,,0.0
686,GADD45A rs681673,,15.0
687,EWSR1::FLI1 Fusion,"In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5‚Äô exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3‚Äô exons (from exon 9, coding the DNA binding domain) of FLI1.",90.0
689,BRCA2 TRUNCATING MUTATION,,2.5
690,BRCA1 Alu insertion,,7.5
691,HOXB1 G84E,,0.0
692,KLLN PROMOTER METHYLATION,,30.0
693,EGFR D761Y,,7.5
694,CRBN Mutation,,7.5
695,TSC1 R1062W,,8.0
696,STK11 Mutation,,40.0
697,PDGFRA Amplification,,3.0
698,EWSR1::DDIT3 Fusion,,7.5
699,EGFR G719,"This is a ""bucket"" variant for evidence that refers generically to missense variants happening at this position such as: G719A, G719D, G719S.",25.0
701,EGFR S720,,7.5
702,CYP2D6 Loss-of-function,,20.0
703,FUS::DDIT3 Fusion,,70.0
704,EGFR K757R,,7.5
705,EGFR E746G,,2.5
706,MLH1 E13fs,,2.5
707,EGFR Exon 20 Insertion,,105.0
708,MSH2 R383*,,2.5
709,MLH1 V534R,,2.5
710,UGT1A1 UGT1A1*28,,50.0
711,MLH1 G606FS*2,,2.5
712,MLH1 c.790+1G>A,,2.5
713,UGT1A1 UGT1A1*60,,20.0
714,MLH1 K618DEL,,2.5
715,MLH1 P138T,,2.5
716,MLH1 R687FS,,2.5
717,EGFR V769_D770insASV,,7.5
718,DPYD DPYD*2A HOMOZYGOSITY,,50.0
719,DPYD DPYD*13 HOMOZYGOSITY,,50.0
720,FOS::v Fusion,,7.5
721,DPYD RS67376798 HOMOZYGOSITY,,50.0
722,MLH1 R100*,,2.5
723,WWTR1::CAMTA1 Fusion,,40.0
724,MLH1 T117M,,2.5
725,MLH1 Q426FS,,2.5
726,MLH1 V49A,,2.5
727,MLH1 D667FS,,2.5
728,MLH1 M1L,,2.5
729,MLH1 *757L,,2.5
730,MLH1 R265G,,2.5
731,MLH1 V213FS,,2.5
732,MLH1 N551T,,2.5
733,MLH1 A424T,,2.5
734,MLH1 Q149*,,2.5
735,MLH1 R226*,,2.5
736,MSH6 I972F,,0.0
737,MLH1 P536FS,,2.5
738,MLH1 G67R,,2.5
739,MLH1 I68S,,2.5
740,MLH1 G65D,,2.5
741,MLH1 A681V,,2.5
742,MSH6 P138T,,2.5
743,MSH2 V273FS,,2.5
744,MSH2 E28FS,,2.5
745,VHL E55FS (c.163_164delGA),,2.5
746,MSH6 I891FS,,2.5
747,VHL E55RfsTer11 (c.163delG),,7.5
748,MSH6 R1242H,,2.5
749,PMS2 R315*,,2.5
750,MLH1 M490T,,2.5
751,MSH2 K172*,,2.5
752,VHL A56FS (c.164_165insG),,7.5
753,HOXB13 G84E,,40.0
754,MSH2 E483G,,2.5
755,TNKS2::PDGFRA Fusion,,7.5
756,MSH6 V352I,,2.5
757,MSH6 R1242C,,2.5
758,SLCO1B1 RS4149056,,15.0
759,SLCO1B1 N130D,,15.0
760,TYMS RS34743033,,15.0
761,ACTB::GLI1 Fusion,"Fusion of the hedgehog pathway component gene GLI1 to the Œ≤-actin gene (ACTB)  has been described as a mechanism of GLI1,and by extension hedgehog pathway, activation. These fusions have been described in histologically distinctive soft tissue tumours showing a pericytic phenotype.  Gene fusions retain the DNA-binding zinc finger domains of GLI1 and it is likely that the replacement of the promoter region of GLI1with that of the ubiquitously expressed ACTB gene leads to deregulation of GLI expression and its downstream target genes.",15.0
762,ERBB3 V855A,,2.0
763,FGFR2::BICC1 Fusion,,38.0
764,FGFR2::AHCYL1 Fusion,,23.0
765,CDKN2B METHYLATION,,20.0
766,CHEK2 1100DELC,,15.0
768,CHEK2 I157T,,15.0
769,CHEK2 IVS2+1G>A,,10.0
770,PTPRD V253I,,10.0
771,VHL A56fs (c.164_165insA),,5.0
772,VHL E55= (c.165G>A),,5.0
773,RRM1 Overexpression,,2.0
774,RRM2 OVEREXPRESSION,,2.0
775,POLE Mutation,,15.0
776,MET D1228V,,20.0
777,RB1 Mutation,,10.0
778,SQSTM1::NTRK1 Fusion,,45.0
779,ETV6::NTRK3 Fusion,,314.0
780,RUNX1 K83E,,10.0
781,RUNX1 Y260*,,7.5
782,RUNX1 R135FSX177,,10.0
784,RUNX1 D198Y,"D198Y was observed in a pedigree with a history of Familial platelet disorder with predisposition to acute myeloid leukemia. It occurs within the Runt domain of RUNX1, known to be associated with the disease.",7.5
785,RUNX1 A107P,,12.5
786,MSH2 Loss,,7.5
787,MSH6 LOSS,,7.5
788,RUNX1 T148HFSX9,,5.0
789,ETV6 R399C,,0.0
790,ETV6 R369Q,,0.0
791,ETV6 P214L,,0.0
792,DDX41 R164W,,7.5
793,ERBB2 Y772_A775DUP,,0.0
794,ERBB2 G776L,,7.5
796,ERBB2 M774DELINSWLV,,7.5
797,PTPRB Loss-of-function,,18.0
798,VHL A149S (c.445G>T),,17.5
799,HLA-C COPY-NEUTRAL LOSS OF HETEROZYGOSITY,,7.5
800,JAK1 S703I,,4.0
801,EPCAM 3' Exon Deletion,,20.0
802,MAP2K1 K57T,,0.0
803,ARAF S490T,,2.5
804,GNAS R201C,,5.0
805,FGFR3 Mutation,,70.0
807,VHL M54IFS (c.162_166delGGAGG),,2.5
808,FGFR3::TACC3 Fusion,,22.5
809,AKT3 UPREGULATION,,0.0
810,AKT3 DEPLETION,,0.0
811,SMO W535L,,0.0
812,PTEN R173C,,13.0
813,ALK Alternative Transcript (ATI),A novel ALK transcript (alternative isoform) that initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19 produces three protein products with slight variation in size and all containing the tyrosine kinase domain. ALK(ATI) products have been shown to stimulate oncogenic pathways and promote tumourigenesis in vivo. ALK(ATI) expression was found in 11% of melanomas examined and rarely in other cancer types.,20.0
814,BRAF G469R,,0.0
815,BRAF G469V,,0.0
816,BRAF APC,,0.0
817,VHL Exon 1-3 Deletion,,17.5
818,VHL Exon 1 Deletion,,20.0
819,VHL Exon 1-2 Deletion,,7.5
820,VHL M1FS (c.1_17del17),,2.5
821,VHL M1? (c.1-1_20del21),,2.5
822,VHL M1? (c.3G>A),,2.5
823,VHL N7D (c.19A>G),,2.5
824,VHL P25L (c.74C>T),,7.5
825,VHL P59fs (c.173_174insC),,7.5
826,VHL Y98FS (c.291_310del20),,2.5
827,NBN Loss,,0.0
828,HRAS Q61L,,0.0
829,KIT D419del,,0.0
830,CREBBP Deletion,,0.0
831,NTRK3 EXPRESSION,,0.0
832,CSF1 Overexpression,,0.0
833,ROS1 Overexpression,,0.0
834,NTRK1 Overexpression,,20.0
835,EGFR T725M,,0.0
836,PDGFRA P577S,,3.0
837,PDGFRA R841K,,3.0
838,PDGFRA H845Y,,3.0
839,PDGFRA G853D,,3.0
840,MITF Overexpression,,0.0
841,MTAP Underexpression,,1.0
842,VPS37A Underexpression,,3.0
843,YAP1 Overexpression,,0.0
844,BTK T316A,,10.0
845,ERBB2 T862A,,3.0
846,ERBB2 V773A,,1.0
847,ERBB2 N857S,,1.0
848,ERBB2 H878Y,,1.0
849,ERBB2 Overexpression,,77.5
850,GNAS R201,,15.0
851,GNAS c.393T>C,,165.0
852,NRAS G12D,,7.5
853,TP53 G245S,,10.0
854,IDH1 R132L,,0.0
855,PIK3CA E545Q,,7.5
856,PIK3CA E545A,,0.0
857,PIK3CA E545G,,2.0
858,PIK3CA E545V,,0.0
859,PIK3CA Q546K,,5.0
860,PIK3CA Q546E,,0.0
861,PIK3CA Q546P,,0.0
862,PIK3CA Q546R,,0.0
863,PIK3CA Q546L,,0.0
864,EGFR L747_S752del,,0.0
865,EGFR S752_I759delSPKANKEI,,0.0
867,NRAS Q61H,,5.0
868,NRAS G60E,,0.0
869,NRAS G13C,,0.0
870,NRAS G13R,,5.0
871,NRAS G12C,,7.5
872,NRAS G12S,,0.0
873,PTEN R130Q,,0.0
874,PTEN G165R,,0.0
875,ATM T2666A,,3.0
876,ATM L2890V,,0.0
877,ATM R3008C,,3.0
878,ATM R3008H,,0.0
879,KRAS A146P,,7.5
880,KRAS A146T,,21.0
881,KRAS Q61H,,10.5
882,KRAS Q61L,,7.5
883,KRAS Q61R,,7.5
884,KRAS Q61K,,7.5
885,KRAS G13C,,0.0
886,KRAS G12FS,,0.0
887,KRAS G12S,,38.0
888,TP53 R306X,,0.0
889,TP53 E286K,,2.0
890,TP53 R282W,,3.0
891,TP53 C275Y,,0.0
892,TP53 R273L,,0.0
893,TP53 V272M,,0.0
894,TP53 R248L,,0.0
895,TP53 R248FS,,0.0
896,TP53 Y220C,,15.5
897,TP53 R213X,,0.0
898,TP53 C135W,,3.0
899,STK11 Loss,,0.0
900,IDH1 R132FS,,0.0
901,IDH1 R132G,,0.0
902,IDH1 R132S,,0.0
903,PIK3CA R88Q,,7.5
904,PIK3CA N345K,,2.5
905,PIK3CA C420R,,15.5
906,PIK3CA P539R,,0.0
907,PIK3CA E542Q,,0.0
908,PIK3CA E545D,,0.0
909,PIK3CA Y1021C,,0.0
910,PIK3CA M1043V,,0.0
911,PIK3CA M1043I,,0.0
912,PIK3CA H1047Y,,0.0
913,PIK3CA G1049S,,0.0
914,PIK3CA G1049R,,7.5
915,PDGFRA V561D,,8.5
916,PDGFRA R748G,,0.0
917,PDGFRA D842_H845DELDIMH,,2.0
918,PDGFRA Y849S,,0.0
919,KIT D496V,,0.0
920,KIT Y503_F504insAY,,2.0
921,KIT N512D,,0.0
922,KIT K550_W557del,,2.0
923,KIT K550_K558del,,5.0
924,KIT P551L,,0.0
925,KIT M552_W557DEL,,0.0
926,KIT Y553D,,0.0
927,KIT Y553_K558DEL,,0.0
928,KIT DEL 554-558,,0.0
929,KIT E554D,,0.0
930,KIT V555_Q556DEL,,0.0
931,KIT V555_P573DEL,,0.0
932,KIT W557R,,0.0
933,KIT W557G,,0.0
934,KIT W557T,,0.0
935,KIT W557_K558del,,14.5
936,KIT W557_E561del,,0.0
937,KIT K558Q,,0.0
938,KIT K558_V559del,,5.0
939,KIT K558R,,0.0
940,KIT V559DEL,,0.0
941,KIT V559_V560DEL,,0.0
942,KIT V559D,,11.5
943,KIT V559A,,0.0
944,KIT V559G,,0.0
945,KIT V560D,,14.5
946,KIT V560G,,5.0
947,KIT V560FS,,0.0
948,KIT T574A,,0.0
949,KIT Q575L,,0.0
950,KIT P577L,,0.0
951,KIT D579del,,5.0
952,KIT K642E,,10.0
953,KIT T661I,,0.0
954,KIT S692L,,0.0
955,KIT Q694K,,0.0
956,KIT H697Y,,0.0
957,KIT D816H,,7.5
958,KIT D816Y,,0.0
959,KIT D816FS,,0.0
960,KIT D820Y,,14.5
961,KIT N822H,,2.0
962,KIT N822K,,0.0
963,KIT Y823D,,7.5
964,KIT A829P,,8.0
966,BRAF G469A,,5.0
967,BRAF G469E,The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.,6.0
968,EGFR R108K,,3.0
969,EGFR T263P,,3.0
970,EGFR A289V,,3.0
971,EGFR G598V,,3.0
972,EGFR G719C,,0.0
973,EGFR G719A,,5.0
974,EGFR G729R,,0.0
975,EGFR V742A,,0.0
976,EGFR E746_A750del,,19.5
977,EGFR E746_T751>I,,5.0
978,EGFR E746_T751delinsA,,0.0
979,EGFR E746V,,0.0
980,EGFR L747_A750delinsP,,0.0
981,EGFR L747_T751delLREAT,,0.0
982,EGFR L747_T751delinsQ,,0.0
983,EGFR E746_S752delinsD,,0.0
984,EGFR L747_T751delinsP,,0.0
985,EGFR L747_P753>Q,,0.0
986,EGFR L747_P753delinsS,,7.5
987,EGFR D761N,,0.0
988,EGFR V774L,,0.0
989,EGFR R776H,,0.0
990,EGFR G810S,,0.0
991,EGFR R831H,,3.0
992,EGFR L838V,,2.0
993,EGFR K860E,,0.0
994,EGFR L861Q,,10.5
997,ABL1 G250E,,0.0
1002,ABL1 F317L,,0.0
1003,ABL1 M351T,,0.0
1005,NOTCH1 L1600P,,0.0
1006,NOTCH1 L1574P,,0.0
1007,NOTCH1 R1598P,,0.0
1008,NOTCH1 L1678P,,0.0
1009,TP53 V272L,,0.0
1010,TP53 G245D,,3.0
1011,PTEN R130G,,0.0
1012,PTEN R130L,,0.0
1013,PTEN R173H,,0.0
1014,TP53 R342X,,0.0
1015,TP53 E298X,,0.0
1016,TP53 E286V,,0.0
1017,TP53 E285K,,0.0
1018,TP53 D281E,,3.0
1019,TP53 D281G,,0.0
1020,TP53 D281H,,0.0
1021,TP53 R280S,,0.0
1022,TP53 R280I,,0.0
1023,TP53 P278S,,3.0
1024,TP53 A276V,,3.0
1025,TP53 C275G,,0.0
1026,TP53 R273G,,0.0
1027,TP53 F270S,,3.0
1028,TP53 R267P,,0.0
1029,TP53 G266R,,3.0
1030,TP53 D259Y,,0.0
1031,TP53 I255S,,0.0
1032,TP53 T253P,,0.0
1033,TP53 G245V,,0.0
1034,TP53 G244S,,3.0
1035,TP53 M243V,,0.0
1036,TP53 C242F,,0.0
1037,TP53 C242S,,0.0
1038,TP53 C242Y,,3.0
1039,TP53 S241C,,0.0
1040,TP53 M237I,,7.0
1041,TP53 Y236C,,0.0
1042,TP53 Y234C,,0.0
1043,TP53 Y234S,,0.0
1044,TP53 V216L,,0.0
1045,TP53 V216M,,0.0
1046,TP53 R213L,,0.0
1047,TP53 V203L,,0.0
1048,TP53 L201F,,0.0
1049,TP53 E198*,,0.0
1050,TP53 R196X,,0.0
1051,TP53 I195N,,0.0
1052,TP53 L194P,,0.0
1053,TP53 H193R,,0.0
1054,TP53 P190L,,0.0
1055,TP53 H179Q,,0.0
1056,TP53 H179R,,3.0
1057,TP53 H179Y,,3.0
1058,TP53 H179D,,0.0
1059,TP53 R174W,,0.0
1060,TP53 V173L,,0.0
1061,TP53 Y163C,,0.0
1062,TP53 M160K,,0.0
1063,TP53 A159V,,0.0
1064,TP53 A159S,,0.0
1065,TP53 R158P,,0.0
1066,TP53 V157F,,4.0
1067,TP53 P151H,,3.0
1068,TP53 C141W,,0.0
1069,TP53 K132R,,0.0
1070,TP53 K132T,,0.0
1071,TP53 K132E,,0.0
1072,TP53 K132Q,,0.0
1073,TP53 L130V,,0.0
1074,TP53 Y103X,,0.0
1075,TP53 V73L,,0.0
1076,TP53 D42Y,,0.0
1077,KRAS Q61P,,0.0
1078,KRAS Q61E,,0.0
1079,KRAS Q61FS,,0.0
1080,BRAF G464V,,5.0
1081,BRAF D594N,,0.0
1082,TP53 R282L,,0.0
1083,TP53 R213P,,0.0
1084,TP53 H178D,,0.0
1085,TP53 C135Y,,0.0
1086,TP53 R337L,,0.0
1087,TP53 K132N,,0.0
1088,TP53 A161T,,3.0
1089,TP53 Y126N,,0.0
1090,TP53 C176Y,,0.0
1091,TP53 Q331X,,0.0
1092,TP53 E180X,,0.0
1093,KRAS L19F,,0.0
1094,KRAS K117N,,0.0
1095,BRAF F595L,,0.0
1096,CSF1R Y571D,,0.0
1097,DNMT3A W893S,,0.0
1098,DNMT3A R882P,,0.0
1099,DNMT3A R882H,,0.0
1100,DNMT3A R882C,,0.0
1101,NOTCH1 F1592S,,0.0
1102,DNMT3A K577X,,0.0
1103,KIT P834L,,0.0
1104,KRAS Q22K,,0.0
1105,NOTCH1 Q2459X,,0.0
1106,NOTCH1 Q2409X,,0.0
1107,NOTCH1 Q2391X,,0.0
1108,NOTCH1 Q2315X,,0.0
1109,NOTCH1 C1685F,,0.0
1110,NOTCH1 V1676D,,0.0
1111,NOTCH1 Y1619N,,0.0
1112,NOTCH1 I1616N,,0.0
1113,NOTCH1 Q1614K,,0.0
1114,NOTCH1 L1600Q,,0.0
1115,NOTCH1 R1586P,,0.0
1116,NOTCH1 L1585R,,0.0
1117,NOTCH1 V1577A,,0.0
1118,NOTCH1 V1577E,,0.0
1119,NOTCH1 L1574Q,,0.0
1120,JAK3 V674A,,0.0
1121,JAK3 A572V,,0.0
1122,JAK3 E183G,,0.0
1123,JAK3 R172Q,,0.0
1124,JAK3 L156P,,0.0
1125,PIK3CA H1047L,,12.5
1127,ATM P292R,,0.0
1128,ATM M1FS,,0.0
1129,ATM K293*,,3.0
1130,ATM R2459C,,0.0
1131,ATM Q984E,,0.0
1132,ATM F1025L,,3.0
1133,ATM Q1084*,,0.0
1134,ATM D1930V,,2.0
1135,ATM R2034P,,0.0
1136,ATM E2187*,,3.0
1137,ATM L2427P,,3.0
1138,ATM F2732V,,3.0
1139,ATM R777FS,,0.0
1140,ATM K468FS,,2.0
1141,ATM V1268FS,,0.0
1142,ATM D1682H,,3.0
1143,ATM A2062V,,3.0
1144,ATM R1575H,,0.0
1145,ATM A2274T,,0.0
1146,ATM C2488Y,,3.0
1148,NOTCH1 F1592C,,0.0
1149,NRAS G12V,,0.0
1150,PIK3CA R38H,,0.0
1151,PIK3CA E453K,,0.0
1152,PIK3CA R93W,,5.0
1153,PIK3CA G106V,,0.0
1154,PIK3CA R108H,,0.0
1155,EGFR R776C,,0.0
1156,EGFR S784F,,0.0
1157,ABL1 E292V,,2.0
1159,BRAF T599I,,0.0
1160,BRAF N581S,,5.0
1161,EGFR A864T,,0.0
1162,EGFR N826S,,0.0
1163,EGFR V851A,,0.0
1164,AKT1 E49K,,0.0
1165,AKT1 L52R,,0.0
1166,AKT1 D323H,,0.0
1167,BRAF R462I,,0.0
1168,BRAF I463S,,0.0
1169,BRAF G464E,,0.0
1170,BRAF G466A,,0.0
1171,BRAF E586K,,0.0
1172,BRAF A728V,,2.0
1173,BRAF V600G,,0.0
1174,PIK3CA R38C,,0.0
1175,PIK3CA G106R,,0.0
1176,PIK3CA K111E,,0.0
1177,PIK3CA P124L,,0.0
1178,PIK3CA E365K,,0.0
1179,PIK3CA E453Q,,0.0
1180,KIT S501_A502INSAY,,0.0
1181,KRAS R164Q,,3.0
1182,KRAS T74P,,0.0
1183,PDGFRA V533E,,0.0
1184,PDGFRA S566_E571>R,,0.0
1185,PDGFRA N659S,,0.0
1186,PDGFRA H650Q,,0.0
1187,PDGFRA H845_N848>P,,0.0
1188,EGFR E746_T751delinsVA,,0.0
1189,ERBB2 S310Y,,0.0
1190,ERBB2 P707S,,0.0
1191,ERBB3 A232V,,0.0
1192,ERBB3 P262H,,0.0
1193,ERBB3 T389K,,0.0
1194,ERBB3 Q809R,,0.0
1195,ERBB3 S846I,,0.0
1196,ERBB3 E928G,,0.0
1197,ERBB3 V104L,,0.0
1198,ERBB3 R426W,,0.0
1199,ERBB3 V1035D,,0.0
1200,AKT2 D324H,,0.0
1201,AKT3 E17K,,3.0
1202,AKT3 L51R,,0.0
1203,AKT3 D320H,,0.0
1204,ABL1 L384M,,5.5
1206,ABL1 L387F,,7.0
1207,ABL1 G398R,,5.0
1208,PIK3CA K111N,,13.0
1209,PIK3CA I391M,,5.0
1210,BRCA1 M1V,,0.0
1211,BRCA1 M1I,,0.0
1212,BRCA1 C61G,,0.0
1213,BRCA1 C64Y,,0.0
1214,BRCA1 R71G,,0.0
1215,BRCA1 R71K,,0.0
1216,BRCA1 R1495M,,0.0
1217,BRCA1 E1559K,,0.0
1218,BRCA1 D1692N,,0.0
1219,BRCA1 R1443*,,0.0
1220,BRCA1 Q1467*,,0.0
1221,BRCA2 M1R,,0.0
1222,BRCA2 M1I,,0.0
1223,BRCA2 V159M,,0.0
1224,BRCA2 V211L,,0.0
1225,BRCA2 V211I,,0.0
1226,BRCA2 R2336P,,0.0
1227,BRCA2 R2336H,,0.0
1228,TP53 V143A,,0.0
1229,MGMT Underexpression,,65.0
1230,TERT Overexpression,,0.0
1231,RRM1 Underexpression,,100.0
1232,PTPRF EXPRESSION,,0.0
1233,AEBP1 Overexpression,,0.0
1234,RET C609Y,"There is some functional evidence that this variant leads to reduced RET activity (PMID: 9230192) and increased cell proliferation and resistance to apoptosis (PMID: 16715139). It has been widely reported in both familial and sporadic cases of multiple endocrine neoplasia type 2 with medullary thyroid cancers. Despite extensive WGS and Exome coverage for a combined total of ~150k alleles in the GNOMAD browser, this variant has never been observed.",20.0
1235,MDM2 Amplification,,0.0
1236,MDM4 EXPRESSION,,0.0
1237,KIT N822K,,29.5
1238,KIT C809G,,7.5
1239,KIT D820A,,7.5
1240,KIT D820G,,7.5
1241,KIT T670I,,21.5
1242,MDM4 Amplification,,0.0
1243,BRAF Amplification,,17.5
1244,MAP2K1 F53L,,0.0
1245,ROS1 G2032R,,2.5
1246,MAP2K1 K57N,,17.0
1247,CTAG1B Overexpression,,15.0
1248,CTAG2 Overexpression,,15.0
1249,ALK L1198F,,0.0
1250,SMO Amplification,,0.0
1251,v::NTRK3 Fusion,,105.0
1252,LMNA::NTRK1 Fusion,,115.0
1253,BRD4 Overexpression,,0.0
1254,NTRK1 Amplification,,17.5
1255,NTRK3 Amplification,,5.0
1257,CDK2 CYTOPLASMIC EXPRESSION,,0.0
1258,DCC EXPRESSION,,15.0
1259,CTNNB1 T41A,,55.0
1260,CTNNB1 S45F,,80.0
1261,CTNNB1 S45P,,35.0
1262,JAK3 M511I,,0.0
1263,JAK3 V722I,,0.0
1264,JAK3 S61C,,0.0
1265,JAK1 P429S,,0.0
1266,JAK1 W690*,,0.0
1267,ARID1A Loss,,7.0
1268,VHL W8* (c.24G>A),,2.5
1269,ALK F1245V,,7.5
1270,CTNNB1 Activating Mutation,,4.0
1272,BRAF T599dup,,0.0
1273,MERTK OVEREXPRESSION,,3.0
1274,TP53 CONSERVED DOMAIN MUT,"This conserved domain mutation variant covers mutations in regions of p53 reported to be highly conserved during evolution. These regions span codons 117-143 (region II), 171-181 (region III), 234-258 (region (IV), and 270-286 (region V). Region I covers approximately codons 10 through 25 but does not appear in all studies on conserved domain mutations. There is overlap with these regions and reported regions of hotspot p53 mutations, where it is observed that hotspots for detrimental mutation correspond to more highly evolutionary conserved regions. While there is agreement and overlap between different reports, the literature does not seem to indicate an exact consensus on these regions of human p53 at this time, but the four highly conserved regions are part of the DNA binding domain, and are reported to exist within codons 97 to 292.",15.0
1275,AKT3 Overexpression,,7.0
1276,FLT3 D835V,,19.0
1277,MYC Overexpression,,9.0
1278,ERBB2 L755P,,2.0
1279,ERBB2 T798M,,2.0
1280,TP53 Overexpression,,65.0
1281,TP53 ALTERATION,P53 ALTERATION is a bucket type variant used in studies which is constructed by combining all cases of p53 mutation together with p53 overexpression. This includes cases which have p53 mutation or overexpression alone or as well as cases where both occur in combination.,60.0
1282,ERBB2 L768S,,0.0
1283,ERBB2 L638S,,0.0
1284,ERBB2 V773,,0.0
1285,ERBB2 V773L,,0.0
1286,ERBB2 K753E,,0.0
1287,ERBB2 L753E,,0.0
1288,ERBB2 K755S,,0.0
1290,KIT V559,,0.0
1291,NRAS G13V,,0.0
1292,TP53 L3 Domain Mutation,,0.0
1293,GNAS R201H,,5.0
1294,ERBB2 NON-AMPLIFICATION,,0.0
1295,HRAS G12D,,0.0
1296,BRAF V600A,,0.0
1297,EGFR L747_E749DELLRE,,0.0
1298,EGFR E884K,,0.0
1299,HRAS Q61R,,0.0
1300,HRAS Q61K,,0.0
1301,HRAS G13R,,0.0
1302,HRAS G12V,,0.0
1303,KRAS G13R,,0.0
1304,KRAS G13S,,0.0
1305,FLT3 D835E,,0.0
1306,MAP2K2 F57C,,0.0
1307,PIK3CA D549N,,0.0
1308,FGFR3 K650E,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,10.0
1309,KIT P577_D579DELPYD,,0.0
1310,KIT D816G,,0.0
1311,KIT N822K,,0.0
1312,BRAF V600L,,0.0
1313,BRAF V600M,,0.0
1314,EGFR V689M,,0.0
1315,EGFR L692F,,0.0
1316,EGFR P699S,,0.0
1317,EGFR N700D,,0.0
1318,EGFR Q701X,,0.0
1319,EGFR L703V,,0.0
1320,EGFR E709K,,0.0
1321,EGFR E709Q,,0.0
1322,EGFR E709A,,0.0
1323,EGFR E709G,,0.0
1324,EGFR E709D,,0.0
1325,EGFR L718R,,0.0
1326,EGFR L718FS,,0.0
1327,EGFR G719R,,0.0
1328,EGFR G719D,,7.5
1329,EGFR G721D,,0.0
1330,EGFR L730F,,0.0
1331,EGFR W731R,,0.0
1332,EGFR W731X,,0.0
1333,EGFR P733L,,0.0
1334,EGFR E734K,,0.0
1335,EGFR G735S,,0.0
1336,EGFR I744T,,0.0
1337,EGFR I744M,,0.0
1338,EGFR K745R,,0.0
1339,EGFR E746K,,0.0
1340,EGFR E746_T751delELREAT,,0.0
1341,EGFR E746_S752>A,,0.0
1342,EGFR L747X,,0.0
1343,EGFR L747_T751>S,,0.0
1344,EGFR L747FS,,0.0
1345,EGFR A750P,,0.0
1346,EGFR S752Y,,0.0
1347,EGFR N756D,,0.0
1348,EGFR E758G,,0.0
1349,EGFR I759N,,0.0
1350,EGFR V765M,,0.0
1351,EGFR S768N,,0.0
1352,EGFR V769L,,0.0
1353,EGFR D770_N771insSVD,,0.0
1354,EGFR H773_V774insH,,0.0
1355,EGFR G810D,,0.0
1356,EGFR N826K,,0.0
1357,EGFR L828F,,0.0
1358,EGFR D830N,,0.0
1359,EGFR D830Y,,0.0
1360,EGFR R832C,,0.0
1361,EGFR R836C,,0.0
1362,EGFR R836L,,0.0
1363,EGFR D837N,,0.0
1364,EGFR D837Y,,0.0
1365,EGFR L838P,,7.5
1366,EGFR A839T,,0.0
1367,EGFR A839S,,0.0
1368,EGFR A840V,,0.0
1369,EGFR R841M,,0.0
1370,EGFR L844M,,0.0
1371,EGFR T847I,,5.0
1372,EGFR P848Q,,0.0
1373,EGFR P848L,,0.0
1374,EGFR V851I,,5.0
1375,EGFR T854A,,0.0
1376,EGFR D855G,,0.0
1377,EGFR G857R,,0.0
1378,EGFR G857V,,0.0
1379,EGFR L858M,,0.0
1380,EGFR L858FS,,0.0
1381,EGFR L858Q,,0.0
1382,EGFR A859T,,0.0
1383,EGFR A859V,,0.0
1384,EGFR L861M,,0.0
1385,EGFR L861R,,7.5
1386,EGFR G863D,,0.0
1387,EGFR A864V,,0.0
1388,EGFR E865K,,0.0
1389,EGFR E868K,,0.0
1390,EGFR E868G,,3.0
1391,EGFR Y869X,,0.0
1392,EGFR A871T,,0.0
1393,EGFR A871G,,0.0
1394,EGFR A871V,,0.0
1396,ABL1 L387M,,15.0
1397,HRAS G13V,,0.0
1398,KIT V459A,,0.0
1399,KRAS A59T,,0.0
1400,ALK F1174C,,0.0
1401,ALK T1151M,,0.0
1402,ABL1 T277A,,0.0
1403,ABL1 S438C,,0.0
1404,ABL1 E450G,,0.0
1405,KIT P551_E554delPMYE,,6.0
1406,KIT W557_V559insC,,0.0
1407,PIK3CA S158L,,7.5
1408,PIK3CA E81K,,5.0
1409,PIK3CA G1049A,,0.0
1410,EGFR G666V,,0.0
1411,FBXW7 R505C,,0.0
1412,FBXW7 R505H,,0.0
1413,ALK F1174V,,0.0
1414,ABL1 L298V,,2.5
1415,ABL1 F311I,,0.0
1416,ABL1 L364I,,0.0
1417,ABL1 E453Q,,5.0
1418,ARID1A Q456*,,0.0
1419,EGFR S768_D770dup,,7.5
1420,EGFR D770_N771insG,,7.5
1421,EGFR H773_V774insNPH,,7.5
1422,EGFR D770_N771insGL,,10.0
1423,EGFR A763_Y764insFQEA,,5.0
1424,EGFR EGFRVIII,,0.0
1425,KRAS G13V,,5.0
1426,PDGFRA D842_M844del,,0.0
1427,EGFR L747FS*10,,0.0
1428,MTOR Q2223K,,0.0
1429,CDKN2A W110*,,0.0
1430,CDKN2A A20P,,0.0
1432,ABL1 M343T,,2.0
1433,ABL1 F317V,,0.0
1434,ABL1 E279K,,7.5
1435,ABL1 Q300R,,5.0
1436,ABL1 F311L,,7.0
1437,ABL1 N331S,,2.5
1438,ABL1 L364P,,2.5
1439,ABL1 H396P,,18.0
1441,ABL1 I432T,,0.0
1442,ABL1 E450V,,5.0
1443,ABL1 E453K,,2.5
1444,ABL1 E453A,,5.0
1445,ABL1 P480A,,2.5
1446,ABL1 F486Y,,0.0
1447,PDGFRA W559_R560DELWR,,0.0
1448,PDGFRA L579M,,0.0
1449,KIT Q556_I571DEL,,0.0
1450,KIT Y553_W557DELYEVQW,,0.0
1451,KIT V555_I571DEL,,0.0
1452,FLT3 E611_F612INS25,,0.0
1453,KIT K550_W557delKPMYEVQW,,0.0
1454,KIT T417_D419DELTYDINSI,,0.0
1455,KIT D579_H580insIDPTQLPYD,,0.0
1456,KIT Y570_L576DEL,,0.0
1457,KIT K558delinsNP,,3.0
1458,KIT V560_L576DEL,,6.0
1459,KIT V569_L576DEL,,0.0
1460,MAPK1 E278E,,0.0
1461,ALK L1196Q,,0.0
1462,ALK L1152P,,0.0
1463,BRCA1 W1815X,,2.0
1464,ALK L1198P,,0.0
1465,ERBB2 G776INSV_G/C,,0.0
1466,KIT A502_Y503insAY,,7.0
1467,KIT D816E,,8.0
1468,SMO D473G,,0.0
1469,SMO D473Y,,0.0
1470,SMO S278I,,0.0
1471,SMO W281C,,0.0
1472,SMO Q477E,,0.0
1473,EGFR L747_A750INSP,,0.0
1474,EGFR D770_N771insGT,,0.0
1475,EGFR V774_C775insHV,,0.0
1476,EGFR V769_D770INSASV,,0.0
1477,EGFR D770_N771insNPG,,3.0
1478,SMO L412F,,0.0
1479,EGFR W731L,,3.0
1480,EGFR E734Q,,3.0
1481,EGFR T785A,,3.0
1482,EGFR C797Y,,3.0
1483,EGFR Y801H,,3.0
1484,SMO V321M,,0.0
1485,EGFR E709_T710>D,,0.0
1486,EGFR V769A,,0.0
1487,EGFR A767_V769dupASV,,7.5
1488,EGFR L747_S752delinsQ,,7.5
1489,EGFR N771>GY,,0.0
1490,EGFR P546S,,0.0
1491,SMO W281L,,0.0
1492,SMO G497W,,0.0
1493,SMO I408V,,0.0
1494,SMO C469Y,,0.0
1495,SMO T241M,,0.0
1496,SMO A459V,,0.0
1497,SMO S533N,,0.0
1498,PTCH1 W170X,,0.0
1499,PTCH1 W712X,,0.0
1500,PTCH1 Q787X,,0.0
1501,PTCH1 Q17X,,0.0
1502,PIK3CA R1023Q,,0.0
1503,ABL1 H201L,,0.0
1504,ABL1 Y232S,,0.0
1505,ABL1 M237V,,0.0
1506,ABL1 I242T,,0.0
1507,ABL1 G250V,,0.0
1508,ABL1 Q252R,,0.0
1509,ABL1 E258D,,0.0
1510,ABL1 L273M,,0.0
1511,ABL1 E281K,,0.0
1512,ABL1 V289I,,0.0
1513,ABL1 Y342H,,0.0
1514,ABL1 D363Y,,0.0
1515,ABL1 A365V,,0.0
1516,ABL1 A366G,,0.0
1517,ABL1 V379I,,19.5
1518,ABL1 M388L,,0.0
1519,ABL1 Y393C,,0.0
1521,ABL1 S417Y,,5.0
1522,ABL1 I418V,,0.0
1523,ABL1 I418S,,0.0
1524,ABL1 P441L,,0.0
1525,ABL1 E450K,,0.0
1526,ABL1 E450Q,,0.0
1527,ABL1 E450A,,0.0
1528,ABL1 E453V,,0.0
1529,ABL1 E459G,,0.0
1530,ABL1 M472I,,0.0
1531,ABL1 P480L,,0.0
1532,ABL1 G514S,,0.0
1533,ABL1 F317I,,3.0
1534,MAP2K1 E203K,,0.0
1535,BRAF G596R,,6.0
1536,NF1 R163X,,0.0
1537,FLT3 G846S,,0.0
1538,FLT3 Y591_V592INSVDFREYE,,0.0
1539,FLT3 E588_Y589INSKYFYVDFRE,,0.0
1540,FLT3 V592_D593INSDFREY,,0.0
1541,EGFR E746_S752>I,,0.0
1542,EGFR E746_T751>V,,0.0
1543,EGFR E746_A750>IP,,0.0
1544,EGFR E746_T751>IP,,0.0
1545,EGFR E746_P753>VS,,0.0
1546,EGFR K745_E749delKELRE,,0.0
1547,ABL1 C475V,,5.0
1548,ABL1 N336S,,5.0
1549,ROS1 D2033N,,0.0
1550,POLD1 Y956N,,0.0
1551,SCN8A Q225X,,0.0
1552,PXDNL P1460T,,0.0
1553,PAPPA2 Y1520X,,0.0
1554,POLE4 A59E,,0.0
1555,POLD1 C284Y,,0.0
1556,POLD1 E374K,,0.0
1557,MET D1010Y,,0.0
1558,BRAF G596V,,0.0
1559,MET D1010N,,0.0
1560,PIK3R2 N561D,,3.0
1561,PIK3CA D350G,,2.0
1562,NRAS Q179X,,0.0
1564,ABL1 R351W,,9.0
1565,ABL1 G340L,,3.0
1566,BRAF V600_K601DELINSD,,0.0
1567,KIT S628N,,9.5
1568,MET D1010H,,0.0
1569,ALK R1192P,,0.0
1570,EGFR N771delinsVH,,0.0
1571,BRAF DELNVTAP,,0.0
1572,EGFR M766_A767insAI,,0.0
1573,EGFR Y764_V765insHH,,0.0
1574,EGFR D770_N771insGY,,0.0
1575,EGFR P772_H773insYNP,,7.5
1576,EGFR P772_V774insPHV,,7.5
1577,LYN Y508F,,0.0
1578,ROS1 S1986Y,,0.0
1579,ROS1 S1986F,,0.0
1580,EGFR Y69FS*11,,0.0
1581,ERBB4 G1109C,,0.0
1582,ESR1 E380Q,,0.0
1583,ESR1 L536R,,0.0
1584,FBXW7 S668FS*39,,0.0
1585,FBXW7 L403FS*34,,0.0
1586,FBXW7 G579W,,0.0
1587,FBXW7 R658Q,,0.0
1588,RAF1 R391W,,3.0
1589,JAK2 Splice Site (c.1641+2T>G),,7.5
1590,ARID1A P1175FS*5,,2.0
1591,ALK R214H,,0.0
1592,PSMD4 Amplification,,0.0
1593,CDK6 Amplification,,0.0
1594,ACVR1 G328V,,35.0
1595,v::RET Fusion,,192.5
1596,RET V804L,,0.0
1597,RET G810A,,0.0
1598,RET Mutation,,95.0
1599,FGFR3::v Fusion,,7.5
1600,FGFR3 G691R,,0.0
1601,CHEK1 Overexpression,,4.0
1602,VHL E12D (c.36G>C),,0.0
1603,TP53 R158H,,9.0
1604,TP53 R249S,,7.0
1605,TP53 R280K,,4.0
1606,TP53 R280T,,4.0
1607,TP53 R158L,,4.0
1608,RET C634R,,0.0
1609,VHL E46* (c.136G>T),,10.0
1610,VHL E52K (c.154G>A),,15.0
1611,VHL E52fs* (c.156G>T),,0.0
1612,VHL E55* (c.163G>T),,7.5
1613,VHL G39fs (c.114del),,0.0
1614,VHL L158P (c.473T>C),,30.0
1615,VHL R167Q (c.500G>A),R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2Œ±. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2Œ± and suprressed tumorgenesis.,110.0
1616,VHL S183C (c.548delC),,0.0
1617,VHL Y98H (c.292T>C),,67.5
1618,VHL H115Q (c.345C>A),,5.0
1619,VHL F119L (c.357C>G),,22.5
1620,VHL A149T (c.445G>A),,5.0
1621,VHL T157I (c.470C>T),,32.5
1622,VHL R161Q (c.482G>A),,72.5
1623,VHL R167W (c.499C>T),,112.5
1624,VHL L178P (c.533T>C),,50.0
1625,VHL F76I (c.226T>A),,0.0
1626,VHL V62fs (c.180del),,0.0
1628,VHL Q73* (c.217C>T),,27.5
1630,VHL N78H (c.232A>C),,32.5
1631,VHL N78S (c.233A>G),,72.5
1632,VHL N78T (c.233A>C),,5.0
1633,VHL S80I (c.239G>T),,15.0
1634,VHL P86fs (c.254_255insC),,10.0
1635,VHL P86A (c.256C>G),,5.0
1636,VHL P86L (c.257C>T),,27.5
1637,VHL W88R (c.262T>A),,10.0
1638,VHL S111FS (c.331delA),,10.0
1639,VHL S111N (c.332G>A),,12.5
1640,VHL S111R (c.333C>G),,15.0
1641,EGFR Gain-of-function,,20.0
1642,VHL Y112* (c.336C>A),,10.0
1643,VHL W117C (c.351G>T),,22.5
1644,VHL L129Q (c.386insAGA),,10.0
1645,VHL L135* (c.404T>A),,17.5
1646,VHL N150fs (c.449del),There are no similar variants in ClinVar with this exact genomic location.,7.5
1647,VHL P154fs (c.462delA),,7.5
1648,VHL C162R (c.484T>C),,22.5
1649,VHL C162F (c.485G>T),,22.5
1650,VHL C162W (c.486C>G),,32.5
1651,VHL V166D (c.497T>A),,10.0
1652,VHL L184P (c.551T>C),,32.5
1653,VHL E186* (c.556G>T),,15.0
1654,VHL E186K (c.556G>A),,5.0
1655,VHL R167fs (c.502insTTGTCCGT),,0.0
1656,VHL R176fs (c.526del),,17.5
1657,VHL Q145H (c.435_436delGC),,0.0
1658,VHL P154L (c.461C>T),,25.0
1659,VHL L158fs (c.471dupT),,5.0
1660,VHL S183* (c.548C>A),,15.0
1661,VHL A56fs (c.166_167insA),,5.0
1663,VHL S65W (c.194C>G),,105.0
1664,VHL S65L (c.194C>T),,72.5
1665,VHL V66* (c.196delG),,0.0
1667,VHL R79P (c.236G>C),,7.5
1668,VHL S80R (c.240T>G),,12.5
1669,VHL L89P (c.266T>C),,27.5
1670,VHL E94* (c.280G>T),,40.0
1671,VHL P103FS (c.309_310delTG),,7.5
1672,VHL R113* (c.337C>T),,52.5
1673,VHL G114C (c.340G>T),,12.5
1674,VHL L118P (c.353T>C),,45.0
1676,VHL N131fs (c.390_391del),,15.0
1677,VHL F136S (c.407T>C),,47.5
1678,VHL L153fs (c.457delC),There are two similar variants in ClinVar at this exact genomic location with ClinVar IDs: 526670 and 486714.,17.5
1679,VHL L158V (c.472C>G),,22.5
1680,VHL R161* (c.481C>T),,85.0
1681,VHL R167G (c.499C>G),,0.0
1682,VHL V170F (c.508G>T),,7.5
1683,VHL I180V (c.538A>G),,7.5
1684,VHL L184R (c.551T>G),,7.5
1685,VHL Y185* (c.555C>G),,15.0
1686,VHL Q195* (c.583C>T),,60.0
1687,VHL S65* (c.194C>A),,15.0
1688,VHL G93fs (c.278delG),,0.0
1689,VHL D121G (c.362A>G),,17.5
1690,VHL F136C (c.407T>G),,12.5
1691,VHL V84L (c.250G>T),,10.0
1692,VHL S72fs (c.214del),,10.0
1694,VHL Q96P (c.287A>C),,0.0
1696,VHL L116V (c.346C>G),,10.0
1697,VHL W117* (c.351G>A),,0.0
1698,VHL L118R (c.353T>G),,0.0
1699,VHL N141fs (c.422del),,0.0
1700,VHL C162Y (c.485G>A),,27.5
1701,VHL V166F (c.496G>T),,17.5
1702,VHL V170D (c.509T>A),,40.0
1703,VHL R177* (c.529A>T),,7.5
1704,VHL L188fs (c.563del),,0.0
1705,VHL E186del (c.558_560delAGA),,0.0
1706,POLE P286R,,15.0
1707,POLE V411L,,15.0
1708,POLE S459F,,15.0
1710,VHL E70* (c.208G>T),,27.5
1711,VHL F76S (c.227T>C),,7.5
1712,VHL L188V (c.562C>G),,15.0
1713,VHL P81S (c.241C>T),,20.0
1714,VHL L101G (c.301_302delinsGG),Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.302T>C (p.Leu101Pro; L101P) (https://www.ncbi.nlm.nih.gov/clinvar/variation/480963/),5.0
1715,VHL T105P (c.313A>C),,12.5
1716,VHL R107P (c.320G>C),,7.5
1717,VHL L118fs (c.352_353insA),,7.5
1718,VHL N167T (c.392A>C),,0.0
1719,VHL T133fs (c.397del),,15.0
1720,VHL D143fs (c.430delG),,7.5
1721,VHL Q164* (c.490C>T),,30.0
1722,VHL Y175D (c.523T>G),,7.5
1723,VHL V181fs (c.540_543del),,7.5
1724,VHL Q96* (c.286C>T),,22.5
1725,VHL P86R (c.257C>G),,17.5
1726,VHL G144* (c.430G>T),,7.5
1727,VHL L128F (c.381_382delinsTT),,0.0
1728,VHL L188P (c.563T>C),,15.0
1729,VHL S111C (c.330_331delinsTT),Note that there is a different variant reported at this amino acid position of VHL in ClinVar. Clinvar ID: 565557,7.5
1731,VHL R161P (c.482G>C),,7.5
1732,VHL Q164R (c.491A>G),,20.0
1733,VHL G114R (c.340G>C),,12.5
1734,VHL G93D (c.278G>A),,0.0
1735,VHL G93S (c.277G>A),,22.5
1736,VHL L101R (c.302T>G),,0.0
1737,VHL L188Q (c.563T>A),,10.0
1738,VHL K159E (c.475A>G),,0.0
1739,EGFR Rare Exon 18-21 Mutation,"Rare exon 18-21 mutations in EGFR consist of all EGFR mutations excluding sensitizing L858R substitutions and exon 19 deletions, as well as resistance mutation T790M.",30.0
1740,VHL P192fs (c.575delC),,0.0
1741,VHL Y112H (c.334T>C),,10.0
1742,EGFR L861,,15.0
1743,VHL R64P (c.191G>C),,7.5
1744,VHL N131fs (c.393_394delinsA),,0.0
1745,VHL E189fs (c.565del),,15.0
1747,VHL I151T (c.452T>C),,25.0
1748,VHL K159fs (c.473dup),,7.5
1749,VHL S68P (c.202T>C),,7.5
1750,VHL S80N (c.239G>A),,25.0
1751,VHL V130F (c.388G>T),,0.0
1752,CIC Loss,,0.0
1753,ETV1 Overexpression,,0.0
1754,ETV5 Overexpression,,0.0
1755,ATXN1L Loss,,0.0
1756,ATM Loss,,0.0
1757,ATM F858L,,0.0
1759,VHL Q145* (c.433C>T),,10.0
1760,VHL E134* (c.400G>T),,0.0
1761,VHL H115P (c.344A>C),,7.5
1762,VHL L128R (c.383T>G),,17.5
1763,VHL L169P (c.506T>C),,17.5
1764,VHL L178R (c.533T>G),,15.0
1765,VHL M54fs (c.161dup),,17.5
1766,EGFR G719D,,0.0
1767,EGFR L747P,,5.0
1768,EGFR V774A,,7.5
1769,VHL F91* (c.272_273delinsAA),,10.0
1770,EGFR V774M,,5.0
1771,EGFR K806E,,5.0
1772,EGFR N826Y,,5.0
1773,EGFR V834I,,7.5
1774,EGFR L838P,,0.0
1775,EGFR N842S,,5.0
1776,EGFR T847I,,0.0
1777,EGFR V851I,,0.0
1778,VHL P86S (c.256C>T),,42.5
1779,VHL S65P (c.193T>C),,10.0
1780,VHL S72P (c.214T>C),,10.0
1781,VHL T124fs (c.369del),,0.0
1782,VHL L135fs (c.404del),,7.5
1783,VHL R177fs (c.528del),,15.0
1784,VHL W88* (c.264G>A),,7.5
1785,VHL V155E (c.464T>A),,10.0
1786,VHL V170A (c.509T>C),,0.0
1788,VHL F76fs (c.223_224insT),,7.5
1789,VHL K196* (c.586A>T),,5.0
1790,VHL R120G (c.358A>G),,22.5
1791,VHL R161G (c.481C>G),,7.5
1792,VHL R167L (c.500G>T),,7.5
1793,VHL N141fs (c.422_440del),,0.0
1794,VHL D126FS (c.375_376insC),,5.0
1795,VHL E160fs (c.479_480delAG),,10.0
1796,VHL G93R (c.277G>C),,10.0
1797,VHL H115Y (c.343C>T),,10.0
1798,VHL I109FS (c.326delT),,0.0
1799,VHL L153P (c.458T>C),,7.5
1800,VHL L188R (c.563T>G),,7.5
1801,VHL L85fs (c.253_254ins38),,0.0
1803,VHL P103A (c.307C>G),,0.0
1804,VHL P138T (c.412C>A),,10.0
1805,VHL P59fs (c.176delC),,10.0
1806,VHL P59S (c.175C>T),,0.0
1807,VHL P61= (c.183C>G),,0.0
1808,VHL Y175* (c.525C>A),"Note that there is a different variant reported at this amino acid position of VHL in ClinVar, which produces the same protein change. NM_000551.3(VHL):c.525C>G (p.Tyr175Ter), https://www-ncbi-nlm-nih-gov/clinvar/variation/182974/",5.0
1809,VHL Y98C  (c.293A>G),,5.0
1810,VHL V155G (c.464T>G),,2.5
1811,VHL V170G (c.509T>G),,15.0
1812,VHL V66G (c.197T>G),,0.0
1813,VHL V84L (c.250G>C),,0.0
1814,VHL Exon 2 Deletion,,7.5
1815,VHL Exon 3 Deletion,,25.0
1816,VHL EXON 2-3 DELETION,,7.5
1817,VHL S168T (c.503G>C),,0.0
1818,VHL P86S (c.257C>T),,0.0
1819,VHL Q164H (c.492G>C),,0.0
1820,VHL L63P (c.188T>C),,0.0
1821,VHL F119fs (c.354_355del),,0.0
1822,VHL Y156C (c.467A>G),,27.5
1823,VHL Null (Partial deletion of 4.6 Kb),,0.0
1824,VHL R69fs (c.204insG),,5.0
1825,VHL G144fs (c.432insG),,5.0
1827,VHL Null (Partial deletion of Exon 2),,0.0
1828,VHL Null (Partial deletion of Exon 3),,0.0
1829,VHL N131K (c.393C>A),,10.0
1830,VHL T105fs (c.315insAC),,0.0
1831,VHL P71fs (c.211insT),,7.5
1832,VHL E70K (c.208G>A),"The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.",37.5
1833,VHL H115Q (c.345C>G),,22.5
1834,VHL H191FS (c.571delC),,7.5
1835,VHL Null (c.1-?_463+?del),,0.0
1836,VHL L140fs (c.417_418delTC),,7.5
1838,VHL P154= (c.462A>C),Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.462A>G (p.Pro154=).(https://www.ncbi.nlm.nih.gov/clinvar/variation/411977/),15.0
1839,VHL S80R (c.238A>C),,32.5
1840,VHL R60FS (c.179delG),,7.5
1841,VHL I109TfsX50 (c.326delT),,0.0
1842,VHL W88S (c.263G>C),,12.5
1843,VHL Y156D (c.466T>G),,17.5
1844,VHL Y156* (c.468T>G),,7.5
1845,VHL Y175* (c.525C>G),,30.0
1846,VHL V130L (c.388G>C),,12.5
1847,VHL Exon 2-3 Deletion,,0.0
1848,VHL Splice Site (c.463+1G>A),,0.0
1850,VHL Splice Site (c.464-1G>A),,5.0
1851,VHL R167fsX4 (c.499_504delinsT),,0.0
1852,VHL E173* (c.517G>T),,0.0
1853,VHL V194fs (c.581_582del),,7.5
1854,VHL Null (c.-678-?_340+?del),,0.0
1855,VHL Null (c.-678-?_642+?del),,0.0
1856,VHL R82P (c.245G>C),,17.5
1857,VHL N100fsX131 (c.298_299InsA),,0.0
1858,SUFU Deletion,,0.0
1859,PTCH1 Deletion,,0.0
1860,VHL Splicing alteration (c.553+1G>A),,0.0
1861,VHL Splicing alteration (c.553+5G>C),,0.0
1862,VHL *214L (c.641G>T),,10.0
1863,VHL *214W (c.642A>G),,5.0
1864,VHL *214C (c.642A>T),,5.0
1865,VHL G144fs (c.431delG),,0.0
1866,VHL Splice Site (c.464-1G>T),"There are three similar variants in ClinVar with this exact genomic position with ClinVar IDs: 223221, 223220, and 43603 of which only 223221 is an exact match (NM_000551.3:c.464-1G>T).",12.5
1868,VHL Splice Site (c.464-2A>T),,5.0
1870,VHL Q132* (c.394C>T),,10.0
1872,VHL L129fs (c.384delT),,7.5
1873,VHL L178Q (c.533T>A),,12.5
1874,VHL Splice Site (c.463+1G>C),,5.0
1875,VHL V74G (c.221T>G),,15.0
1876,VHL H115R (c.344A>G),,10.0
1877,VHL N131S (c.392A>G),,7.5
1878,VHL Q73FS (c.215delC),,0.0
1879,VHL S111R (c.333C>A),,0.0
1880,VHL S168FS (c.503delG),,0.0
1881,VHL P172fs  (c.516delT),,0.0
1882,VHL Y112N (c.334T>A),,0.0
1883,VHL R107G  (c.319C>G),,7.5
1884,VHL G93C (c.277G>T),,7.5
1885,VHL G93V (c.278G>T),,7.5
1886,VHL L198Q  (c.593T>A),,12.5
1887,VHL S65A (c.193T>G),,7.5
1888,VHL S68W (c.203C>G),One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 625222 C>T).,7.5
1889,VHL Y156N (c.466T>A),,7.5
1890,VHL P61fs (c.183insC),,7.5
1892,VHL Null (Complete deletion),,0.0
1893,VHL Splice Site (c.341-1G>A),,0.0
1895,VHL Splicing alteration (c.464-1G>C),"There are three variants in ClinVar at this exact position: (ClinVar ID: 223220, ClinVar ID:223221, and ClinVar ID:43603). ClinVar ID: 223220 is an exact match.",0.0
1896,VHL L85P (c.254T>C),,5.0
1897,VHL R108dup (c.322_324dup),,5.0
1899,VHL A149fs (c.449del14-nt),,5.0
1900,VHL 3'UTR alteration (c.639+10C>G),,5.0
1902,VHL G114S (c.340G>A),,5.0
1903,VHL W117fs (c.349dup),,5.0
1904,VHL A122I (c.364_365GC>AT),,12.5
1905,VHL N150fs (c.445_458del),,5.0
1906,VHL I151M (c.453C>G),,5.0
1907,VHL Splicing alteration (c.462-2A>G),,0.0
1909,VHL L163H (c.488T>A),,5.0
1911,VHL C162fs (c.483del),,5.0
1912,VHL Null (Partial deletion of Exons 2 & 3),,7.5
1913,VHL N78I (c.233A>T),,5.0
1914,VHL I147V (c.439A>G),,0.0
1915,VHL W88FS (c.263_265delGGCinsTT),,5.0
1916,VHL K159fs (c.477_478insCA),,5.0
1917,VHL Q73FS (c.217delC),,5.0
1918,VHL A149fs (c.445delG),,5.0
1919,VHL G104A (c.311G>C),,15.0
1920,VHL R107H (c.320G>A),,10.0
1921,VHL S111C (c.331A>T),,17.5
1922,VHL V155L (c.463G>C),,10.0
1923,CTNNB1 Exon 3 Deletion,,0.0
1924,VHL Splice Site (c.463+1G>T),Two similar variants at this exact genomic location are reported in ClinVar (ClinVar ID 526679 G>A and ClinVar ID 223217 G>C).,0.0
1926,DICER1 E1705K,,20.0
1927,DICER1 D1709N,,37.5
1928,DICER1 E1813Q,,22.5
1929,VHL D126Y (c.376G>T),,0.0
1930,VHL T124I (c.371C>T),,0.0
1931,VHL P146fs (c.437del),,7.5
1932,VHL W88R (c.262T>C),,7.5
1933,VHL H115fs (c.344del),,7.5
1934,VHL P102fs (c.305delC),,7.5
1935,VHL G144R (c.430G>A),,0.0
1936,VHL H125P (c.374A>C),,0.0
1937,ACVR1 Gain-of-Function,,15.0
1938,VHL Q164H (c.491G>C),,0.0
1939,STK11 F354L,,0.0
1940,VHL P192S (c.574C>T),,0.0
1941,VHL Splice Region (c.463+3A>G),There is an identical variant match in ClinVar at this exact genomic position with ClinVar ID: 428796 (A>G).,0.0
1942,VHL Y175N (c.523T>A),,7.5
1943,VHL Y175C (c.524A>G),,7.5
1944,VHL V87A (c.260T>C),,0.0
1945,VHL P97L (c.290C>T),,0.0
1946,VHL L184H (c.551T>A),,0.0
1947,VHL R69fs (c.204insG),,0.0
1949,VHL G106fs (c.316insA),,0.0
1950,VHL Splice Site (c.340+1G>T),"Two very similar variants are reported in ClinVar at this exact genomic position: (ClinVar ID 223190, G>A) and (ClinVar ID 182973 G>C).",0.0
1951,VHL Splice Site (c.463+2T>C),,27.5
1952,VHL V155M (c.463G>A),,0.0
1953,VHL Splice Site (c.464-1G>C),"There are three variants in ClinVar at this exact position: (ClinVar ID: 223220, ClinVar ID:223221, and ClinVar ID:43603). ClinVar ID: 223220 is an exact match.",5.0
1954,VHL Splice Site (c.464-2A>G),,15.0
1955,VHL Q164L (c.491A>T),,7.5
1958,VHL Null (Partial deletion of Exon 1),,0.0
1959,VHL Null (Partial deletion of Exons 1 & 2),,0.0
1960,VHL P81L (c.242C>T),,0.0
1961,VHL T152I (c.455C>T),,0.0
1963,VHL L63fs (c.189_192delGCGC),,0.0
1964,VHL F76del (c.227_229del),Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).,120.0
1965,VHL R82_V84del (c.243_251del),,17.5
1966,VHL P40fs (c.118ins),,7.5
1967,VHL T152fs (c.455insA),,15.0
1968,VHL T157fs (c.472ins),,7.5
1969,VHL Splice Site (c.464-2A>C),,0.0
1970,VHL T157fs (c.472ins1-nt),,0.0
1971,VHL I151fs (c.452insA),,0.0
1972,VHL F158ins (c.472insTTT),,0.0
1973,VHL G93_Y98del (c.275_292del),,7.5
1974,VHL E160fs (c.477del),,7.5
1975,VHL V66del (c.197_220del),,5.0
1976,VHL S183fs (c.548delC),,0.0
1977,VHL V84M (c.250G>A),,5.0
1979,VHL Null (Partial deletion),,0.0
1980,VHL Splice Region (c.340+5G>C),,5.0
1981,VHL D197N (c.589G>A),,0.0
1982,VHL S80G (c.238A>G),,0.0
1983,VHL F76L (c.228C>G),,0.0
1984,ARID1A Underexpression,,34.0
1986,VHL R82L (c.245G>T),,0.0
1988,VHL N78D (c.232A>G),,0.0
1989,VHL N78Y (c.232A>T),,0.0
1990,VHL Splice Site (c.340+1G>A),,50.0
1991,VHL Y185* (c.555C>A),,0.0
1993,VHL P95R (c.284C>G),,0.0
1994,VHL P103L (c.308C>T),,0.0
1995,VHL F119S (c.356T>C),,0.0
1996,VHL P138L (c.413C>T),,0.0
1997,VHL P61fs (c.181delCCGT),,0.0
1998,VHL S68* (c.203C>A),,0.0
1999,VHL C77del (c.229_231delTGC),,0.0
2000,VHL W88C (c.264G>C),,0.0
2001,VHL Q132P (c.395A>C),,17.5
2002,VHL D198fs (c.592_593delCT),,0.0
2003,VHL E94FS (c.279delC),,5.0
2004,VHL P97= (c.291C>G),,0.0
2005,VHL G114dup (c.342dupGGT),,5.0
2006,VHL S65FS (c.194delC),,7.5
2007,VHL Q73fs (c.214insGCCC),,7.5
2008,VHL C77fs (c.228dup),,17.5
2009,VHL Splice Site (c.341-2A>C),,12.5
2010,VHL Intronic deletion (c.341-13delCGTTTCCAACAATTTCTCGGTGT),,5.0
2011,VHL G123fs (c.369_375delGACACAC),,2.5
2012,VHL H125fs (c.374insA),,7.5
2013,VHL K159fs (c.474_476delGAAinsC),,7.5
2014,VHL Y175* (c.525delC),,7.5
2015,VHL L188fs (c.562delC),,10.0
2016,VHL K196fs (c.584_585delAG),,10.0
2017,VHL D197FS (c.589delG),,7.5
2018,VHL T202fs (c.606insA),,7.5
2019,VHL R113FS (c.337delC),,7.5
2020,VHL A56fs (c.166dup),,7.5
2021,VHL P61FS (c.182_185delCCGT),,10.0
2022,VHL Splice Region (c.463+3A>T),One similar variant at this exact genomic location has been entered into ClinVar (ClinVar ID: 428796 A>G).,0.0
2023,VHL K196E (c.586A>G),,0.0
2024,VHL R161= (c.481C>A),,5.0
2025,VHL N90I (c.269A>T),,0.0
2026,VHL I151F (c.451A>T),,5.0
2027,VHL W88* (c.263G>A),,7.5
2028,VHL 3'UTR alteration (c.*70C>A),,5.0
2029,VHL G114fs (c.326_339dupTCCACAGCTACCGA),,0.0
2030,VHL D121H (c.361G>C),,0.0
2031,VHL Q145Tfs* (c.432_433insA),,0.0
2032,VHL S111R (c.331A>C),,0.0
2033,VHL L128P (c.383T>C),,0.0
2034,VHL F76fs (c.222_225dup),,0.0
2035,AR V9 EXPRESSION,,0.0
2036,VHL Y98FS (c.291delC),,10.0
2037,VHL S183L (c.548C>T),,0.0
2038,VHL N150S (c.449A>G),,5.0
2039,CTLA4 EXPRESSION,,0.0
2040,CX3CL1 Underexpression,,0.0
2041,FANCA S1088F,,0.0
2042,SLC3A2::NRG1 Fusion,,15.0
2043,FGFR4 Overexpression,,0.0
2044,RAD50 L1237F,,10.0
2045,BTK MUTATION,,20.0
2046,PLCG2 MUTATION,,25.0
2047,TSC2 Loss-of-function,,0.0
2048,MTOR Gain-of-Function,,0.0
2049,VHL E94K (c.280G>A),,0.0
2050,EGFR Wildtype,,20.0
2051,VHL R79C (c.235C>T),,0.0
2052,VHL Y175C (c.524A>G),,0.0
2053,VHL M54I (c.162G>C),,0.0
2054,ATP1B1::NRG1 Fusion,,15.0
2055,SDC4::NRG1 Fusion,,7.5
2056,TSPYL1 P62S,,0.0
2057,VHL R177ins (c.531insCTGAGAGTAAAGCCTGAA),,5.0
2058,VHL Null (Large deletion),,20.0
2059,ERRFI1 E384Ter,,0.0
2060,VHL Partial deletion of 0.7 Kb,,0.0
2061,VHL Partial deletion of 1 Kb,,0.0
2062,VHL Partial deletion of 1.2 Kb,,0.0
2063,VHL Partial deletion of 1.5 Kb,,0.0
2064,VHL Partial deletion of 11 Kb,,0.0
2065,VHL Partial deletion of 12 Kb,,0.0
2066,VHL Partial deletion of 3.5 Kb,,0.0
2067,VHL Partial deletion of 3 Kb,,0.0
2068,VHL Partial deletion of 7.5 Kb,,0.0
2069,VHL Partial deletion of 7 Kb,,0.0
2070,VHL Partial deletion of 8.2 Kb,,0.0
2071,DICER1 D1709G,,10.0
2072,DICER1 D1709E,,7.5
2073,DICER1 D1810H,,0.0
2074,DICER1 D1810Y,,0.0
2075,DICER1 D1810N,,0.0
2076,DICER1 E1813G,,0.0
2077,DICER1 E1813K,,0.0
2078,FGFR2::v Fusion,,95.0
2079,EGFR::RAD51 Fusion,,30.0
2080,KDR Overexpression,,0.0
2081,FLT4 Amplification,,0.0
2082,FGFR2 FGFR2 mutations,,0.0
2083,PDCD1LG2 EXPRESSION,,0.0
2084,LAG3 EXPRESSION,,0.0
2085,DLL3 Expression,,0.0
2086,KMT2E::ASNS Fusion,,0.0
2087,BAP1 ALTERNATIVE TRANSCRIPT (ATI),,3.0
2088,BAP1 Loss,,0.0
2089,EGFR M766_A767insASV,,7.5
2090,EGFR D770delinsGY,,10.0
2091,EGFR delL747_P753insS,,0.0
2092,EGFR E746_A750del,,0.0
2093,EGFR P772_H773insH,,0.0
2094,STRN::ALK Fusion,,7.5
2095,BARD1 Loss-of-function,,3.0
2097,BRAF G496A,,5.0
2098,BRAF G466V,,14.0
2099,BRAF G606E,,5.0
2100,BRAF P731T,,5.0
2101,BRAF intron 9 rearrangement,,20.0
2102,BRAF intron 10 rearrangement,,20.0
2103,MACF1::BRAF Fusion,,5.0
2105,CUX1::BRAF Fusion,,5.0
2106,ASS1 Loss,,6.0
2107,FLCN Mutation,,0.0
2108,FLCN Loss,,0.0
2109,BCL2 Mutation,,15.0
2110,KMT2D Loss,,0.0
2111,RASA1 Loss-of-function,,3.0
2112,ATM Loss-of-function,,0.0
2113,KDM5C Mutation,,0.0
2114,BARD1 ISOFORM EXPRESSION,,0.0
2115,TPT1 Overexpression,,0.0
2116,TLK2 Amplification,,3.0
2117,VHL R82C (c.244C>T),,0.0
2118,VHL W88L (c.263G>T),,0.0
2119,VHL S111G (c.331A>G),,0.0
2120,VHL I151M (c.453C>G),,0.0
2121,VHL E160* (c.478G>T),,0.0
2122,VHL I180N (c.539T>A),,0.0
2123,VHL L198R (c.593T>G),,0.0
2124,VHL T100A (c.298A>G),,0.0
2125,VHL W117* (c.350G>A),,0.0
2126,VHL I151S (c.452T>G),,0.0
2127,VHL Q96fs (c.286insT),,0.0
2128,VHL G104fs (c.309delT),,0.0
2129,VHL N174fs (c.520delA),,0.0
2130,DBI PROMOTER DEMETHYLATION,,0.0
2131,EGFR A702S,,0.0
2133,EGFR Exon 18 deletion,,0.0
2135,EGFR I744_K745insKIPVAI,,0.0
2138,VHL L63fs (c.187delC),,0.0
2139,VHL P61fs (c.181delC),,0.0
2140,VHL R82_V84del (c.244_252del),,10.0
2141,VHL A56_P59del (c.166_178del),,7.5
2142,VHL G104fs (c.310delG),,0.0
2143,VHL Q132fs (c.395_396delAA),,0.0
2145,VHL M54_A56del (c.159_168del),,0.0
2146,VHL V74fs (c.213_232del),,0.0
2147,VHL F76_N78del (c.226_232del),,0.0
2148,VHL N141fs (c.421_422delAA),,0.0
2149,VHL R161fs (c.481insC),,0.0
2150,VHL P172fs (c.514delC),,0.0
2151,ACVR1 R258G,,0.0
2152,AMER1 R358X,,0.0
2153,CRLF2 V2del,,0.0
2154,CTNNB1 p.S45F,,0.0
2155,CRLF2 G24R,,0.0
2156,ACVR1 G328W,,5.0
2157,CTNNB1 S37C,,0.0
2158,DROSHA E518K,,0.0
2159,ACVR1 G328E,This mutation occurs within the kinase domain of ACVR1 and has been shown to be activating of downstream BMP signaling with increased cell proliferation in cells overexpressing this variant.,7.5
2161,CRLF2 F232C,,0.0
2162,v::NRG1 Fusion,"NRG1 fusions have been described in cases of invasive mucinous adenocarcinoma of the lung, pancreatic ductal adenocarcinoma, cholangiocarcinoma and lung adenocarcinoma. In many cases these tumors were negative for the more common known driver genes of these diseases (e.g., KRAS wild-type pancreatic ductal adenocarcinoma). These events have been proposed as an attractive therapeutic target and some promising results have been observed with pan-HER inhibitors such as afatinib.",57.5
2163,STRN::NTRK2 Fusion,,7.5
2165,PDE4DIP::NTRK1 Fusion,,12.5
2166,VHL G144E (c.431G>A),,5.0
2167,VHL I147T (c.440T>C),,0.0
2168,VHL Splice Region (c.463+8C>T),,5.0
2169,VHL G104= (c.312C>G),Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.312C>T (p.Gly104=; G104=) https://www-ncbi-nlm-nih-gov/clinvar/variation/456582/,2.5
2170,VHL F91L (c.273C>G),Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.273C>A (p.Phe91Leu; F91L) (https://www-ncbi-nlm-nih-gov/clinvar/variation/411978/),5.0
2171,VHL L128fs (c.382del),,0.0
2172,VHL W88fs (c.261dup),,7.5
2174,VHL E55fs (c.162delG),,0.0
2175,VHL R60fs (c.178_179del),,0.0
2176,VHL P61_S65del (c.183_195del),,0.0
2177,VHL E70fs (c.209_210delAG),,0.0
2178,VHL L85fs (c.253delC),,0.0
2179,VHL P86fs (c.255_256delGC),,0.0
2180,VHL P86H (c.257C>A),,0.0
2181,VHL L89H (c.266T>A),,0.0
2182,VHL N90fs (c.269delA),,0.0
2183,VHL E94_P97del (c.281_291del),,0.0
2184,VHL K114fs (c.339_340delAG),,0.0
2185,VHL L116fs (c.347delT),,0.0
2186,VHL L118fs (c.349_350insG),,0.0
2187,VHL T124fs (c.370_371insTGCAGGA),,0.0
2188,VHL N131fs (c.389delT),,0.0
2189,VHL S139fs (c.415insC),,0.0
2190,VHL N141fs (c.420delC),,0.0
2191,VHL N141fs (c.422_428del),,0.0
2192,VHL G144fs (c.429_430insGGAC),,0.0
2193,VHL G144fs (c.430_433delGGAC),,0.0
2194,VHL Q145H (c.435G>T),,0.0
2196,VHL T157fs (c.469delA),,0.0
2197,VHL L158_K159del (c.472_477del),,0.0
2198,VHL V166fs (c.498delC),,0.0
2199,VHL L169_V170del (c.505_510del),,0.0
2200,VHL K171fs (c.512_516delAGCCT),,0.0
2201,VHL H191fs (c.570_574delCCACC),,0.0
2202,VHL I206fs (c.615delinsAA),,0.0
2203,ERBB2 L869R,,0.0
2204,ERBB2 T798I,,3.0
2205,EGFR A750T,,0.0
2206,EGFR R705K,,5.0
2207,EGFR Rare Mutation,This subset of EGFR mutations consists of mutations other than L858R and exon 19 deletion. Reports of responsiveness to tyrosine kinase inhibitors in this EGFR mutation subgroup do not differ widely from those reported for known common sensitizing EGFR mutations.,5.0
2213,ABL1 L248R,,7.0
2216,ABL1 F317S,,1.0
2219,MLH1 Glu34Lys (c.100G>A),,0.0
2220,IL7R S185C,,0.0
2221,IL7R V253G,,0.0
2222,IL7R exon 6 mutations,,0.0
2223,P2RY8::CRLF2 Fusion,"The P2RY8-CRLF2 fusion has been associated with the BCR-ABL1-like (Philadelphia (Ph)-like) molecular subtype of B-ALL, but it has also been observed in other genetic subtypes including hyperdiploid, iAMP21 and B-ALL with dic(9;20). The fusion is generated by a ~320-kb interstitial deletion in Xp22 (in the so-called pseudo-autosomal (PAR) region) which fuses the exon 1 of P2RY8 with the exon 1 of CRLF2. The P2RY8-CRLF2 fusion has been shown to be enriched in Down syndrome B-ALL cases. CRLF2 rearrangements are also significantly associated with activating mutations of JAK1 or JAK2, deletion or mutation of IKZF1, and Hispanic/Latino ethnicity.",0.0
2232,ABL1 F317C,,2.0
2233,AKT1 Overexpression,,3.0
2235,PIK3CA Overexpression,,0.0
2236,PIK3R2 Overexpression,,2.0
2237,PREX2 R172I,,10.0
2238,TF Loss,,0.0
2239,PTEN WILD TYPE,,0.0
2240,VHL 3p26.3-25.3 11Mb del,,7.5
2243,ABL1 E459K,,25.0
2244,ABL1 TKD Mutation,,60.0
2246,VHL c.128-?_250+?,,5.0
2247,VHL c.251-?_429+?,,0.0
2248,ABL1 P-Loop Mutation,,30.0
2249,ABL1 Non-P-Loop Mutation,,30.0
2250,RHEB Y35N,,0.0
2251,BRCA1 COPY-NEUTRAL LOSS OF HETEROZYGOSITY,,0.0
2252,BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY,,0.0
2253,VHL V130I (c.388G>A),"Two clinvar entries at this same genomic location with 2 different nucleotide changes result in 2 different amino acid changes at aa130. (Clinvar ID: 496061 (V130F, c.388G>T); 2229 (V130L, c.388G>C)",0.0
2254,VHL L118P (c.353T>C) and R107G  (c.319C>G),,0.0
2255,VHL Null (c.1-?_340+?del),,0.0
2256,VHL Q203TfsX53 (c.606dupA),,0.0
2257,PBLD Underexpression,,0.0
2258,EWSR1::NR4A3 Fusion,,0.0
2259,ERRFI1 Underexpression,,0.0
2260,CSF3R T618I,,14.0
2261,CALR Mutation,,50.0
2262,MPL MUTATION,,0.0
2263,MAP2K1 56_61QKQKVG>R,,0.0
2265,PTPN6 Underexpression,,0.0
2266,TRIM63::NTRK1 Fusion,,0.5
2267,DDR2::NTRK1 Fusion,,0.5
2268,GON4L::NTRK1 Fusion,,0.5
2269,ETV6::NTRK2 Fusion,,13.0
2270,CRKL Amplification,,0.0
2271,BRAF D594K,,30.0
2272,FGFR3 V555L,,0.0
2273,FGFR3 V555M,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,2.0
2274,FGFR3 L608V,,0.0
2276,FGFR3 R248C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,8.0
2277,FGFR3 Y373C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,21.0
2278,FGFR3 G380R,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,2.0
2279,FGFR3 G370C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,3.0
2281,BRAF Non-V600,,45.0
2282,ERCC1 Underexpression,,30.0
2283,ERCC1 Overexpression,,0.0
2284,SDHB p.193_196dupSTSC (c.577_588dupAGCACCAGCTGC),ClinGen Canonical Allele Identifier: CA658820851,5.0
2285,FGFR2 Underexpression,,0.0
2286,SMAD4 FRAMESHIFT MUTATION,,0.0
2287,MAP2K1 E102_I103delEI,,0.0
2288,SMAD4 Loss-of-function,,0.0
2289,H3-3A K28M,"K28M is a highly recurrent mutation in this gene in multiple cancer types but particularly well known in brain cancers. In amino acid position 27 of H3F3A there is an arginine (R). The medically relevant Lysine (K) is in position 28. Also UNIPROT records the lysine in position 28. However, K27M is common in the literature so is included as a synonym.",65.0
2290,FGFR2 Overexpression,,0.0
2291,SPRY2 UNDEREXPRESSION,,0.0
2292,NR2F2 OVEREXPRESSION,,0.0
2293,H3-3B K36M,,20.0
2294,H3-3A G34W,,20.0
2296,VHL F136fs (c.407delC),,0.0
2297,KMT2C Loss-of-function,,0.0
2298,VHL H191D (c.571C>G),,0.0
2300,VHL P154S (c.460C>T),,0.0
2301,VHL G104V (c.311G>T),,7.5
2302,VHL t(1;3)(q32;q13.3),,0.0
2303,VHL P40R (c.119C>G),,0.0
2304,VHL c.‚àí213‚àí ?_463 ?del,,7.5
2305,VHL V87fs (c.259_260insA),,7.5
2306,VHL c.89c297 ,,0.0
2308,VHL c.341-59_341-14del,,7.5
2310,VHL V166A (c.497T>C),,7.5
2311,VHL 235 (CAG-TAG),,0.0
2312,VHL Rearrangement,,10.0
2313,VHL P138R (c.413C>G),,2.5
2314,VHL Splicing alteration (c.341-1G>A),,0.0
2315,VHL A50= (c.150C>G) and Splice Site (c.463-1G>T),,0.0
2316,VHL Q132Hfs*45 (c.343_395dup),,0.0
2317,VHL Q73Pfs*59 (c.217dupC),,0.0
2318,VHL V74Sfs*53 (c.219_232delGGTCATCTTCTGCA),,0.0
2319,VHL D121Mfs*38 (c.361delG),,0.0
2320,VHL V66Gfs*89 (c.197_209del),,5.0
2321,VHL R79_S80del (c.236_241delGCAGTC),,5.0
2322,VHL D92G (c.275A>G),,5.0
2323,VHL Y98C (c.293A>G),,0.0
2324,VHL N141fs (c.422_440del),,0.0
2326,VHL Y156_T157del (c.465_470del),,0.0
2327,VHL Splice Site (c.341-1G>T),There is a similar but non identical variant to this one in ClinVar (Clinvar ID: 823743; NM_000551.4(VHL):c.341-1G>A).,0.0
2328,VHL G114Vfs*45 (c.339delA),,7.5
2330,VHL Splice Site (c.464-2G>A),,0.0
2331,VHL R167P (c.500G>C),,7.5
2332,VHL L178P (c.532C>T),,7.5
2333,VHL N131K (c.393C>G),,0.0
2334,VHL Splice Region (c.463+3A>C),One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 428796 A>G).,0.0
2335,VHL S72fs (c.216delC),,0.0
2336,VHL H110P (c.329A>C),,0.0
2337,VHL Splicing alteration (IVS2-1G>T),,0.0
2338,VHL Exon 1 del (151nt),,0.0
2339,VHL E52* (c.154G>T),,0.0
2340,VHL L158Q (c.473T>A),At same genomic location a clinvar entry with a different base change and amino acid substitution (Clinvar ID 182980; L158P c.473T>C),0.0
2341,PRKCB D427N,,3.0
2342,VHL R176fs (c.526del),,0.0
2343,VHL W117C (c.351G>X),,0.0
2344,VHL T104fs (c.313_315delC),,0.0
2345,VHL EXON 1-2 DELETION and BRK1 DELETION,,0.0
2346,VHL M54fs (c.160delA),,0.0
2347,VHL P59fs (c.176insAGCAdelTCCTGCGCT),,0.0
2348,VHL F119L (c.355T>C),,0.0
2349,VHL I151N (c.452T>A),,0.0
2350,VHL V155fs (c.464_468delTGTAT),,0.0
2351,VHL L163P (c.488T>C),,0.0
2352,VHL D197Rfs* (c.588_588dupA),,0.0
2353,VHL Y98S (c.293A>C),,0.0
2354,VHL I151T (c.452T>C),,0.0
2355,VHL A149fs (c.446delG),,0.0
2357,VHL Y98N (c.292T>A),,0.0
2359,VHL R167fs (c.501insTTGTCCGT),,0.0
2360,VHL I75del (c.221delTCA),,0.0
2361,VHL *214G (c.640T>G),,5.0
2362,VHL *214C (c.641_642insC),,5.0
2363,VHL N131S (c.392A>G),,0.0
2364,VHL G114V (c.341G>T),Note that this variant occurs at the first base of the second exon of VHL. This exon is known to be skipped in some transcripts. RNA splicing effect should be considered in the interpretation.,0.0
2365,VHL Partial deletion of 4 Kb,,0.0
2366,VHL V194G (c.581T>G),,0.0
2367,VHL R120T (c.359G>C),,0.0
2368,VHL P138fs (c.410dup),,0.0
2370,VHL M54Gfs*77 (c.160_161delAT),,0.0
2371,VHL L198Wfs*4 (c.592delC),,0.0
2372,VHL K196fs (c.588insA),,0.0
2373,VHL Y98S (c.293A>C),,0.0
2374,VHL L198P (c.593T>C),,0.0
2375,VHL E160V (c.479A>T),,0.0
2376,VHL S183W (c.548C>G),,0.0
2377,VHL Splice Site (c.341-2A>G),,0.0
2378,VHL L163F (c.487C>T),,0.0
2379,VHL L85_E94del (c.254_283del30bp),,0.0
2380,VHL c.516_517dupGTCAAGCCT and c.532_542delCTGGACATCGTinsATTA,,0.0
2381,VHL L129P (c.386T>C),,5.0
2382,VHL V62Efs*71 (c.185_193delTGCTGCGCTinsAGCA),,0.0
2383,VHL R69AFS*63 (c.204_205insG),,0.0
2384,VHL S80fs (c.239del),,7.5
2385,VHL S80fs (c.239_245del),,0.0
2386,VHL V87E (c.260T>A),,0.0
2387,VHL D92fs (c.275delinsCC),,0.0
2388,VHL P97Afs*35 (c.287_288insA),,0.0
2389,VHL H110PFS*49 (c.329delA),,0.0
2390,VHL S111fs (c.332del),,0.0
2391,VHL Splice Region (c.340 3_340 10delACGGGCCCinsCG),,0.0
2393,VHL H115FS (c.343delC),,0.0
2394,VHL W117G (c.349T>G),,0.0
2395,VHL W117R (c.349T>A),,0.0
2396,VHL W117S (c.350G>C),,0.0
2397,VHL E134_V142del (c.402_428del),,0.0
2398,VHL Q145fs (c.433_437delCAGCC),,0.0
2399,VHL P146Gfs*14 (c.435_436insGG),,0.0
2400,VHL E160fs (c.480delG),,0.0
2401,VHL C162* (c.486C>A),,0.0
2402,VHL E189_D190del (c.565_570delGAAGAC),,0.0
2404,"VHL c.(?_Ôºç213)_(*3705_?)del (Exon1, 2, 3 deletion)",,0.0
2405,VHL R82G (c.244C>G),"Note that while there is no exact match for this variant in ClinVar there are two close matches that affect the same amino acid position:

- NM_000551.3(VHL):c.245G>T (p.Arg82Leu). https://www.ncbi.nlm.nih.gov/clinvar/variation/526675/
- NM_000551.3(VHL):c.245G>C (p.Arg82Pro). https://www.ncbi.nlm.nih.gov/clinvar/variation/193118/",0.0
2406,VHL D126N (c.376G>A),,0.0
2407,VHL Splice Region (c.340+3_340+10delinsCG),"There are no identical variants in ClinVar with this exact genomic location. However, there are several variants in ClinVar involving disruption of this donor site by deletion or substitution of bases.",0.0
2408,VHL S65L (c.194C>T),,0.0
2409,VHL L101R (c.302T>G),,0.0
2410,VHL R108fs (c.323delGC),,0.0
2412,VHL V114R (c.341T>C),,0.0
2413,VHL H115Q (c.346C>A),,0.0
2414,VHL S139F (c.416C>T),,0.0
2415,VHL F190L (c.568T>C),,0.0
2416,VHL L198fs (c.592del),,0.0
2418,VHL M54fs (c.160_175del),,0.0
2419,VHL P61fs Stop at 121(c.180_208del),,0.0
2420,VHL N67fs (c.197_213del),,0.0
2421,VHL V84fs (c.249_255del),,0.0
2422,VHL L89R (c.266T>G),,0.0
2423,NRAS Amplification,,0.0
2424,VHL G104fs*158 (c.311delC),,0.0
2425,VHL R120fs*158 (c.359delG),,0.0
2426,VHL D121_A122del (c.361_366del),,2.5
2427,VHL D126G (c.377A>G),,0.0
2428,VHL G127fs (c.381delG),,0.0
2429,VHL T133fs*157 (c.397_400delACTG),,0.0
2430,VHL L135fs (c.405delA),,0.0
2431,VHL F137fs (c.408insT),,0.0
2432,VHL L140fs*158 (c.419delT),,0.0
2433,VHL G144fs (c.431del),,0.0
2434,VHL N150fs (c.447del),,2.5
2435,VHL T157fs*158 (c.469delA),,0.0
2436,VHL L163fs*169 (c.488delT),,0.0
2437,MYC Amplification,,0.0
2438,PTPN12 Loss-of-function,,0.0
2439,v::ABL1 Fusion,,0.0
2440,ETV6 Mutation,,0.0
2441,RET V804M,,7.5
2443,HRAS Q61,,10.0
2444,v::ABL2 Fusion,,3.0
2445,v::JAK2 Fusion,,20.0
2446,PTPN11 D61Y,,0.0
2447,SETBP1 D868N,,0.0
2448,ETV6::ABL1 Fusion,,32.5
2449,CTNNB1 G34V,,0.0
2450,AGGF1::PDGFRB Fusion,,0.0
2451,NOTCH3 Overexpression,,0.0
2452,IKZF1 D186fs (c.556del),,0.0
2453,VHL N131T (c.392A>C),A similar but distinct variant the same position has been reported in ClinVar (c.392A>G (p.Asn131Ser); https://www.ncbi.nlm.nih.gov/clinvar/variation/496062/). It involves the same base position but a different nucleotide change leading to a different amino acid change.,15.0
2454,HEY1::NCOA2 Fusion,HEY1-NCOA2 is a specific and recurrent translocation in mesenchymal chondrosarcoma.  The resulting chimeric transcription factor consists of the HEY1 DNA binding domain (exons 1-4) and two activating domains and a histone methyltransferase-interacting domain from NCOA2 (exon 13-23).,70.0
2455,PAX3::FOXO1 Fusion,,38.0
2456,PAX7::FOXO1 Fusion,,55.0
2457,CDK9 Overexpression,,0.0
2458,VEGFA Overexpression,,0.0
2459,PARP1 OVEREXPRESSION,,3.0
2460,JAK2 F694L,,5.0
2461,EPOR Overexpression,,0.0
2463,PIK3CA Wildtype,,15.0
2464,DICER1 E1813 mutations,,0.0
2465,KIT K642R,,0.0
2466,NUP98::NSD1 Fusion,,20.0
2467,ASCL1 EXPRESSION,,0.0
2468,HDAC2 Expression,,0.0
2469,LZTR1 LOSS-OF-FUNCTION,,0.0
2470,DICER1 R392fs and E1813D,,0.0
2471,IRS2 Amplification,,0.0
2472,EGFR I462K,,0.0
2473,EGFR I462R,,0.0
2474,EGFR S464L,,0.0
2475,EGFR S464T,,0.0
2476,EGFR G465E,,0.0
2477,EGFR G465V,,0.0
2478,EGFR K467N,,0.0
2479,EGFR K489Q,,0.0
2480,EGFR K489E,,0.0
2481,EGFR I491K,,0.0
2482,EGFR I491R,,0.0
2483,EGFR S492C,,0.0
2484,EGFR V441G,,0.0
2485,EGFR V441D,,0.0
2486,EGFR V441F,,0.5
2487,EGFR S442R,,0.0
2488,EGFR S442I,,0.0
2489,EGFR F404I,,0.0
2490,EGFR F404V,,0.0
2491,EGFR T415M,,0.0
2492,FLT3 Amplification,,15.0
2493,KIT T417_D419delinsY,,5.0
2494,KIT F506_F508DUP,,2.5
2495,KIT K484_G487DEL,,2.5
2496,PDGFRA Exon 18 Mutation,,2.5
2497,TP53 V135A,,0.0
2499,CBFA2T3::GLIS2 Fusion,,60.0
2501,ATF7IP::PDGFRB Fusion,,0.0
2502,VHL c.-77_-32del,,0.0
2503,VHL c.-61_-51dup11,,0.0
2504,ALK Overexpression,,0.0
2505,CDK4 Overexpression,,0.0
2506,KDR Amplification,,0.0
2507,CBL Y371H,,7.5
2508,v::BRAF Fusion,,0.0
2509,v::NTRK2 Fusion,,30.0
2510,FGFR1 Mutation,,0.0
2511,PTPN11 Mutation,,0.0
2512,KIT Exon 13 Mutation,,5.0
2513,SMARCA4 Loss,,4.0
2514,KDM6A R1213*,,0.0
2515,BRCA1 R71M,,0.0
2516,FBXW7 R465H,,0.0
2517,TP53 C238Y,,2.75
2518,KRAS Activating Mutation,,0.0
2519,BRAF Exon 15 Mutation,,7.5
2520,KIT Wildtype,,10.0
2521,H3-3A MUTATION,,20.0
2522,ATRX DELETION,,0.0
2523,CDKN2A Deletion,,20.0
2524,MYB AMPLIFICATION,,20.0
2525,FAM131B::BRAF Fusion,,0.0
2526,ERBB2 Activating Mutation,,0.0
2527,ERBB2 A775_G776insYVMA,,0.0
2528,FGFR1 Internal Duplication,,20.0
2529,NUP214::ABL1 Fusion,"The NUP214 -ABL1 fusion is composed of part of the NUP214 (Nucleoporin 214) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 34 of NUP214 to exon 2 of ABL1 (NUP214-ABL1 34-2). In T-ALL, the fusion is typically expressed from amplified extrachromosomal bodies (episomes) that arise when the genomic region from ABL1 to NUP214 circularizes to generate the NUP214-ABL1 fusion. In B-ALL, the fusion commonly results from an intrachromosomal duplication involving chromosome 9, with breakpoints within the NUP214 and ABL1 genes. The fusion has been identified in 6% of cases of T-lymphoblastic leukemia and rare cases of B-lymphoblastic leukemia by multiplex ligation-dependent probe amplification, single nucleotide polymorphism array, real-time polymerase chain reaction, and fluorescence in situ hybridization targeting the ABL1 gene. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the WD40 repeat and coiled-coil domains of NUP214 and the SH2, tyrosine kinase, and F actin binding domains of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and MAPK and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The case report that illustrates the clinical significance of the NUP214-ABL1 fusion describes a 6-year-old boy and a 15-year-old girl with BCR-ABL1-like B-lymphoblastic leukemia with normal karyotype. Both patients demonstrated minimal residual disease after induction chemotherapy, and later experienced relapse after either consolidation therapy or bone marrow transplant. Dasatinib was then prescribed and follow-up information is available for the older child, who successfully achieved a complete response for three months before succumbing to the disease. The clinical details of this case could predict response to treatment with tyrosine kinase inhibitors and is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).",27.0
2530,SSBP2::JAK2 Fusion,,25.0
2531,CRLF2 F232C,,0.0
2532,IGH::CRLF2 Fusion,,20.0
2533,BRAF EXON 15 MUTATION,,0.0
2534,MYB::GATA1 Fusion,,0.0
2535,EZH2 Y646S,,3.0
2536,MPL W515L,,0.0
2537,FOXO3 Mutation,,0.0
2538,TGFBR3 TGFBR3,,0.0
2539,EPHB2 EPHB2,,0.0
2540,CDKN1A rs1801270,,15.0
2542,EPHB2 D679N (c.2035G>A),,0.0
2543,"RB1 IVS20, A-G, -2",,0.0
2544,MSH2 L173P,,0.0
2545,EP300 G1506V,,0.0
2546,ERBB2 I654V,,0.0
2547,SNX2::ABL1 Fusion,"The SNX2-ABL1 fusion is composed of part of the SNX2 (Sorting Nexin 2) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 3 of SNX2 to exon 4 of ABL1 (SNX2-ABL1 3-4). The fusion is the result of a reciprocal translocation t(5;9)(p23.2;q34.12) and has been identified by RT-PCR, Sanger sequencing, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the sorting nexin, N-terminal domain of SNX2 and the SH2, tyrosine kinase, and F actin binding domains of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The SNX2-ABL1 fusion has been documented in six young men between the ages of 7 and 29 years with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. Two patients had tyrosine kinase inhibitors (imatinib and dasatinib + imatinib) added to their chemotherapy regimens that, while producing initially encouraging results, ultimately did not prevent these individuals from succumbing to their disease. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors and is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).",30.5
2548,WEE1 Overexpression,,0.0
2550,RCSD1::ABL1 Fusion,"The RCSD1-ABL1 fusion is composed of part of the RCSD1 (RCS Domain Containing 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 2 or, more frequently, exon 3 of RCSD1 to exon 4 of ABL1 (RCSD1-ABL1 3-4). The fusion is the result of a reciprocal translocation t(1;9)(q24.2;q34.12) and has been identified by FISH/karyotype, RT-PCR, Sanger sequencing, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the ABL1 SH2, actin binding domain, and tyrosine kinase domain, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The RCSD1-ABL1 fusion has been documented in greater than fifteen pediatric and adult patients with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. The majority that that were exposed to tyrosine kinase inhibitors (TKIs: imatinib, dasatinib, or ponatinib) experienced durable remissions until the TKIs were discontinued. The clinical details of these cases may predict response to treatment with TKIs and are the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).",80.5
2551,FOXP1::ABL1 Fusion,"The FOXP1-ABL1 fusion is composed of part of the FOXP1 (Forkhead box P1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 27 of FOXP1to exon 4 of ABL1 (FOXP1-ABL1). The fusion is the result of a reciprocal translocation t(3;9)(p12;q34) and has been identified by RT-PCR, Sanger sequencing, and NGS. FOXP1 is critical for the transcriptional regulatory network of B lymphopoiesis; it may also act as a tumor suppressor gene. Absence or deficiency of FOXP1 during early B-cell development may block pro-B cell to pre-B cell development. The FOXP1-ABL1 fusion protein leads to activated tyrosine kinase and may further alter the critical cellular function of these 2 genes. Clinical significance: The FOXP1-ABL1 fusion has been documented in 3 young adult patients (2 male, 1 female) with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. One patient had tyrosine kinase inhibitors (dasatinib) added to the chemotherapy regimens, who had bone marrow tested negative for MRD at end of consolidation. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors. Functional studies are needed to substantiate the efficacy of TKI treatment of this particular ABL-class fusion.",10.0
2552,PTK2B::KDM6A Fusion,,0.0
2553,PTK2B::STAG2 Fusion,,0.0
2554,DGKH::ZFAND3 Fusion,,0.0
2555,IL2RB::MYH9 Fusion,,0.0
2558,NF1 VARIANTS,,0.0
2559,NTRK1 G595R,,0.0
2560,NTRK3 G623R,,0.0
2561,B2M Mutation,,0.0
2562,v::ROS1 Fusion,"ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement",50.0
2564,KIT V555_V559DEL,,5.0
2565,KIT K550_K559DEL,,5.0
2566,PAX5 P80R,,50.0
2568,CBL Mutation,,0.0
2569,CBL Q294E,,0.0
2570,CBL S80N,,0.0
2571,CBL V391I,,0.0
2572,CBL W802*,,0.0
2573,CDKN2A Mutation,,40.0
2574,PBRM1 Loss-of-function,,0.0
2575,DEK::AFF2 Fusion,,0.0
2576,KIF5B::MET Fusion,,0.0
2578,PIK3CA E545X,,0.0
2579,PIK3CA H1047X,,50.0
2580,TP53 R213*,,0.0
2581,MTOR T1977K,,0.0
2582,MTOR C1483F,,0.0
2583,MTOR F1888L,,0.0
2584,MTOR S2215F,,0.0
2585,MTOR L2230V,,0.0
2586,PSMD4 Overexpression,,0.0
2587,CCNE1 Underexpression,,0.0
2588,TP53 C135F,,0.0
2589,TP53 Y205,,0.0
2590,TP53 G245,,0.0
2591,TP53 K132,,0.0
2592,TP53 R248,,0.0
2593,TP53 G266,,0.0
2594,TP53 R273,,0.0
2595,TP53 P278,,0.0
2596,ERBB2 A129,,0.0
2597,TP53 W146,,0.0
2598,TP53 A129,,0.0
2599,TP53 E204,,0.0
2600,TP53 L114,,0.0
2601,TP53 P153,,0.0
2602,TP53 T170,,0.0
2603,TP53 D184,,0.0
2604,TP53 L206,,0.0
2605,KIT D820E,,0.0
2606,KIT Y553N,,0.0
2607,KIT P577_D579DEL,,0.0
2608,CRLF2 Overexpression,,0.0
2609,IKZF1 IKZF1 deletion,,0.0
2610,EGFR R832L,,0.0
2611,FLT3 FLT3,,0.0
2612,FGFR1OP2::FGFR1 Fusion,,2.0
2613,IKZF1 Loss-of-function,,20.0
2614,EGFR M766Q,,0.0
2615,CCND2 Amplification,,0.0
2616,CCND3 Amplification,,0.0
2618,NFE2L2 Mutation,,15.0
2619,EML6::ALK Fusion,,0.0
2620,TP53 V274S,,0.0
2621,ZNF217 AMPLIFICATION,,0.0
2622,PRKN R275W,,0.0
2623,PRKN Loss,,0.0
2624,FUBP1 LOSS-OF-FUNCTION,,0.0
2626,STAG2 LOSS-OF-FUNCTION,,0.0
2627,BRCA1 ATM,,0.0
2628,PALB2 Mutation,,40.0
2629,MPL Mutation,,0.0
2630,ZRSR2 MUTATION,,0.0
2631,NRG1 NRG1 FUSIONS,,0.0
2632,PIK3CA E545,,40.0
2633,CDK12 Mutation,,40.0
2634,BRAF K601,,0.0
2635,BRAF L597,,0.0
2636,BRAF D594,,0.0
2637,BRAF G596,,0.0
2638,CAD::ALK Fusion,,7.5
2639,GOPC::ROS1 Fusion,,3.0
2640,CD74::NRG1 Fusion,,0.0
2641,APP::NRG1 Fusion,,7.5
2642,RABL3 MUTATION,,0.0
2643,MET R1004G,,7.5
2644,BRAF K439Q,,0.0
2645,BRAF K439T,,0.0
2646,TP53 S241F,,3.0
2647,MET Exon 14 Mutation,,0.0
2648,NAB2::STAT6 Fusion,,0.0
2649,FGFR2 N549H,,0.0
2650,FGFR1 V561M,,0.0
2651,TEK R849W,,0.0
2652,FGF19 EXPRESSION,,0.0
2653,FGF19 Overexpression,,20.0
2654,FLT3 ITD N676K,,0.0
2655,TP53 R157H,,0.0
2656,PRNCR1 rs1456315,,0.0
2657,PIK3CA G363A,,0.0
2658,PIK3CA C971R,,0.0
2659,PIK3CA R975S,,0.0
2660,CDKN2A D108Y,,0.0
2661,BRAF G466E,,0.0
2662,BRAF L525R,,0.0
2663,BRAF N486_P490del,,7.5
2664,BRAF T488_P492del,,0.0
2665,BRAF P490_Q494del,,0.0
2667,ALK G1128A,,0.0
2668,BRAF D594E,,0.0
2669,BRAF Class 2 Mutations,,0.0
2670,BRAF Class 3 Mutations,,0.0
2671,BRAF F247L,,0.0
2672,BRAF R558Q,,0.0
2673,BRAF L485F,,0.0
2674,MAP2K1 V211D,,0.0
2675,KMT2A::v Fusion,,0.0
2676,BRCA1 gBRCAm,,0.0
2677,WNT11 Overexpression,,0.0
2681,MBD4 Frameshift,,0.0
2682,ALK G1202del,,0.0
2683,DRD5 low expression,,0.0
2684,H3C2 K27M,,20.0
2686,FLT3 G697R,,0.0
2687,VHL Y112C (c.355A>G),,0.0
2689,BRAF V600_K601>E,,7.5
2690,BRAF V600_S602>DT,,0.0
2691,BRAF G469,,15.0
2692,BRAF G593D,,0.0
2693,BRAF T599_V600insT,,0.0
2694,BRAF V601E,,0.0
2695,BRAF A598V,,7.5
2696,FGF19 Expression,,0.0
2697,IDH1 R132X,,0.0
2698,JAK2 R683G,,0.0
2699,TMPRSS2::ETV1 Fusion,,0.0
2701,BRAF D594H,,0.0
2702,NECTIN4 D594H,,0.0
2703,MAP2K1 V60E,,0.0
2704,MAP2K1 G128V,,0.0
2705,MAP2K1 V154I,,0.0
2706,MAP2K1 P124L,,0.0
2707,MAP2K1 G276W,,0.0
2708,MAP2K1 F53Y,,0.0
2709,MAP2K2 C125S,,0.0
2710,MAP2K2 V35M,,0.0
2711,MAP2K2 L46F,,0.0
2712,MAP2K2 N126D,,0.0
2713,MITF Amplification,,0.0
2714,HOXD8 mutation,,0.0
2715,ATF7IP::JAK2 Fusion,"The ATF7IP-JAK2 fusion is composed of part of the ATF7IP (Activating Transcription Factor 7 Interacting Protein) gene at the 5‚Äô end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 10 of ATF7IP to exon 8 of JAK2 (ATF7IP-JAK2 10-8), exon 13 of ATF7IP to exon 16 of JAK2 (ATF7IP-JAK2 13-16), or exon 13 of ATF7IP to exon 17 of JAK2 (ATF7IP-JAK2 13-17). The fusion is predicted to result from a reciprocal translocation t(9;12) (p24;p13.1), and has been identified by RNA sequencing and Sanger sequencing in three adult patients with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil and MDN1 domains from ATF7IP and the JH2 pseudokinase and JH1 kinase domains from JAK2. The coiled coil domain is hypothesized to constitutively activate the JAK2 kinase domain, thereby upregulating the pathway shared with signal transducers and activators of transcription (STATs). Clinical significance: The novel ATF7IP-JAK2 fusion has been documented in three cases for which specific clinical information is unavailable. A pre-clinical xenograft model containing the fusion was sensitive to exposure to the JAK2 inhibitor, ruxolitinib. Therefore, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",15.0
2716,EBF1::JAK2 Fusion,"The EBF1-JAK2 fusion is composed of part of the EBF1 (Early B-Cell Factor Transcription Factor 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 14 of EBF1 to exon 17 of JAK2 (EBF1-JAK2 14-17). The fusion is predicted to result from a reciprocal translocation t(5;9) (q33.3;p24), and has been identified by RNA sequencing in one adolescent patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the DNA binding, immunoglobulin-life fold, and helix-loop-helix domains from EBF1 and an intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the EBF1-JAK2 fusion protein has not been performed. Clinical significance: The novel EBF1-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",7.5
2717,PPFIBP1::JAK2 Fusion,,15.0
2718,STRN3::JAK2 Fusion,"The STRN3-JAK2 fusion is composed of part of the STRN3 (Striatin 3) gene at the 5‚Äô end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 9 of STRN3 to exon 17 of JAK2 (STRN3 -JAK2 9-17). The fusion is predicted to result from a reciprocal translocation t(9;14) (p24;q12), and has been identified by RNA sequencing in one pediatric patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the Striatin domain from STRN3 and the JH2 pseudokinase domain and intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the STRN3-JAK2 fusion protein has not been performed. Clinical significance: The novel STRN3-JAK2 fusion has been documented in a single case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",7.5
2719,TPR::JAK2 Fusion,"The TPR-JAK2 fusion is composed of part of the TPR (Translocated Promoter Region, Nuclear Basket Protein) gene at the 5‚Äô end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 39 of TPR to exon 17 of JAK2 (TPR -JAK2 39-17). The fusion stems from a reciprocal translocation t(1;9) (q31.1;p24), and has been identified by FISH and RNA sequencing in one young adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the TPR/MLP1/MLP2-like protein domain from TERF2 and the JH2 pseudokinase domain and intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the TPR-JAK2 fusion protein has not been performed. Clinical significance: The novel TPR-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",7.5
2720,SMAD4 R361C,,2.5
2721,SMAD4 D351H,,0.0
2722,SMAD4 E330A,,0.0
2723,ERBB2 Exon 20 Insertion,,25.0
2724,NTRK3 G623E,,0.0
2725,ROS1 S1986Y/F,,0.0
2726,ROS1 R2033N,,0.0
2727,SMAD4 D537Y,,0.0
2728,ETV6::JAK2 Fusion,"The ETV6-JAK2 fusion is composed of part of the ETV6 (ETS Variant Transcription Factor 6) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 4 of ETV6 to exon 17 of JAK2 (ETV6-JAK2 4-17), exon 5 of ETV6 to exon 12 of JAK2 (ETV6-JAK2 5-12), or exon 5 of ETV6 to exon 19 of JAK2 (ETV6-JAK2 5-19). The fusion results from the reciprocal translocation t(9;12)(p24;p13), cytogenetically cryptic, and has been identified by FISH and RNA sequencing. The fusion gene is expressed from the der(9) chromosome. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the PNT domain from ETV6 and JH1 kinase domain from JAK2. The ETV6 PNT domain is hypothesized to result in dimerization, which leads to aberrant JAK2 kinase domain activation. Depending on the breakpoint variant, the fusion protein may also contain the JAK2 JH2 pseudokinase domain. The inclusion of the JH1 domain may affect functional effects and disease specificity of the abnormal fusion. Functionally, the fusion results in aberrant activation of JAK2 kinase, leading to activation of downstream signaling through the signal transducers and activators of transcription (STATs). The ETV6-JAK2 fusion is associated with hematologic malignancies and has been observed in B-lymphoblastic leukemia (~10%), T-lymphoblastic leukemia (isolated cases), and myeloid/lymphoid neoplasms with eosinophilia and gene rearrangements (rare cases). Clinical significance: As a diagnostic biomarker, the ETV6-JAK2 fusion in B-lymphoblastic leukemia is associated with the BCR-ABL1-like subtype. As a prognostic marker, the ETV6-JAK2 fusion has been associated with high-risk disease. As a predictive marker, the ETV6-JAK2 fusion has been shown by limited pre-clinical data and case reports to predict response to treatment with JAK2 inhibitors. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",25.0
2729,BCR::JAK2 Fusion,"The BCR-JAK2 fusion is composed of part of the BCR (Breakpoint Cluster Region) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 14 of BCR to exon 17 of JAK2 (BCR-JAK2 4-17) and exon 1 of BCR to exons 15 (BCR-JAK2 1-15), 17 (BCR-JAK2 1-17), or 19 (BCR-JAK2 1-19). The fusion results from the reciprocal translocation t(9;22)(p24;p11.2), and has been identified by karyotype analysis, FISH, RT-PCR, targeted ligation amplification (TLA), and RNA sequencing. The fusion gene is expressed from the der(9) chromosome. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil domain from BCR and the JH1 kinase domain from JAK2. Depending on the breakpoint variant, the fusion protein may also contain the JAK2 JH2 pseudokinase domain. In pre-clinical studies, the coiled coil domain of BCR has been shown to mediate oligomeric activation of the JAK2 kinase domain, thereby promoting downstream signaling by signal transducers and activators of transcription (STATs). The BCR-JAK2 fusion is associated with hematologic malignancies and has been observed in myeloproliferative neoplasms with eosinophilia (multiple cases), B-lymphoblastic leukemia (multiple cases), acute myeloid leukemia (a rare case), and B-cell lymphoma (rare case of Burkitt lymphoma). Clinical significance: As a diagnostic biomarker in B-lymphoblastic leukemia, the BCR-JAK2 fusion is frequently observed in the BCR-ABL1-like subtype. As a prognostic marker, the fusion appears to be associated with high-risk disease in pediatric and adult populations. As a predictive marker, patients whose diseases exhibit the BCR-JAK2 fusion have experienced partial responses or even complete remission with hydroxyurea and/or interferon alfa. Case reports have demonstrated the limited utility of tyrosine kinase inhibitors. One patient diagnosed with a myeloid neoplasm initially responded to the JAK2 inhibitor ruxolitinib, but relapsed after 18 months. Current research has suggested a survival advantage following allogeneic or autologous stem cell transplantation.",35.0
2730,PAX5::JAK2 Fusion,"The PAX5-JAK2 fusion is composed of part of the PAX5 (Paired Box 5) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 5 of PAX5 to exon 19 of JAK2 (PAX5-JAK2 5-19). The fusion is hypothesized to result from an intrachromosomal translocation, inversion, or deletion of chromosome 9 (involving loci p13 and p24), and has been identified by RNA sequencing, RT-PCR, Sanger sequencing, and FISH in patients B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the DNA-binding paired domain from PAX5 and the JH1 kinase domain from JAK2. A pre-clinical study has revealed that this fusion protein deregulates the PAX5 transcriptional pathway while also autophosphorylating the JAK2 kinase domain, thereby promoting downstream signaling by signal transducers and activators of transcription (STATs). Clinical significance: As a diagnostic biomarker, the PAX5-JAK2 fusion in B-lymphoblastic leukemia is frequently associated with the BCR-ABL1-like subtype. As a prognostic marker, the fusion has been associated with intermediate to high-risk disease. As a predictive marker, the PAX5-JAK2 fusion has been shown in pre-clinical data to predict response to treatment with JAK2 inhibitors. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",30.0
2731,TERF2::JAK2 Fusion,,7.5
2732,USP25::JAK2 Fusion,,7.5
2733,ZNF274::JAK2 Fusion,,7.5
2734,RFX3::JAK2 Fusion,,7.5
2735,VHL P138= (c.414A>G),,0.0
2736,VHL M1? (c.3G>A),,0.0
2737,VHL M211L (c.631A>C),,0.0
2739,VHL Exon 1 (Frameshift),,0.0
2740,BRCA2 K3326*,,7.5
2741,MAP2K2 H123Q,,0.0
2742,MAP2K2 G132D,,0.0
2743,MAP2K2 G132S,,0.0
2745,VHL t(2;3)(q35;q21),,0.0
2746,VHL R120* (c.358A>T),,0.0
2747,VHL N90H (c.268A>C),One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 633017 A>T).,0.0
2748,VHL P154Rfs (c.461_462delCA),,0.0
2749,VHL Q164H (c.492G>T),,0.0
2750,VHL DelPhe76 (c.225del3bp),,0.0
2751,"VHL c.298dupA, Frameshift",,0.0
2752,NRF1::BRAF Fusion,,7.5
2753,CDKN2A c.151-1G>C,,7.5
2754,ABL1 T315V,,2.0
2756,ABL1 E292L,,2.0
2757,ABL1 F317R,,2.0
2761,CTNNB1 Exon 3 Mutation,,55.0
2762,DPYD EXON 11-19 DELETION,,10.0
2763,MET::ATXN7L1 Fusion,,7.5
2764,NUDT15 Inactivating Mutation,,0.0
2765,NT5C2 R238W,,13.0
2766,NT5C2 S445F,,13.0
2767,NT5C2 Mutation,,20.0
2768,KMT2A KMT2A rearragements,,0.0
2770,ABL1 E98G,,10.0
2773,FGFR1 Overexpression,,0.0
2774,FGFR2 P253R,,7.5
2775,FGFR3 Amplification,,0.0
2776,FGFR4 Amplification,,0.0
2777,TACSTD2 Overexpression,,0.0
2780,IL6 Overexpression,,2.0
2781,EGFR G719X,,0.0
2782,MET Y1003H,,0.0
2783,ALK Expression,,0.0
2784,ABCB1 Overexpression,,8.0
2785,PRPS1 PRPS1 MUTATION,,20.0
2786,LYN OVEREXPRESSION,,4.0
2787,PRPS1 T303S,,7.0
2788,PRPS1 L191F,,9.0
2789,PRPS1 D183E,,7.0
2790,PRPS1 K176N,,7.0
2791,PRPS1 G174E,,0.0
2792,PRPS1 N144S,,9.0
2793,PRPS1 N114D,,0.0
2794,PRPS1 S103I,,4.0
2795,PRPS1 S103N,,7.0
2796,PRPS1 S103T,,8.0
2797,PRPS1 A190V,,0.0
2798,PRPS1 A190T,,26.0
2799,VHL 106insR (c.316insGCC),,7.5
2801,VHL Deletion,,5.0
2802,PRPS1 D183H,,0.0
2803,PRPS1 Y311C,,0.0
2804,PRPS1 D139G,,3.0
2805,PRPS1 C77S,,3.0
2806,PRPS1 I72V,,3.0
2807,PRPS1 V53A,,3.0
2808,PRPS1 A87T,,4.0
2809,PRPS1 M115T,,4.0
2810,EWSR1::WT1 Fusion,,20.0
2811,CTNNB1 exon 3 mutations,,0.0
2813,PDGFRA Overexpression,,3.0
2814,FGFR2 W290C,,0.0
2815,FGFR2 S320C,,0.0
2816,FGFR2 K660E,,0.0
2820,ABL1 N146S,,7.5
2824,STAT1 Overexpression,,0.0
2825,JAK1 S646F,,0.0
2826,MET H1094L,,0.0
2827,SDHB Mutation,,0.0
2828,CHEK2 R474C c.1420C>T,,7.5
2829,BCL2 G101V,,8.0
2830,RUNX1 G336fs563X (c.1007_1013del),,0.0
2831,RUNX1 A28fsX109 (c.83insG),,0.0
2832,RUNX1 D96H (c.238G>C),,0.0
2833,RUNX1 K90fsX101,,0.0
2834,RUNX1 R292X (c.877C>T),,0.0
2835,MGMT Expression,,0.0
2837,LPP::HMGA2 Fusion,,0.0
2838,HMGA2::LPP Fusion,,0.0
2839,VEGFC Overexpression,,0.0
2840,BCR::PDGFRA Fusion,,7.5
2841,COL1A1::PDGFB Fusion,,27.5
2842,PDGFRB Overexpression,,7.5
2843,OFD1::JAK2 Fusion,"The OFD1-JAK2 fusion is composed of part of the OFD1 (Oral-Facial-Digital Syndrome 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. OFD1 is a centrosomal protein of primary cilia implicated in Oral-Facial-Digital Syndrome type 1, but it has not been previously described in hematologic malignancies. The published breakpoint joins exon 22 of OFD1 to exon 13 of JAK2 (OFD1-JAK2 22-13). This fusion is predicted to result from a reciprocal translocation t(X;9)(p22;p24), and has been identified in two patients by RNA sequencing, one of which demonstrated the abnormal karyotype 46,XY,-17+mar[11]/46,XY[9]. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the FERM and SH2 domains from OFD1 and the JH2 pseudokinase and JH1 kinase domains from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the OFD1-JAK2 fusion protein is reportedly underway. Clinical significance: The novel OFD1-JAK2 fusion has been documented in one 3-year-old and one 11-year-old boy with BCR-ABL1-like B-lymphoblastic leukemia. Both children successfully maintained first complete remission following induction chemotherapy and allogeneic hematopoietic stem cell transplantation, with as long as 6 years of follow up. While neither patient was treated with a JAK2 inhibitor, the JH1 kinase domain present within the OFD1-JAK2 fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",10.0
2844,SMU1::JAK2 Fusion,"The SMU1-JAK2 fusion is composed of part of the SMU1 (SMU1 DNA Replication Regulator and Splicesomal Factor) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 18 of SMU1 to exon 12 of JAK2 (SMU1-JAK2 18-12). The fusion is hypothesized to result from an intrachromosomal translocation, inversion, or deletion of chromosome 9 (involving loci p21 and p24), and has been identified by RNA sequencing in an older adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the LisH, CTLH, HisP, and Wd40 domains from SMU1 and the JH2 pseudokinase and JH1 kinase domains from JAK2. Pre-clinical data demonstrates increased JH1 kinase expression as a result of the SMU1-JAK2 fusion event, which is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Clinical significance: The novel SMU1-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",7.5
2845,SNX29::JAK2 Fusion,"The SNX29-JAK2 fusion is composed of part of the SNX29 (Sorting Nexin 29) gene at the 5‚Äô end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 18 of SNX29 to exon 13 of JAK2 (SNX29 -JAK2 18-13). It is predicted to result from a reciprocal translocation t(9;16) (p24;q13.13), and has been identified by RNA sequencing in one normal-karyotype adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the RUN and PX_RUN domains from SNX29 and the JH2 pseudokinase and JH1 kinase domains from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the SNX29-JAK2 fusion protein has not been performed. Clinical significance: The novel SNX29-JAK2 fusion has been documented in a single case that successfully maintained complete remission without relapse following induction chemotherapy. While the patient was not treated with a JAK2 inhibitor, the JH1 kinase domain present within the SNX29-JAK2 fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",7.5
2846,ZNF430::JAK2 Fusion,"The ZNF430-JAK2 fusion is composed of part of the ZNF430 (Zinc Finger Protein 430) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 4 of ZNF430 to exon 19 of JAK2 (ZNF430-JAK2 4-19). The fusion is predicted to result from a reciprocal translocation t(9;19)(p24;p12), and has been identified by RNA sequencing in one adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the KRAB_A-box domain from ZNF430 and the JH1 kinase domain from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the ZNF430-JAK2 fusion protein has not been performed. Clinical significance: The novel ZNF430-JAK2 fusion has been documented in one case for which clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",7.5
2847,MIR21 Overexpression,,0.0
2848,KRAS A146,,15.0
2849,IL33 Overexpression,,0.0
2850,WDR12 OVEREXPRESSION,,0.0
2851,PLK1 OVEREXPRESSION,,0.0
2852,ACVR1 Mutation,,15.0
2853,CXCL10 EXPRESSION,,0.0
2854,CCN2 Overexpression,,0.0
2855,STAT5B Y665F,,0.0
2856,MIGA1::BRAF Fusion,,0.0
2857,PCNA K164R LOSS-OF-MODIFICATION,,0.0
2858,EZH2 Y646F,"Y646F has been reported as one of the most recurrent alterations of EZH2 in DLBCL, FL and other malignancies. This mutation is thought to alter methyltransferase activity of EZH2 and confer sensitivity to EZH2 inhibitors such as tazemetostat.",14.0
2859,BRCA2 P655R,,0.0
2860,KRAS V14I,,0.0
2861,TPM3::NTRK1 Fusion,,77.0
2862,CDK5 Expression,,0.0
2863,MAEA E151INT,,0.0
2864,TP53BP1 D353E,,0.0
2865,ARID2 R1273* (c.3817C>T),,0.0
2867,EGFR L797S,,0.0
2868,EGFR L718Q,,0.0
2869,EGFR L718V,,0.0
2870,PIK3CA V955I,,10.0
2871,NF2 c.1396C>T,,5.0
2872,EGFR C797G,,0.0
2873,EGFR L792H,,0.0
2874,TP53 P278A,,0.0
2875,FOXC2 Overexpression,,0.0
2876,ZEB1 Overexpression,,0.0
2877,CUL7 Overexpression,,0.0
2878,ABL1 Double Ph,,10.0
2879,ABL1 K356dup,,0.0
2880,FLT3 D835Y,,6.0
2881,VHL I180T (c.539T>C),"An entry at the same genomic location causing a different amino acid substitution (Clinvar ID: 625262; c.539T>G, I180S)",0.0
2882,VHL R82_V84del (c.243delGCGCGTCGT),,0.0
2883,CSF1R Expression,,0.0
2884,VHL S72Afs*? (c.213_214insGCCC),,0.0
2885,VHL F26del (c.227delTCT),,0.0
2886,VHL P154L (c.461C>T),,0.0
2890,VHL c.-195G>A,,0.0
2891,VHL c.*294G>A,,0.0
2892,PML K227_T233del,,0.0
2893,PML S214L,,0.0
2894,PML A216T,,0.0
2895,BCL2 G101A,,0.0
2896,BCL2 F104S,,0.0
2897,BCL2 F104L,,0.0
2898,BCL2 R107_R110dup,,0.0
2899,BCL2 A113G,,0.0
2900,BCL2 L119V,,0.0
2901,MYOD1 L122R,,165.0
2902,RET G810,,0.0
2903,VHL c.-195G>A/C,,0.0
2904,VHL c.1149A>G,,0.0
2905,VHL E70Dfs(c.210delG),,0.0
2906,VHL I151T(c.452T>C),,0.0
2908,VHL c.652T>A,,0.0
2909,VHL D143= (c.429C>T),,0.0
2910,VHL c.340+770T>C,,0.0
2911,CDK6 EXPRESSION,,2.0
2912,CDK4 EXPRESSION,,0.0
2913,VHL R197_L198ins7(c.572_592dup),,0.0
2914,VHL p.F76del,,0.0
2915,VHL G34Rfs(c.99_100insA),,0.0
2916,VHL c.56_57DupInvCGGGAGGC,,0.0
2917,VHL S65T (c.193T>A),"Two clinvar entries at this same genomic location (Clinvar ID: 547829, 223160) with different base changes result in different amino acid changes (T>G = S65A) and T>C = S65P)",0.0
2918,ATM c.902-1G>T,,3.0
2919,ATM c.7089+1del,,3.0
2920,ATM c.7515+1_2del,,3.0
2921,CD79B MUTATION,,0.0
2922,FLT3 N676K,,0.0
2923,EWSR1::ATF1 Fusion,,0.0
2924,FLT3 Y693,,0.0
2925,VHL Y98N (c.292T>A),,0.0
2926,GATA1 p.Ser51Alafs*86,,0.0
2927,BCL2 D103Y,,0.0
2928,BCL2 V156D,,0.0
2929,BCL2 R129L,,0.0
2930,BCL2 D103V,,0.0
2931,BCL2 D103E,,0.0
2934,FGFR2 Y376C,,0.0
2935,VHL L128F (c.382C>T),,5.0
2937,VHL L128fs (c.381del),,0.0
2938,NTRK3 R248C,,0.0
2939,FLT3 Y842C,,20.0
2940,FLT3 F691L,,6.0
2941,GATA2 Mutation,,0.0
2942,CARD11 MUTATION,,0.0
2943,TP53 Mutations,,0.0
2944,FLT3 D835I,,2.0
2945,VHL P61_C77del (c.181_231del),,0.0
2946,VHL Y98C (c.293A>G),,0.0
2947,VHL L135*,,0.0
2948,PIK3CA H1-47R,,0.0
2949,VHL S139fs,,0.0
2951,BCL2 F104I,,8.0
2952,VHL 180fs*22 (c.540delC),,0.0
2954,VHL G104fs*23 (c.309_322del14),,0.0
2955,VHL V181fs (c.541delG),,0.0
2956,VHL P25L (c.74C>T) and P86T (c.256C>A),,0.0
2958,VHL V166Dfs*9 (c.480_481insCGATGCCTCCAGGT),,0.0
2959,VHL N78S (c.233A>G),,0.0
2960,VHL L178P (c.533T>A),,0.0
2961,VHL C162W (c.486C>G),,0.0
2962,VHL L89P (c.266T>C),,0.0
2963,VHL S183* (c.548C>A),,0.0
2964,VHL Partial deletion of 2 Kb,,0.0
2965,VHL C77_N78insL (c.230_231insTCT),,12.5
2966,VHL L169= (c.505C>T),"Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.507A>C (p.Leu169=, L169L)(https://www.ncbi.nlm.nih.gov/clinvar/variation/238110/)",0.0
2967,VHL V181fs (c.540_543delCGTC),,0.0
2968,VHL G127_L128delinsGF (c.381_382delinsTT),,0.0
2969,VHL Exon Deletion,,0.0
2970,VHL c.‚Äì65_‚Äì55dup11,,0.0
2971,VHL 3' UTR alteration (c.*1149A>G),,0.0
2972,VHL R167G (c.500G>A),,0.0
2973,VHL S80I (c.239G>T),,0.0
2974,VHL F?C (c.?T>G),,0.0
2975,VHL E189Kfs*? (c.565delG),,0.0
2976,VHL Splice Region (c.464-3C>T),,0.0
2977,VHL Single Allele Deletion,,0.0
2980,NUP98::KDM5A Fusion,,0.0
2981,PALB2 Oncogenic Mutations (loss of function alterations),,0.0
2982,ATM Oncogenic Mutations (loss of function alterations),,0.0
2983,MN1::CXXC5 Fusion,,20.0
2984,GATA1 Mutation,,0.0
2985,RBM15::MRTFA Fusion,,20.0
2987,FLT3 ITD & TKD MUTATIONS,,0.0
2988,VHL L140PfsX4 (c.418dup),,0.0
2989,VHL N78S (c.233A>G),,0.0
2991,VHL H125Y (c.373C>T),,0.0
2992,VHL D179N (c.535G>A),,0.0
2993,VHL Y98C (c.293A>G ),,0.0
2994,VHL Y98* (c.294C>G),,0.0
2995,RUNX1::RUNX1T1 Fusion,,120.0
2996,WT1 Mutations,,0.0
2997,TLX3::BCL11B Fusion,,0.0
2998,VHL F148Lfs*11 (c.444del),,0.0
2999,VHL T152P (c.454A>C),,0.0
3001,VHL R108Hfs*23 (c.323_324del),,0.0
3002,VHL D121N (c.361G>A),,0.0
3003,SDHA R31* (c.91C>T),,0.0
3004,VHL S38P (c.112T>C),,0.0
3005,VHL I75Sfs*84 (c.223del),,0.0
3006,VHL E189fs (c.565del),,0.0
3007,NPM1 MUTATION,,0.0
3008,MECOM Overexpression,,0.0
3009,ETV6::RUNX1 Fusion,,70.0
3010,KMT2A Rearrangement,,0.0
3011,VHL W117Cfs*42 (c.351del),,0.0
3012,VHL F148* (c.443_455delinsA),,5.0
3013,NTRK2 R458G,,0.0
3014,VHL Q96_P102del (c.287_307del),,0.0
3015,VHL I75S (c.224T>G),,0.0
3016,NTRK2 A203T,,0.0
3017,MEF2D MEF2D Rearrangement,,0.0
3019,VHL T100Nfs*32 (c.298dupA),,0.0
3020,VHL Null (c.1-?_642+?del),,0.0
3021,GNA11 G209P,,0.0
3022,GNAQ G209P,,0.0
3023,VHL I75Yfs*57 (c.224dupT),,0.0
3024,VHL K196* (c.586AÔºûT),,0.0
3025,VHL D126Efs* (c.377_378insG),,0.0
3027,KANK1::NTRK2 Fusion,,30.0
3028,VHL c.463+43A>G,,0.0
3029,FLT3 D839G,,0.0
3030,VHL c.340+7G>A,,0.0
3031,VHL P154= (c.462A>G),,0.0
3032,VHL N150fs (c.447del),,0.0
3033,VHL L89S (c.265C>T),,0.0
3034,FLT3 M664I,,0.0
3035,FLT3 K663Q,,0.0
3036,FLT3 D839A,,0.0
3037,FLT3 D839N,,0.0
3038,FLT3 D839H,,0.0
3039,VHL C162Wfs*12(c.485dupG),,0.0
3040,VHL K159Efs*15(c.473dupT),,0.0
3041,VHL L129Wfs*?(c.383delT),,0.0
3042,VHL A50= (c.150C>G),Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.150C>A (p.Ala50=; A50=)(https://www.ncbi.nlm.nih.gov/clinvar/variation/238101/),0.0
3043,VHL c.-65_-55dup11,,0.0
3044,VHL N141fs (c.422_440del),,0.0
3045,VHL R107Pfs*25(c.314_315insC),,0.0
3047,VHL Null (Partial VHL deletion),,0.0
3048,VHL D126N (c.376G>A) / S183L (c.548C>T),,0.0
3049,VHL Null (deletion),,0.0
3050,VHL P154S (c.460C>T),,0.0
3051,VHL Y156H (c.466T>C),,0.0
3052,VHL Null (c.341-?_463+?del),,0.0
3053,VHL V62Cfs*5 (c.180del),,10.0
3054,VHL P86Afs*46 (c.254_255insC),,0.0
3055,VHL N150Ifs*9 (c.449del),,0.0
3056,VHL R176Gfs*26 (c.526del),,0.0
3057,VHL Null (large 3' deletion),,0.0
3058,VHL V62Gfs*66 (c.185_195del),,0.0
3059,VHL P95Rfs*64 (c.284del),,0.0
3060,VHL R177_L178ins6 (c.531_532ins18),,0.0
3062,VHL Y156S (c.467A>C),Clinvar entry at same genomic location with different base and amino acid change (Clinvar ID 43600; Y156C c.467A>G),0.0
3063,VHL A122V (c.365C>T),,0.0
3064,VHL A149fs (c.444dup),,0.0
3065,VHL *214Gext*14 (c.640T>G),,0.0
3066,VHL G144R (c.430G>C),,0.0
3067,VHL L163I (c.487C>A),Clinvar entry at same genomic location with different amino acid change (Clinvar ID 480772; c.487C>T L163F),0.0
3068,VHL P97L (c.290C>T) and L116P (c.347T>C),,0.0
3069,KRAS Wildtype,,2.0
3070,FLT3 N841I,,0.0
3071,SMARCB1 Loss,,50.0
3072,ATRX Mutation,,15.0
3073,EML4::ALK e6::e19,,0.0
3074,PDGFRA V658A,,0.0
3075,EGFR G12V,,0.0
3076,RBPMS::MET Fusion,,0.0
3077,FLT3 ITD&F691(I/L),,0.0
3078,FLT3 ITD & D835(V/Y/F/H),,0.0
3079,FLT3 ITD & Y842C,,0.0
3080,FLT3 ITD & D839G,,0.0
3081,FLT3 G697S,,0.0
3082,FLT3 N841K,,0.0
3083,GOLGA5::JAK2 Fusion,"The GOLGA5-JAK2 fusion is composed of part of the GOLGA5 (Golgin A5) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 10 of GOLGA5 to exon 12 of JAK2 (GOLGA5-JAK2 10-12). The fusion is predicted to result from a reciprocal translocation t(9;14)(p24;q32), and has been identified in one patient by RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil domain from GOLGA5 and an aberrantly activated JH1 kinase domain from JAK2, which is thought to upregulate the pathway shared with signal transducers and activators of transcription (STATs). The inclusion of the JH1 domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The novel GOLGA5-JAK2 fusion has been documented in one 10-year-old boy with BCR-ABL1-like B-lymphoblastic leukemia with complex karyotype. The clinical details of this case could predict response to treatment with JAK2 inhibitors. A xenograft model created from the patient's malignant cells demonstrated clearance of the leukemic clone in murine peripheral blood upon exposure to ruxolitinib. Moreover, this drug was added to the child's treatment regimen, resulting in nearly undetectable levels of the GOLGA5-JAK2 fusion measured after 64 days of therapy. The patient has reportedly remained in remission 20 months after CAR T-cell infusion and allogeneic hematopoietic stem cell transplantation. This child was included in the currently ongoing prospective clinical trial evaluating the efficacy of JAK2 inhibitors in treating pediatric B-lymphoblastic leukemia with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",7.5
3084,FGFR4 G636C,,0.0
3085,FGFR4 N535K,,0.0
3086,FGFR4 V550E,,0.0
3087,FLT3 ITD and co-mutations,,0.0
3088,FLT3 ITD D651G,,0.0
3089,FLT3 ITD  N676D,,0.0
3090,FLT3 ITD I687F,,0.0
3091,PIK3CA Rare Mutation,,10.0
3092,LMNA::NTRK1 e2::e10,,0.0
3093,LMNA::NTRK1 e2::e11,,0.0
3094,LMNA::NTRK1 e11::e10,,0.0
3095,RET G810C,,0.0
3096,RET G810S,,0.0
3097,RET Y806C,,0.0
3098,RET Y806N,,0.0
3099,RET V738A,,0.0
3100,FLT3 D835 & I836,,0.0
3101,FLT3 I836,,0.0
3102,FLT3 Y589D,,0.0
3103,FLT3 Y842H,,0.0
3104,"PRKAR1A PRKAR1A LOH, allelic imbalance 17q",,0.0
3105,TSPYL1 R62S,,0.0
3106,KIT N505I,,0.0
3107,KIT N505R,,0.0
3108,KIT Y503A,,0.0
3109,KIT F504A,,0.0
3110,BRAF V600_S605delinsDV,,0.0
3111,ATRX Underexpression,,0.0
3112,ACTL6A Overexpression,,0.0
3113,VHL R120fs (c.358_359insAC),,7.5
3114,VHL C77fs (c.230del),,7.5
3115,VHL Q96_P97delinsH (c.288_290del),,7.5
3116,VHL G144fs (c.429_439del),,7.5
3117,VHL P103H (c.308C>A),,0.0
3118,MYCN Overexpression,,0.0
3119,VHL W88*,,0.0
3120,BCOR::CCNB3 Fusion,,10.0
3121,CIC::DUX4 Fusion,,37.5
3122,CTNNB1 G34R,,0.0
3123,CTNNB1 S33F,,0.0
3124,CTNNB1 I35K,,0.0
3125,CTNNB1 D32Y,,0.0
3126,AKT1 S473 Phosphorylation,,15.0
3128,IGF1R Overexpression,,20.0
3129,VHL D213E (c.639T>G),,0.0
3130,VHL V62fs (c.180delG),,0.0
3131,VHL Null (point mutation codon 238),,0.0
3132,VHL G93A (c.278G>C),,0.0
3133,VHL t(3;6)(p12.3;q24.3),,0.0
3134,VHL t(3;12)(q13.13;q24.23),,0.0
3135,KRAS P34R,,0.0
3136,CBL c.1477C>T,,0.0
3137,RANBP2::ABL1 Fusion,"The RANBP2-ABL1 fusion is composed of part of the RANBP2 (RAN Binding Protein 2) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 18 of RANBP2 to exon 2 of ABL1 (RANBP2-ABL1 18-2). The fusion is the result of a reciprocal translocation t(2;9)(p12.3;q34.12) and has been identified by FISH/karyotype and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, includes the leucine zipper of RANBP2 and the tyrosine kinase of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The RANBP2-ABL1 fusion has been documented in several juvenile and young adult patients with B-lymphoblastic leukemia, some of which were further classified as BCR-ABL1 (Ph)-like subtype. One 20-year-old female patient has been documented as being treated with dasatinib (140 mg daily) added to her clinical trial chemotherapy. While she experienced a brief response, her disease eventually relapsed and she expired. The use of tyrosine kinase inhibitors is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).",10.0
3138,ZMIZ1::ABL1 Fusion,"The ZMIZ1-ABL1 fusion is composed of part of the ZMIZ1 (Zinc Finger MIZ-Type Containing 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The most commonly published breakpoint joins exon 18 of ZMIZ1 to exon 2 of ABL1 (ZMIZ1-ABL1 18-2). The fusion is the result of a reciprocal translocation t(9;10)(q34.12;q22.3) and has been identified by FISH/karyotype, RT-PCR, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, which contains one of the proline-rich domains of ZMIZ1 and the ABL1 tyrosine kinase domain. Similar to other oncogenic fusion proteins, the proline-rich domain of ZMIZ1 is involved in protein-protein interactions, and therefore the fusion may encode a constitutively activated tyrosine kinase that upregulates the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Patients harboring the ZMIZ1-ABL1 fusion are hypothesized to be eligible for imatinib therapy.",32.5
3139,CENPC::ABL1 Fusion,"The CENPC-ABL1 fusion is composed of part of the CENPC (Centromere Protein C) gene at the 5‚Äô end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The CENPC-ABL1 fusion is in-frame and it has been documented in one pediatric patient with high risk BCR-ABL1-like B-lymphoblastic leukemia.",5.0
3140,NUP153::ABL1 Fusion,"The NUP153-ABL1 fusion is composed of part of the NUP153 (Nucleoporin 153) gene at the 5‚Äô end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein, and the inclusion of the ABL1 tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. The NUP153-ABL1 has been documented in one pediatric patient with BCR-ABL1-like B-lymphoblastic leukemia, as detected by RNA kinome capture and transcriptome sequencing.",5.0
3141,LSM14A::ABL1 Fusion,"The LSM14A-ABL1 fusion is composed of part of the LSM14A (LSM14A mRNA processing body assembly factor) gene at the 5‚Äô end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The fusion is in-frame and it has been documented in two patients with BCR-ABL1-like B-lymphoblastic leukemia (Ph-like ALL). The first patient was a child with high risk Ph-like ALL and the second patient was a 36 years old male who had a poor prednisone response and did not reach complete remission after vincristine-dexamethasone-rituximab or a combination of dasatinib and chemotherapy. The second patient died early of sepsis in a context of uncontrolled disease (survival 2 months).",10.0
3142,MSH3 K383fs,,0.0
3143,PDGFRA Mutation,,7.5
3144,VHL Null (large rearrangement),,0.0
3145,VHL Null (c.341-?_463+ ?del),,0.0
3146,ZHX2 Overexpression,,0.0
3147,VHL L163R (c.488T>G),,0.0
3148,HDAC2 Overexpression,,0.0
3149,SPOP M117V,,0.0
3150,ERCC2 N238S,,0.0
3151,TP53 R110L,,0.0
3152,FLT3 ITD & Y597F,,0.0
3153,FLT3 ITD & L601F,,0.0
3154,CDKN2A D84N,,0.0
3155,PTEN G36R,,0.0
3156,SFPQ::ABL1 Fusion,"The SFPQ -ABL1 fusion is composed of part of the SFPQ (Splicing factor proline and glutamine rich) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 9 of SFPQ to exon 4 of ABL1 (SFPQ -ABL1). The fusion is the result of a reciprocal translocation t(1;9)(p34;q34) and has been identified by RT-PCR, Sanger sequencing, and RNA sequencing. The role of the partner gene SFPQ in this fusion remains to be investigated. SFPQ encodes for a protein belonging to a new functionally related group of fusion partners for tyrosine kinases involved in pre-mRNA processing. The presence of 2 coiled-coil domains in the 9 remaining exons of SFPQ could theoretically lead to SFPQ‚ÄìABL1 oligomerization, thus leading to constitutive activation of the resulting tyrosine kinase, as reported with other partner genes. Though uncommon, this translocation might be targeted by tyrosine kinase inhibitors. Clinical significance: The SFPQ -ABL1 fusion has been documented in six patients (3 male, 3 female) between the ages of 10 and 34 years with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. Two patients had tyrosine kinase inhibitors (dasatinib + imatinib) added to their chemotherapy regimens, who did not have relapse. One additional patient who did not have tyrosine kinase inhibitor also did not suffer from relapse. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors. Functional studies are needed to substantiate the efficacy of TKI treatment of this particular ABL-class fusion.",32.5
3157,CDKN2A D108N,,0.0
3158,CTCF P378L,,0.0
3159,PIK3CB E1051K,,0.0
3160,NF1 R1276Q,,0.0
3161,PIK3CA D939G,,0.0
3162,VHL L101G (c.301_302delCTinsGG),,0.0
3163,VHL F136V (c.406T>G),,0.0
3164,VHL Null (rearrangement),,0.0
3165,VHL Null (11 kb 3' deletion),,0.0
3166,VHL P81S (c.241C>T) and L188V (c.562C>G),,0.0
3167,PPP2R1A P179R,,4.0
3168,SPOP R121Q,,0.0
3169,SPOP M117I,,0.0
3170,TYK2 Pro1104Ala,,0.0
3172,EGFR N771_P772insL,,2.5
3173,TNFRSF17 Gain,,0.0
3174,HDAC9 Overexpression,,0.0
3175,FOXF1 Overexpression,,0.0
3176,FLT3 N841T,,0.0
3177,ATRX Deletion,,3.0
3178,HDAC9 p.L33R,,0.0
3180,BAG4::FGFR1 Fusion,,0.0
3181,CDKN1A rs1059234,,15.0
3182,CDKN1A rs1801270 and rs1059234,,0.0
3184,MEN1 Loss-of-function,,0.0
3185,VHL N174Lfs (c.520_521del),,0.0
3186,TP53 P250L,,5.0
3187,BTK Expression,,0.0
3188,BLK Expression,,0.0
3189,VEGFA VEGF165b Overexpression,,0.0
3190,VEGFA overexpression of VEGF-Axxxa,,0.0
3191,VEGFA low ratio of VEGF165b/VEGFtotal,,0.0
3192,VEGFA Overexpression of VEGF121,,0.0
3193,VEGFA Overexpression of VEGF121 and VEGF110,,0.0
3194,FLT3 Q575Œî,,0.0
3195,FLT3 Y572Œî,,0.0
3196,FLT3 E573Œî,,0.0
3197,FLT3 S574Œî,,0.0
3198,TCF19 EXPRESSION,,0.0
3199,LZTR1 G248R,,0.0
3200,CDKN2A E88K,,0.0
3201,CDKN2A D84Y,,0.0
3202,CDKN2A D84H,,0.0
3203,CDKN2A L16P,,0.0
3204,PIK3CA E39K,,0.0
3205,PIK3CA C604R,,0.0
3206,PIK3CA D350N,,0.0
3207,CTCF R377H,,0.0
3208,PTEN H93R,,0.0
3209,KRAS G10_A11insG,,4.0
3210,KRAS A11_G12insGA,,4.0
3211,SPOP E47K,,0.0
3212,EGFR R222C,,2.0
3213,SPOP E50K,,0.0
3214,SPOP G75R,,0.0
3215,SPOP S80R,,0.0
3216,SPOP P94A,,0.0
3217,SPOP D140G,,0.0
3218,KDR R1032Q,,2.0
3219,VHL t(3;8)(p13;q24.1),,0.0
3220,VHL Y98Afs(c.282_291dup),,0.0
3221,VHL P192R (c.575C>G),,0.0
3222,VHL K159* (c.474_475insT),,0.0
3223,VHL R177SFS*22 (c.531_542delinsTC),,0.0
3224,FGFR2 Y375C,,0.0
3225,FGFR2 C342R,,0.0
3226,FGFR2 C342Y,,0.0
3227,TBL1XR1::CSF1R Fusion,"The TBL1XR1-CSF1R fusion is composed of part of the TBL1XR1 (Transducin Beta Like 1 X-Linked Receptor 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (Colony Stimulating Factor 1 Receptor) gene at the 3‚Äô end (C-terminus of the fusion protein). CSF1R is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The breakpoint is not published, but is predicted to be the result of a reciprocal translocation t(3;5)(q26.32;q32) and has been identified by RNA sequencing in a single pediatric patient. The consequence of this fusion with respect to treatment response and disease outcome is unknown.",7.5
3228,VHL D92V (c.275A>T),,0.0
3229,VHL Null (del one VHL allele),,0.0
3230,VHL V166SFS*4 (c.496_506del),,0.0
3231,VHL F136LFS*23 (c.408del),,0.0
3232,EZH2 Y646H,,8.0
3233,VHL c.463+37_463+39del,,0.0
3234,VHL V130Wfs*30 (c.385_386dup),,0.0
3235,CD44 CD4v8-v10 and CD44v3-v10,,0.0
3236,CD44 CD44v9,,0.0
3237,CD44 CD44v8-10,,0.0
3238,VHL Splice site (c.463+2A>C),,0.0
3239,ALK I1171T,,10.0
3240,MET M1250T,,0.0
3241,CD44 CD44v6,,20.0
3242,CDKN2A D84G,,0.0
3243,CDKN2A D84V,,0.0
3244,CDKN2A R87P,,0.0
3245,CDKN2A P48L,,0.0
3246,H3-3A G34V,,0.0
3247,H3-3A G34R,,15.0
3248,CDKN2A D108H,,0.0
3249,PIK3R2 G373R,,1.0
3250,PTEN C136R,,3.0
3251,VHL E52*(c.156G>T),,0.0
3252,CDKN2A P81T,,0.0
3253,CD44 CD44s,,0.0
3254,CD44 CD44v5 and CD44v6,,0.0
3255,CD44 CD44v6+/CD44s-,,0.0
3256,CD44 CD44v6 and CD44v10,,0.0
3257,TP53 C176F,,0.0
3258,TP53 R181P,,3.0
3259,TP53 S183L,,0.0
3260,TP53 L194R,,0.0
3261,TP53 C238F,,0.0
3262,TP53 N239D,,0.0
3263,TP53 N239T,,0.0
3264,TP53 M243T,,0.0
3265,TP53 G244V,,0.0
3266,TP53 M246A,,0.0
3267,TP53 M246T,,0.0
3268,TP53 R249G,,0.0
3269,TP53 D259V,,2.0
3270,TP53 K305M,,0.0
3271,PTEN T277R,,0.0
3272,PTEN c.209+5G>A,,0.0
3273,PTEN Y336*,,0.0
3274,PTEN T277I,,0.0
3275,PTEN T277A,,0.0
3276,TEK Cis double mutants,,0.0
3277,TEK T1105N and T1106N,,0.0
3278,TEK Y897C and R915C,,0.0
3279,TEK R849W and R1108*,,0.0
3280,MTOR T1977R,,0.0
3281,MTOR C1483R,,0.0
3282,MTOR L2427Q,,0.0
3283,AR Overexpression of AR-V9,,0.0
3284,TP53 A138V,,0.0
3285,TP53 T125R,,0.0
3286,TP53 P151A,,0.0
3287,TP53 G154S,,0.0
3288,TP53 R174K,,0.0
3289,TP53 R267Q,,0.0
3290,TP53 R283P,,0.0
3291,TP53 R337C,,0.0
3292,TP53 R337H,,0.0
3293,BRAF G469S,,0.0
3297,ARHGAP35 R997*,,0.0
3298,NFE2L2 E82D,,0.0
3299,CIC R215W,,0.0
3300,BRAF G463E,,3.0
3301,RRAS2 Q72L,,0.0
3302,PIK3CA R93Q,,0.0
3304,VHL Splice Site (c.341-6C>T),,0.0
3305,PIK3CA G1007R,,0.0
3306,PIK3CA N1044K,,0.0
3307,MTOR R2152C,,0.0
3308,KLF4 K409Q,,0.0
3309,BRAF G468A,,0.0
3310,BRAF G463V,,0.0
3311,BRAF G465A,,0.0
3312,BRAF N580S,,0.0
3313,BRAF T598I,,0.0
3314,BRAF V599E,,0.0
3315,BRAF R461I,,0.0
3316,BRAF I462S,,0.0
3317,BRAF E585K,,0.0
3318,BRAF F594L,,0.0
3319,BRAF L596V,,0.0
3320,BRAF V600D,,0.0
3321,BRAF V599K,,0.0
3322,BRAF V599R,,0.0
3323,BRAF K600E,,0.0
3324,EP300 Y1414C,,0.0
3325,NFE2L2 G31A,,3.0
3326,PIK3CA P447_L455del,,0.0
3327,AR V1 expression,,0.0
3328,AR AR alternative transcripts,,0.0
3329,AR V567es expression,,0.0
3330,TP53 E285V,,0.0
3331,PALB2 R414X,,0.0
3332,EGFR E114K,,0.0
3333,TPR::NTRK1 Fusion,,17.5
3334,NTRK1 Point Mutations,,0.0
3335,NTRK3 Point Mutations,,0.0
3336,NTRK3 F617L,,5.0
3338,EGFR R165Q,,0.0
3339,KRAS KRAS4A underexpression,,0.0
3340,KRAS KRAS4A,,0.0
3341,TNC TNC-L,,0.0
3342,CEACAM1 CEACAM1-L,,0.0
3343,CEACAM1 CEACAM1-S,,0.0
3344,H3-3A K27,,0.0
3345,ESR2 beta-2 and beta-5,,0.0
3346,ESR2 underexpression beta-1,,0.0
3347,VHL T124del (c.369_371del),,0.0
3348,VHL L198P (c.593T>C) and P25L (c.74C>T),,0.0
3349,ESR2 alternative transcripts,,0.0
3350,LGR5 delta5,,0.0
3351,LGR5 LGR5FL,,0.0
3352,FN1 EDB,,0.0
3353,DNMT3A R736H,,0.0
3354,TOP2A TOP2A/90,,0.0
3355,BRCA1 delta11q,,0.0
3356,EGFR G63R,,0.0
3357,EGFR P596L,,0.0
3358,EGFR K708R,,0.0
3359,VHL P2=(c.6C>G),,0.0
3360,CTNNB1 G34E,,0.0
3361,VHL N150fs (c.446delC),,0.0
3363,ERBB3 D297Y,,0.0
3364,ERBB4 E317K,,0.0
3365,ERBB2 S1050L,,0.0
3366,ERBB3 R1202W,,0.0
3367,ERCC2 Y72C,,0.0
3368,ERCC2 Y14C,,0.0
3369,ERCC2 Y24C,,0.0
3370,ERCC2 S44L,,0.0
3371,ERCC2 T46S,,0.0
3372,ERCC2 E79D,,0.0
3373,ERCC2 E86Q,,0.0
3374,ERCC2 Y209C,,0.0
3375,ERCC2 V242F,,0.0
3376,CD274 v242,,0.0
3377,AIMP2 DX2,,0.0
3378,BCL2L11 Alternative splicing,,0.0
3379,"CD19 delta-ex2, delta-ex5-6",,0.0
3380,BRAF p61BRAF(V600E),,0.0
3381,VHL L140fs*3 (c.419_420delTC),,0.0
3382,FGFR3 Y647C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3383,FGFR3 M528I,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3384,FGFR3 F384L,"This variant was not activating and unable to transform NIH3T3 cells compared to activating mutations in FGFR3. 
This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.",0.0
3385,TAF15::ZNF384 Fusion,,0.0
3387,SMAD4 R496H,,0.0
3388,SMAD4 G419V,,0.0
3389,SMAD4 E330K,,0.0
3390,SMAD4 G386D,,0.0
3391,SMAD4 G252*,,0.0
3392,MECOM t(3;21)(q26.2;q22),,0.0
3393,PAG1::ABL2 Fusion,,0.0
3394,RCSD1::ABL2 Fusion,,0.0
3396,PTEN A126D,,0.0
3397,PTEN H93D,,0.0
3398,PTEN H93Q,,0.0
3399,PTEN H93Y,,0.0
3400,PTEN N94I,,0.0
3401,PTEN P95L,,0.0
3402,PTEN P96Q,,0.0
3403,PTEN Y88C,,0.0
3404,PTEN F90L,,0.0
3405,PTEN E91A,,0.0
3406,PTEN D92A,,0.0
3407,PTEN D92E,,0.0
3408,PTEN D92G,,0.0
3409,PTEN D92H,,0.0
3410,PTEN D92V,,0.0
3411,PTEN R15K,,0.0
3412,PTEN A121E,,0.0
3413,PTEN I122S,,0.0
3414,PTEN H123D,,0.0
3415,PTEN C124S,,0.0
3416,PTEN K125E,,0.0
3417,PTEN G127E,,0.0
3418,KMT2A::AFDN Fusion,,0.0
3419,KMT2A::MLLT10 Fusion,,0.0
3420,KMT2A::ABI1 Fusion,,0.0
3421,PTEN D162G,,0.0
3422,PTEN V166I,,0.0
3423,PTEN I168F,,0.0
3424,PTEN P169H,,0.0
3425,PTEN S170R,,0.0
3426,PTEN T160I,,0.0
3427,PTEN G165E,,0.0
3428,PTEN G165V,,0.0
3429,PTEN G129V,,0.0
3430,PTEN G129R,,0.0
3431,PTEN G129E,,0.0
3432,PTEN K128N,,0.0
3433,PTEN A126S,,0.0
3434,SSBP2::CSF1R Fusion,,0.0
3435,VHL D121Y(c.361G>T),,0.0
3436,JAK2 Overexpression,,0.0
3437,STAT5B Overexpression,,0.0
3438,CCND1 P287S,,0.0
3439,CCND1 P287T,,0.0
3440,FLT3 I836S,,0.0
3441,FLT3 I836T,,0.0
3442,TP53 V157D,,0.0
3443,PMS2 R20Q,,0.0
3444,ERBB2 Q709L,,0.0
3446,ZC3HAV1::ABL2 Fusion,,0.0
3447,TP53 R342P,,3.0
3448,TP53 L330P,,3.0
3449,TP53 L330R,,3.0
3450,TP53 R337P,,3.0
3451,TP53 L344P,,3.0
3452,TP53 K120E,,0.0
3453,TP53 E180K,,0.0
3455,H3-3A G34,,0.0
3456,RIT1 M90I,,0.0
3457,RIT1 Q79L,,0.0
3458,RIT1 Q40L,,0.0
3459,RIT1 A77P,,0.0
3460,RIT1 A77S,,0.0
3461,RIT1 F82L,,0.0
3462,H3-3A K27R,,0.0
3463,TP53 V197E,,0.0
3464,TP53 K120R,,0.0
3465,DDR2 High expression,,0.0
3466,DDR2 Overexpression,,0.0
3467,HDAC6 Overexpression,,0.0
3468,ATXN7 Q39P,,0.0
3469,ATXN7 Q30R,,0.0
3470,ATXN7 P40Q,,0.0
3471,ATXN7 P42_P43insP,,0.0
3472,EZH2 R690C,,0.0
3473,EZH2 C576W,,0.0
3474,EZH2 Y731D,,0.0
3475,EZH2 Y646C,,2.0
3476,BRCA2 R2842C,,0.0
3477,BRCA2 Y2726C,,0.0
3478,BRCA2 D2611G,,0.0
3479,BRCA2 D3073G,,0.0
3480,BRCA2 L2654P,,0.0
3481,BRCA2 G2793E,,0.0
3482,BRCA2 Y2660D,,0.0
3483,BRCA2 G2585R,,0.0
3484,BRCA2 G2793R,,0.0
3485,BRCA2 L2792P,,0.0
3486,BRCA2 R2659G,,0.0
3487,BRCA2 R2784Q,,0.0
3488,BRCA2 G3076V,,0.0
3489,BRCA2 E3002K,,0.0
3490,ASPSCR1::TFE3 Fusion,,59.0
3491,BRCA2 G3076E,,0.0
3492,BRCA2 L2510P,,0.0
3493,BRCA2 D2723A,,0.0
3494,BRCA2 R2784W,,0.0
3495,BRCA2 W2626C,,0.0
3496,BRCA2 G2609D,,0.0
3497,BRCA2 T2722R,,0.0
3498,BRCA2 I2627F,,0.0
3499,BRCA2 D2723G,,0.0
3500,VHL F76fs (c.224_225insA),,0.0
3501,VHL R108dup (c.322_324dupCGC),,0.0
3502,VHL W117fs (c.349dupT),,0.0
3503,VHL E55* (c.162_163insT),,0.0
3504,FLT3 ITD & N841K,,0.0
3505,VHL G104FS (c.309_310delTG),,0.0
3506,BRCA2 L2688P,,0.0
3507,BRCA2 D2723H,,0.0
3508,BRCA2 L2647P,,0.0
3509,BRCA2 N3124I,,0.0
3510,BRCA2 L2653P,,0.0
3511,PIM1 L2V,,3.0
3512,PIM1 P81S,,3.0
3513,PIM1 S97N,,3.0
3514,HOXC10 Overexpression,,0.0
3515,KDR S1100F,,0.0
3516,KDR L840F,,0.0
3517,KDR G800D,,0.0
3518,KDR G800R,,0.0
3519,KDR G843D,,0.0
3520,KDR S925F,,0.0
3521,KDR R1022Q,,0.0
3522,VHL E55fs (c.163dupG),,0.0
3523,VHL N67_V74del (c.197_220del),,0.0
3524,VHL R108fs (c.322_323insTG),,0.0
3525,VHL Q203fs (c.607_608delCA),,0.0
3526,VHL R205fs (c.614_615delGC),,0.0
3527,SMARCB1 LOSS OF NUCLEAR PROTEIN EXPRESSION,,15.0
3528,CYSLTR2 L129Q,,0.0
3529,ACVR1 R206H,,5.0
3530,ACVR1 G356D,,5.0
3531,BRAF Q524L,,0.0
3532,ERBB2 I767M,,0.0
3533,ERBB2 Y835F,,0.0
3534,PIK3CA K944N,,10.0
3535,PIK3CA F930S,,10.0
3536,PIK3CA V955G,,10.0
3537,PIK3CA K966E,,10.0
3538,PIK3CA L938*,,7.5
3539,FBXW7 R465C,,0.0
3540,FBXW7 R479Q,,0.0
3541,FBXW7 R505L,,0.0
3542,NOTCH1 S2514A,,0.0
3543,NOTCH1 T2512A,,0.0
3544,NOTCH1 S2514E,,0.0
3545,NOTCH1 S2514P,,0.0
3546,ETV6 R418G,,0.0
3547,ETV6 N385_R418del,,0.0
3548,JAK1 S729C,,0.0
3549,JAK1 N451S,,0.0
3550,JAK1 E483D,,0.0
3551,JAK1 A1086S,,0.0
3552,TP53 T125T,,4.0
3553,PTPRD R995C,,0.0
3554,PTPRD T781A,,0.0
3555,KMT2A Amplification,,0.0
3556,ABL2 W469C,,0.0
3557,ABL2 Y399C,,0.0
3558,PTPRB Y309C,,0.0
3559,PTPRB W130R,,0.0
3560,FGFR3 E466K,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3561,FGFR3 N540K,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3562,FGFR3 N540S,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3563,FGFR3 K650N,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,2.0
3564,FGFR3 R669G,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3565,FGFR3 R669Q,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3566,FGFR3 D617G,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3567,FGFR3 G637W,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3568,ETV6::NTRK1 Fusion,,3.0
3569,VCL::NTRK2 Fusion,,3.0
3570,AFAP1::NTRK2 Fusion,,3.0
3571,GALNT14 rs9679162,,0.0
3572,VHL S72fs (c.214_215insGCCC),,0.0
3573,AR L57Q,,0.0
3574,AR D221H,,0.0
3575,AR E198G,,0.0
3576,AR A234T,,0.0
3577,AR S296R,,0.0
3578,AR S334P,,0.0
3579,AR P340L,,0.0
3580,AR P504L,,0.0
3581,AR D528G,,0.0
3582,AR K720E,,0.0
3583,VHL W117R (c.349T>C),,0.0
3584,AR R726L,,0.0
3585,AR L744F,,0.0
3586,AR A748V,,0.0
3587,AR N756D,,0.0
3588,VHL M3I(c.3G>A) and M211L (c.631A>C),,0.0
3589,AR V757A,,0.0
3590,AR V757I,,0.0
3591,AR S759P,,0.0
3592,AR Y763C,,0.0
3593,AR A765T,,0.0
3594,AR Q798E,,0.0
3595,FLCN c.1285dupC,,2.5
3596,SLC29A1 Overexpression,,20.0
3598,v::TFE3 Fusion,,65.0
3599,KIT Overexpression,,0.0
3600,HSP90B1 Overexpression,,0.0
3601,KRAS Overexpression,,0.0
3602,COX2 Overexpression,,0.0
3603,BRAF Overexpression,,0.0
3604,VHL G30Dfs*32 (c.89_297del),,0.0
3605,EZH2 Activating Mutation,,35.0
3606,VHL T133Nfs*2 (c.397dup),,0.0
3607,VHL Y175Tfs*27 (c.523del),,0.0
3608,NTRK1 NTRK1 amplification,,0.0
3609,VHL V87fs (c.255_256insC),,0.0
3610,G3BP2::KIT Fusion,,0.0
3611,VHL N150fs (c.448delA),,0.0
3612,VHL E55fs (c.163delG),,0.0
3613,CTCF K365T,,3.0
3614,CCNE2 Overexpression,,0.0
3615,VHL S111I (c.332G>T),,0.0
3616,VHL V165G (c.494T>G),,0.0
3617,VHL Exon 3 Variant,,0.0
3618,ARHGAP35 S866F,,0.0
3619,ARHGAP35 A865_L870delinsV,,0.0
3620,SSTR5 expression,,15.0
3621,VHL L140Sfs*4 (c.417dup),,0.0
3622,BACH2 E788K,,0.0
3623,BACH2 L24P,,0.0
3624,BAP1 C91S,,0.0
3625,SMAD3 R373H,,0.0
3626,U2AF1 I24T,,0.0
3627,VHL N174FS*29 (c.519insAA),,0.0
3628,TP53 P98S,,3.0
3629,TP53 P98L,,3.0
3630,TP53 Y126D,,3.0
3631,TP53 Y126S,,3.0
3632,TP53 K139E,,3.0
3633,TP53 P151S,,3.0
3635,TP53 P152L,,6.0
3636,TP53 I162F,,3.0
3637,TP53 Y163H,,3.0
3638,TP53 Y236S,,3.0
3639,TP53 L252F,,3.0
3640,TP53 E258K,,3.0
3641,TP53 G262D,,3.0
3642,TP53 G266E,,6.0
3643,TP53 L308M,,3.0
3644,TP53 L323P,,3.0
3645,TP53 Q144P,,3.0
3646,TP53 P219H,,3.0
3647,TP53 Y220H,,3.0
3648,TP53 E224K,,3.0
3649,TP53 Y234H,,3.0
3650,TP53 T230S,,3.0
3651,TP53 H168Y,,3.0
3652,TP53 P177S,,3.0
3653,TP53 P177F,,3.0
3654,TP53 P177H,,3.0
3655,TP53 N239S,,3.0
3656,TP53 S241T,,3.0
3657,TP53 M246L,,3.0
3658,TP53 V274F,,3.0
3659,TP53 G279E,,3.0
3660,TP53 D281N,,3.0
3661,TP53 G177E,,0.0
3662,TP53 P152T,,2.0
3663,TP53 R156P,,2.0
3664,TP53 R181C,,2.0
3665,TP53 R181G,,2.0
3666,TP53 R181H,,2.0
3667,TP53 R283H,,2.0
3668,TP53 Y163N,,2.0
3669,TP53 L257P,,2.0
3670,TSC2 D1734E,,0.0
3671,SMAD4 H132Y,,0.0
3674,POLB MUTATION,,0.0
3675,CDKN2B-AS1 EXPRESSION,,0.0
3677,ERCC2 LOSS-OF-FUNCTION,,0.0
3679,YAP1 EXPRESSION,,0.0
3681,KIF3C EXPRESSION,,0.0
3682,BAP1 UNDEREXPRESSION,,0.0
3683,ARID2 EXPRESSION,,0.0
3684,NOS2 OVEREXPRESSION,,0.0
3685,TUBA1C OVEREXPRESSION,,0.0
3686,SPATS2 OVEREXPRESSION,,0.0
3687,MAGI2 OVEREXPRESSION,,0.0
3688,PIK3CD-AS2 OVEREXPRESSION,,0.0
3689,CARD9 UNDEREXPRESSION,,0.0
3690,WTAP OVEREXPRESSION,,0.0
3691,TFB2M OVEREXPRESSION,,0.0
3692,WNT2B OVEREXPRESSION,,0.0
3693,GPD1 OVEREXPRESSION,,0.0
3694,OTUD4 UNDEREXPRESSION,,0.0
3695,ABL2 UNDEREXPRESSION,,0.0
3696,GPX2 OVEREXPRESSION,,0.0
3697,SLC12A2 OVEREXPRESSION,,0.0
3698,MALAT1 OVEREXPRESSION,,0.0
3699,CHD1 LOSS,,0.0
3700,SLC6A14 OVEREXPRESSION,,0.0
3701,BCL11A OVEREXPRESSION,,0.0
3702,MYBL2 OVEREXPRESSION,,0.0
3703,MIR31 OVEREXPRESSION,,0.0
3704,FAM83A OVEREXPRESSION,,0.0
3705,SQLE OVEREXPRESSION,,0.0
3706,NUSAP1 UNDEREXPRESSION,,0.0
3707,LGALS1 OVEREXPRESSION,,0.0
3708,USP10 OVEREXPRESSION,,0.0
3709,ABCC11 OVEREXPRESSION,,0.0
3710,ELFN1-AS1 OVEREXPRESSION,,0.0
3711,USP19 UNDEREXPRESSION,,0.0
3712,MAFB OVEREXPRESSION,,0.0
3713,LTF UNDEREXPRESSION,,0.0
3714,GFOD3P UNDEREXPRESSION,,0.0
3715,CD96 OVEREXPRESSION,,0.0
3716,SST PROMOTER HYPERMETHYLATION,,0.0
3717,ANXA2 OVEREXPRESSION,,0.0
3718,RGL4 UNDEREXPRESSION,,0.0
3719,SULT1B1 UNDEREXPRESSION,,0.0
3720,ABCG2 OVEREXPRESSION,,0.0
3721,GOT1 OVEREXPRESSION,,0.0
3722,GJB7 EXPRESSION,,0.0
3723,HSD17B4 UNDEREXPRESSION,,0.0
3724,STEAP1 OVEREXPRESSION,,0.0
3725,KNL1 OVEREXPRESSION,,0.0
3726,MIR3174 OVEREXPRESSION,,0.0
3727,CAVIN1 EXPRESSION,,0.0
3728,TLR10 OVEREXPRESSION,,0.0
3729,ANXA8 OVEREXPRESSION,,0.0
3730,B4GALNT2 OVEREXPRESSION,,0.0
3731,INHBA OVEREXPRESSION,,0.0
3732,SPATA2 OVEREXPRESSION,,0.0
3733,FOXP3 OVEREXPRESSION,,0.0
3734,MIR185 EXPRESSION,,0.0
3735,LAG3 OVEREXPRESSION,,0.0
3736,TNFSF14 OVEREXPRESSION,,0.0
3737,FUCA1 OVEREXPRESSION,,0.0
3738,PORCN EXPRESSION,,0.0
3739,ASS1 UNDEREXPRESSION,,0.0
3740,RGS16 OVEREXPRESSION,,0.0
3741,MIR484 OVEREXPRESSION,,0.0
3742,CEP55 OVEREXPRESSION,,0.0
3743,CENPA OVEREXPRESSION,,0.0
3744,LRG1 OVEREXPRESSION,,0.0
3745,DGKA OVEREXPRESSION,,0.0
3746,AOC3 OVEREXPRESSION,,0.0
3747,HDAC5 OVEREXPRESSION,,0.0
3748,YTHDF2 OVEREXPRESSION,,0.0
3749,TESC OVEREXPRESSION,,0.0
3750,MIR143 OVEREXPRESSION,,0.0
3751,MACF1 UNDEREXPRESSION,,0.0
3752,OTUD3 OVEREXPRESSION,,0.0
3753,FLI1 OVEREXPRESSION,,0.0
3754,ACKR3 OVEREXPRESSION,,0.0
3755,NEK1 OVEREXPRESSION,,0.0
3756,SNHG4 OVEREXPRESSION,,0.0
3758,HOXA13 OVEREXPRESSION,,0.0
3759,UCP2 OVEREXPRESSION,,0.0
3760,LINC00520 OVEREXPRESSION,,0.0
3761,MPC1 DELETION,,0.0
3762,PALB2 DELETION,,0.0
3763,RBM17 OVEREXPRESSION,,0.0
3764,RAB18 OVEREXPRESSION,,0.0
3765,HHLA2 OVEREXPRESSION,,0.0
3766,CDCA2 OVEREXPRESSION,,0.0
3767,EPS8L3 OVEREXPRESSION,,0.0
3768,EID3 OVEREXPRESSION,,0.0
3769,TGFB2 OVEREXPRESSION,,0.0
3770,PPP2R2A LOSS,,0.0
3771,SPOP OVEREXPRESSION,,0.0
3772,HOTTIP OVEREXPRESSION,,0.0
3773,MIR28 OVEREXPRESSION,,0.0
3774,GNA14 UNDEREXPRESSION,,0.0
3775,ERRFI1 OVEREXPRESSION,,0.0
3776,UPP1 OVEREXPRESSION,,0.0
3777,SERPINH1 OVEREXPRESSION,,0.0
3778,ESR1 Mutation,,30.0
3779,PDCD1 OVEREXPRESSION,,0.0
3780,TNNT2 OVEREXPRESSION,,0.0
3781,LINC00460 OVEREXPRESSION,,0.0
3782,MMP14 OVEREXPRESSION,,0.0
3783,LPAR1 OVEREXPRESSION,,0.0
3784,SNHG6 OVEREXPRESSION,,0.0
3785,BRCA1 Wildtype,,0.0
3786,PDXDC1 MUTATION,,0.0
3787,SERINC2 OVEREXPRESSION,,0.0
3788,CEACAM6 OVEREXPRESSION,,0.0
3789,NRG1 OVEREXPRESSION,,0.0
3790,STAT3 OVEREXPRESSION,,0.0
3791,SMARCA4 ALTERATION,,0.0
3792,LUZP2 UNDEREXPRESSION,,0.0
3793,MAN2A1 EXPRESSION,,0.0
3794,TET1 OVEREXPRESSION,,0.0
3795,SPC25 OVEREXPRESSION,,0.0
3796,MIR320A UNDEREXPRESSION,,0.0
3797,SERPINE1 OVEREXPRESSION,,0.0
3798,DRD1 EXPRESSION,,0.0
3799,ZNF554 UNDEREXPRESSION,,0.0
3800,CTBP2 OVEREXPRESSION,,0.0
3804,AR EXPRESSION,,0.0
3807,H3-3A K27M,,0.0
3809,BRCA1 L136P,,0.0
3810,H3C7 K27M,,0.0
3811,H3C3 k27m,,0.0
3812,H3C14 K27M,,0.0
3813,XPO1 Overexpression,,0.0
3814,ATXN7 Mutation,,0.0
3815,FLT3 N841,,0.0
3816,GALNT14 rs9679162: intron,,0.0
3817,PALB2 Intronic mutations,,0.0
3818,MLH1 mutation,,0.0
3819,MSH2 mutation,,0.0
3820,NFE2L2 G31R,,0.0
3822,IGH::EPOR Fusion,,0.0
3824,AR T878A,,0.0
3825,OCLN::RASGRF1 Fusion,,0.0
3826,KRAS fas,,0.0
3827,SMAD4 D493H,,0.0
3828,NFE2L2 E79Q,,0.0
3829,EGFR R252C,,0.0
3830,BRCA1 H1686R,,0.0
3831,BRCA1 H1686Q,,0.0
3832,BRCA1 S1655F,,0.0
3833,BRCA1 M1652I,,0.0
3834,BRCA1 M1628T,,0.0
3835,BRCA1 R1589P,,0.0
3836,BRCA1 V1534M,,0.0
3837,BRCA1 S1486C,,0.0
3838,BRCA1 V1688del,,0.0
3839,BRCA1 R1699W,,0.0
3840,BRCA1 G1706E,,0.0
3841,BRCA1 G1706A,,0.0
3842,VHL L153Tfs,,0.0
3843,VHL L153Tfs (c.456dup),,0.0
3844,BRCA1 A1708E,,0.0
3845,TP53 N7777R,,0.0
3846,BRCA1 W1718C,,0.0
3847,BRCA1 T1720A,,0.0
3848,BRCA1 D1739G,,0.0
3849,BRCA1 D1739V,,0.0
3850,BRCA1 L1764P,,0.0
3851,CRBN High expression,,0.0
3852,VHL F136L (c.406T>C),,0.0
3853,VHL V155L (c.463G>T),,0.0
3854,SH3PXD2A::HTRA1 Fusion,,0.0
3855,CIC::LEUTX Fusion,,0.0
3856,MAP3K8::v Fusion,,0.0
3860,STAT1 Expression,,0.0
3861,BRCA1 G1770V,,0.0
3862,BRCA1 A1789T,,0.0
3863,BRCA1 W1837R,,0.0
3864,BRCA1 H1862L,,0.0
3865,BRCA1 P1812R,,0.0
3866,BRCA1 V1804D,,0.0
3867,VHL Partial deletion of 10 Kb,,0.0
3868,QKI::RAF1 Fusion,,7.5
3869,KANK4::ALK Fusion,,7.5
3871,PDGFB Rearrangement ,,0.0
3872,TERT C250T,,0.0
3874,DDX41 G320D,,0.0
3875,DDX41 G530D,,0.0
3876,VHL t(3;6)(p13;q25.1),,0.0
3877,VHL t(3;12)(q13.2;q24.1),,0.0
3880,MS4A1 Y86C,,0.0
3881,FGFR3 K650M,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,1.0
3882,PLCG2 N571S,,0.0
3883,PLCG2 D1140E,,0.0
3884,BTK C481Y,,0.0
3885,BTK C481R,,0.0
3886,MS4A1 Mutation,,15.0
3887,FGFR3 K650Q,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,4.0
3889,FGFR3 K650T,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,2.0
3890,FGFR3 I538F,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3891,FGFR3 A391E,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,4.0
3892,FGFR3 K650D,,3.0
3893,FGFR3 K650L,,2.0
3896,FGFR3 N540D,,0.0
3898,FGFR3 G697C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3899,FGFR3 V50I,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3900,FGFR3 S84L,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3901,FGFR3 R124W,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3902,FGFR3 S187Y,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3903,FGFR3 R200C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3904,FGFR3 S217C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3905,FGFR3 C228R,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3906,FGFR3 H274Y,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3907,FGFR3 Y278C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3908,FGFR3 G346E,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3909,FGFR3 S371C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3910,FGFR3 G375C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3911,FGFR3 V390M,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3912,FGFR3 A391V,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3913,FGFR3 T394M,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3914,FGFR3 R399C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3915,FGFR3 P402S,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3916,FGFR3 A452S,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3917,FGFR3 A500T,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3918,FGFR3 K508M,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3919,FGFR3 I538V,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3920,FGFR3 P572A,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3921,FGFR3 C582F,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3922,FGFR3 E627D,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3923,FGFR3 V630M,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3924,FGFR3 D641N,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3925,FGFR3 D641G,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3926,FGFR3 V642M,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3927,FGFR3 H643D,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3928,FGFR3 D646Y,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3929,FGFR3 K650R,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3930,FGFR3 N653H,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3931,FGFR3 V677I,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3932,FGFR3 D762H,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3933,FGFR3 S780C,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3934,FGFR3 D785N,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3935,FGFR3 D786N,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3936,FGFR3 V788M,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3937,FGFR3 R805Q,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3938,FGFR3 G382D,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3939,FGFR3 L8= (c.24C>G),This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,0.0
3940,TFEB t(6;11),,0.0
3941,TFEB 6p21.1 amplification,,0.0
3942,TFEB TFEB amplification,,0.0
3943,EML6 EML6::NTRK3,,0.0
3944,VHL S43_E47del (c.123_137del),,0.0
3945,VHL E55Gfs*77 (c.163dup),,0.0
3946,VHL N67_V74del (c.197_221del),,0.0
3947,VHL R69Afs*63 (c.204dup),,0.0
3948,VHL P71Lfs*61 (c.211_212insT),,0.0
3950,VHL F76_C77del (c.226_231del),,0.0
3951,VHL F76* (c.227T>A; c.228C>A),,0.0
3952,VHL G106Tfs*54 (c.315_316insAC),,0.0
3953,VHL R108Lfs*52 (c.322_323insTG),,0.0
3954,VHL Splice Site (c.340+2_340+6del),,0.0
3955,VHL L140Qfs*3 (c.419_420del),,0.0
3956,VHL K159Efs*15 (c.473dup),,0.0
3957,VHL K159delinsI* (c.475_476insTTT),,0.0
3958,EZH2 Y646N,,6.0
3959,VHL V165Lfs*5 (c.492del),,0.0
3960,VHL L178_D179insRVKPEL (c.531_532insCTGAGAGTAAAGCCTGAA),,0.0
3961,VHL H191Tfs*11 (c.571del),,0.0
3962,VHL Q203Gfs*52 (c.607_608del),,0.0
3963,VHL R205Hfs*50 (c.614_615del),,0.0
3964,VHL R161* (c.481C>T) AND R200fs (c.598del),,0.0
3965,VHL P76del (c.227_229del),,0.0
3966,CTRC::NTRK1 Fusion,,0.0
3967,VHL S65* (c.189_192del),,0.0
3968,VHL K159fs (c.472_473insT),,0.0
3969,TP53 R342STOP,,0.0
3970,TP53 R156H,,3.0
3971,TP53 H178P,,3.0
3972,TP53 G245N,,0.0
3973,TP53 M246R,,0.0
3974,TP53 E68G,,3.0
3975,SOS1 E846K,,0.0
3976,VHL C77Sfs*82 (c.230del),,0.0
3977,VHL S80Ifs*79 (c.239del),,0.0
3978,VHL Q96del (c.287_289del),,0.0
3979,TP53 L111R,,3.0
3980,TP53 H115Y,,3.0
3981,TP53 C124R,,3.0
3982,TP53 L139N,,3.0
3983,TP53 R158G,,3.0
3984,TP53 A161G,,0.0
3985,TP53 V173G,,0.0
3986,TP53 C176S,,0.0
3987,TP53 H193L,,0.0
3988,TP53 V197L,,0.0
3989,TP53 R213Q,,0.0
3990,TP53 G266V,,3.0
3991,TP53 V272G,,3.0
3992,TP53 C275F,,0.0
3993,TP53 L305M,,0.0
3994,TP53 A347G,,0.0
3995,TP53 A83E,,0.0
3996,TP53 A86T,,0.0
3997,TP53 A86E,,0.0
3998,TP53 S127Y,,0.0
3999,TP53 A138K,,0.0
4000,TP53 Q144Q,,0.0
4001,TP53 R158C,,0.0
4002,TP53 A161D,,0.0
4003,TP53 Q167R,,0.0
4004,TP53 A161V,,0.0
4005,TP53 H168R,,0.0
4006,TP53 H168Q,,0.0
4007,TP53 V173M,,0.0
4008,TP53 R181L,,0.0
4009,TP53 P190H,,0.0
4010,TP53 R196Q,,0.0
4011,TP53 S227C,,0.0
4012,TP53 G262C,,0.0
4013,TP53 C277Y,,0.0
4014,TP53 D281Y,,0.0
4015,TP53 K305N,,0.0
4016,TP53 R306E,,0.0
4017,TP53 R337S,,0.0
4019,VHL c.329ins2,,0.0
4020,VHL c.358ins2,,0.0
4021,VHL D143Efs*13 (c.429_438del),,0.0
4022,VHL S168Tfs*2 (c.503_513del),,0.0
4023,VHL E173Rfs*29 (c.516del),,0.0
4024,VHL L198Gfs*57 (c.592_593del),,0.0
4025,VHL c.563ins20,,0.0
4026,POLE L424V,,0.0
4027,VHL N67_V74del (c.198_221del),,0.0
4028,VHL L158dup (c.473_474insTTT),,0.0
4029,VHL E73* (c.217C>T),,0.0
4030,VHL Splice Region (c.340+1_340+5del),,0.0
4032,VHL p25l (C.74C>T) AND D126Rfs*6 (c.375_376insA) AND E55Rfs (c.163delG),,0.0
4033,VHL P25L (c.74C>T) AND D126Rfs*6 (c.375_376insA) AND E55Rfs(c.163delG),,0.0
4035,VHL R167Q (c.500G>A) and I151N (c.452T>A),,0.0
4036,VHL Exon 1-3 Deletion and P81S (c.241C>T),,0.0
4037,VHL Exon 1-3 Deletion and Splice Region (c.340+5G>C),,0.0
4038,VHL  3'UTR alteration (c.*70C>T),,0.0
4039,VHL S111N (c.332G>A) ,,0.0
4040,VHL G144Dfs*15 (c.431del),,0.0
4041,VHL c.502ins8bp,,0.0
4042,VHL G114D (c.340+1G>A),,0.0
4043,VHL V155G (c.464T>G) and c.463+43A>G,,0.0
4044,VHL P2=(c.6C>G) and P81S(c.241C>T),,0.0
4045,PDGFRA K385,,0.0
4046,VHL c.340+770T>C and R200W (c.598C>T),,0.0
4047,VHL V87Gfs*71(c.260_263del) and P81S(c.241C>T),,0.0
4049,VHL C162Y(c.486C>G) and L188V(c.562C>G) and P81S(c.241C>T) and F119L(c.357C>G),,0.0
4050,YES1 Overexpression,,0.0
4051,PDGFRA V544ins,,0.0
4052,VHL S80N (c.239G>A) and P25L (c.74C>T),,0.0
4053,VHL H115Pfs*44(c.344delA) and P61=(c.183C>G),,0.0
4054,VHL 2kb Deletion,,0.0
4055,VHL 5kb Deletion,,0.0
4056,VHL 10kb Deletion,,0.0
4057,VHL Partial Deletion and P61=( c.183C>G),,0.0
4058,VHL R200W (c.598C>T) and V130L (c.388G>C),,0.0
4059,VHL c.‚Äì65_‚Äì55dup11 AND  3' UTR alteration (c.*1149A>G),,0.0
4060,VHL Deletion AND I151S(c.452T>G),,0.0
4061,VHL Deletion AND R200W (c.598C>T),,0.0
4062,VHL Deletion AND R69C (c.205C>T),,0.0
4063,VHL S65L (c.194C>T) AND L89P (c.266T>A),,0.0
4064,VHL Deletion AND R120_121S (c.360_362delAGA),,0.0
4065,VHL c.341-59_341-14del AND F136fs (c.408delT),,0.0
4066,VHL V155= (c.465G>C),,0.0
4067,VHL L188del (c.562_564delCTG),,0.0
4068,VHL Partial deletion of 0.8 kb,,0.0
4069,VHL N90del (c.268_270del),,0.0
4070,VHL P59_R64del (c.174_191del),,0.0
4071,PIK3R1 R348*,,0.0
4072,VHL R79G (c.235C>G),,0.0
4073,VHL T124P (c.370A>C),,0.0
4074,VHL F136C (c.407G>T),,0.0
4075,VHL D143= (c.429C>T) and c.340+770T>C,,0.0
4076,VHL R200W (c.598C>T) and c.340+694_340+711dup,,0.0
4077,VHL c.340+694_340+711dup,,0.0
4078,VHL R167Q(c.500G>A) and c.464-94T>A,,0.0
4079,VHL G144R (c.430G>A) and c.340+694_340+711dup,,0.0
4080,VHL Q164H (c.492G>T) and c.340+574A>T,,0.0
4081,VHL c.340+617C>G and c.340+648T>C,,0.0
4082,VHL  T124I (c.371C>T),,0.0
4083,VHL c.-195G>A AND c.*294G>A,,0.0
4084,VHL  W8* (c.23G>A),,0.0
4085,VHL  L89P (c.266T>A),,0.0
4086,ABL1 D276G,,0.0
4087,MS h,,0.0
4088,F9 G555R,,0.0
4089,AKT2 L78_Q79ins,,0.0
4090,AKT1 D323G,,0.0
4091,AKT1 F55Y,,0.0
4092,AKT1 P68-C77dup,,0.0
4093,VHL L201P (c.602T>C),,0.0
4094,VHL Splice Region (c.340+2T>C),,0.0
4095,VHL R107S (c.319C>A),,0.0
4096,VHL c.340+384G>C,,0.0
4098,VHL N193fs (c.576delA),,0.0
4099,VHL S43_E47dup (c.123_137dup),,0.0
4100,BRCA1  c.212+1G>T,,0.0
4101,VHL P45R (c.134C>G),,0.0
4102,VHL E21A (c.62A>C),,0.0
4103,VHL T105M (c.314C>T),,0.0
4104,VHL L153Q (c.458T>A),,0.0
4105,AURKB Overexpression,,0.0
4106,VHL L188V(c.562C>G),,0.0
4108,TYR GRCh37/hg19 11q14.3(chr11:88960991-88961138)x160,,0.0
4109,EGFR::SEPTIN14 Fusion,,0.0
4110,VOPP1::EGFR Fusion,,0.0
4111,VHL Splice Site (c.341-3T>G),,0.0
4112,FLT3 Q575del,,0.0
4114,VHL V130P (c.388G>T),,0.0
4115,VHL p.L159Es*15 (c.473dup),,0.0
4116,PTPN11 A461T,,0.0
4117,KAT6B Overexpression,,0.0
4118,VHL Exon 3 deletion (c.464-11 T>A),,0.0
4119,SEC61G::EGFR Fusion,,0.0
4120,NTRK3::SCAPER Fusion,,2.5
4121,SCP2::NTRK1 Fusion,,10.0
4122,VHL Splice Site (c.340+563C>T),,0.0
4123,VHL Splice Site (c.340+578C>T),,0.0
4124,VHL Splice Site (c.340+617C>G),,0.0
4125,VHL Splice Site (c.340+682T>C),,0.0
4126,VHL Splice Site (c.340+725A>T),,0.0
4127,VHL Splice Site (c.340+866C>A),,0.0
4128,ETV6::RET Fusion,,0.0
4129,VHL P154Qfs4*(c.461del),,0.0
4130,VHL P154Qfs4*(c.461delC),,0.0
4131,VHL P192L (c.575C>T),,0.0
4132,VHL Null (c.341+1_341‚Äì1),,0.0
4133,VHL P119L (c.355T>C),,0.0
4134,VHL R177Tfs*23 (c.530_536del),,0.0
4135,FGFR3 NM_001163213.1:c.2355_2356del,,0.0
4137,ATRX Loss-of-function,,0.0
4138,EGFR EGFR ITD,,0.0
4139,VHL N131*(c.390dupT),,0.0
4140,BRCA1 L1363P,,0.0
4141,BRCA1 L1407P,,0.0
4142,VHL e,,0.0
4143,VHL E31= (c.93G>A),,0.0
4144,VHL W112C (p.335A>G),,0.0
4145,VHL W112C (c.335A>G),,0.0
4146,VHL  Y112C (c.335A>G),,0.0
4147,VHL V165fs (c.493del),,0.0
4148,EGFR E746_S752insV,,0.0
4149,VHL V74fs (c.220del),,0.0
4150,EGFR::PURB Fusion,,0.0
4151,EGFR::PPARGC1A Fusion,,0.0
4152,VHL t(1;3)(p36.3;p25),,0.0
4154,EGFR::ZNF713 Fusion,,0.0
4156,RRBP1::ALK Fusion,,0.0
4157,EZHIP Overexpression,,0.0
4158,MPL S204P,,0.0
4159,BRCA1 b,,0.0
4160,BRCA1 null variant,,0.0
4161,KRAS R164G,,0.0
4162,EGFR::BRAF Fusion,,0.0
4164,VHL Exon 1 Deletion and c.341-50G>A,,0.0
4165,FGFR1 Overexpression,,0.0
4166,FGFR3 G802_X807del,,0.0
4167,EML4::NTRK3 Fusion,,69.5
4169,KIF5B::EGFR Fusion,,7.5
4170,BRAF V600E AND BRAF V600M,,2.5
4171,ALK Amplification,,0.0
4172,EML4::ALK Fusion AND ALK Amplification,,15.5
4173,BRAF V600E AND BRAF Amplification,,1.0
4174,BRAF Amplification AND ( BRAF V600E OR BRAF V600K ),,10.0
4175,EGFR Amplification AND EGFR::SEPTIN14 Fusion,,5.0
4176,NTRK1 G667S,,0.0
4177,NTRK1 G595R AND NTRK1 G667S,,0.0
4178,EML4::ALK Fusion AND EGFR L858R AND ALK Amplification,,0.0
4179,SRSF2 P95L,,3.0
4180,SRSF2 P95H,,3.0
4181,CIC R201W,,0.0
4182,KLF5 E419K,,2.0
4183,KLF5 E419Q,,2.0
4184,ERC1::ALK Fusion,,0.0
4185,IGHA1::FGFR3 Fusion,,0.0
4186,FGFR3 G802_X807del AND IGHA1::FGFR3 Fusion,,0.0
4187,KDM6A Loss,,0.0
4188,KDM6A Underexpression,,0.0
4189,FLT3 ITD AND KDM6A Loss,,0.0
4190,SMAD2 S276L,,1.0
4191,POLE L424I,,0.0
4192,CDKN2B Deletion,,0.0
4193,POLE P286H,,0.0
4194,PAX5 Deletion,,0.0
4195,ERG Deletion,,0.0
4196,IKZF1 Deletion AND NOT ERG Deletion AND ( P2RY8::CRLF2 Fusion OR CDKN2A Deletion OR CDKN2B Deletion OR PAX5 Deletion ),,0.0
4197,SMARCA2 R1159Q,,3.0
4198,SMARCA2 K755R,,3.0
4199,NFE2L2 E79K,,0.0
4200,NFE2L2 T80K,,0.0
4201,NFE2L2 L30F,,0.0
4202,BRAF Mutation OR v::BRAF Fusion,,0.0
4203,CBL H94Y,,0.0
4204,CBL S80N AND CBL H94Y,,0.0
4205,ALK L1196M,,0.0
4206,EML4::ALK Fusion AND ALK L1198F AND ALK L1196M,,0.0
4210,KRAS G12 OR KRAS G13 OR KRAS Q61,,0.0
4211,EGFR Overexpression AND NOT KRAS Mutation,,0.0
4212,EGFR Overexpression AND KRAS Mutation,,0.0
4213,NOT KRAS Mutation AND ( BRAF V600E OR BRAF D594G ),,0.0
4214,NRAS Mutation OR KRAS Mutation OR BRAF Mutation,,0.0
4215,KMT2C Loss,,0.0
4216,PIK3CA E542K AND PTEN Loss,,0.0
4217,MYB::QKI Fusion,,40.0
4218,MYB Rearrangement,,42.5
4219,ALK E1210K,,0.0
4220,EML4::ALK Fusion AND ALK E1210K,,0.0
4221,EML4::ALK Fusion AND ALK F1245C,,14.5
4222,ALK T1151K,,0.0
4223,EML4::ALK Fusion AND ALK T1151K,,0.0
4224,ALK C1156Y,,0.0
4225,EML4::ALK Fusion AND ALK C1156Y,,29.0
4226,ALK L1152V,,0.0
4227,EML4::ALK Fusion AND ALK L1152V,,0.0
4228,EML4::ALK Fusion AND ALK I1171T,,0.0
4229,EML4::ALK Fusion AND ALK F1174C,,0.0
4230,EML4::ALK Fusion AND ALK L1196M,,21.0
4231,ALK S1206R,,0.0
4232,EML4::ALK Fusion AND ALK S1206R,,0.0
4233,ALK G1269S,,0.0
4234,EML4::ALK Fusion AND ALK G1269S,,0.0
4235,EML4::ALK Fusion AND ALK R1275Q,,0.0
4236,ALK G1202R AND v::ALK Fusion,"ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor 17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.",7.5
4237,EML4::ALK Fusion AND ALK G1202R,,16.0
4238,EML4::ALK Fusion AND ALK G1202R AND ALK L1198F,,0.0
4240,TP53 H214R,,0.0
4241,BRAF V600E AND EZH2 Y646F,,0.0
4242,FLT3LG Expression,,0.0
4243,FLT3 Overexpression AND FLT3LG Expression,,0.0
4244,CHD7::BEND2 Fusion,,2.5
4245,EGFR Amplification AND EGFR EGFRVIII,,0.0
4246,IGH::CRLF2 Fusion AND JAK2 R683G,,0.0
4247,CRLF2 Rearrangement ,,0.0
4248,FLT3 D835N,,0.0
4249,FLT3 D835G,,0.0
4250,FLT3 D593del,,0.0
4251,BRAF V600E AND EGFR L858R AND EGFR T790M,,0.0
4253,EML4::ALK Fusion AND ALK L1198F AND ALK C1156Y,EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156Y-L1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib.,20.0
4254,EML4::ALK Fusion AND ALK G1202R AND ALK L1196M,,0.0
4255,EML4::ALK Fusion AND ALK L1152R,,10.0
4256,HMGA2::EGFR Fusion,,0.0
4257,EGFR::VSTM2A Fusion,,0.0
4258,EGFR::WIF1 Fusion,,0.0
4280,MET Splice Site (c.2888-21_2888-1del),,0.0
4281,MET Splice Site (c.2888-35_2889delinsA),,0.0
4282,MET Splice Site (c.2888-17_2888-3del),,0.0
4283,MET Splice Site (c.2888-10_2911del),,0.0
4284,MET Splice Site (c.2888-37_2888-30del),,0.0
4285,MET Splice Site (c.2888-18_2888-5del),,0.0
4286,MET Splice Site (c.3024_3028+7del),,0.0
4287,MET Splice Site (c.3028+1_3028+2insA),,0.0
4288,MET Splice Site (c.3028+1G>T),,0.0
4289,MET Splice Site (c.3028+1G>A),,0.0
4290,MET Splice Site (c.3028+1G>C),,0.0
4291,MET Splice Site (c.3028+2T>C),,0.0
4292,MET Splice Site (c.3028+2T>A),,0.0
4293,MET Splice Site (c.3028+2T>G),,0.0
4294,MET Splice Site (c.3005_3028+3delinsC),,0.0
4295,MET Splice Site (c.2999_3028+4del),,0.0
4296,MET Splice Site (c.3017_3028+3del),,0.0
4297,MET Splice Site (c.3028_3028+2del),,0.0
4298,MET Splice Site (c.3028_3028+3del),,0.0
4299,MET Splice Site (c.3028_3028+5del),,0.0
4300,MET Splice Site (c.3028G>A),,0.0
4304,v::ALK Fusion AND ALK L1196M,,0.0
4305,EML4::ALK Fusion AND ALK L1198F,,0.0
4306,TYK2 P1104A,,0.0
4307,ALK T1151dup,The ALK variant with duplication of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment.,0.0
4308,EML4::ALK Fusion AND ALK T1151dup,"The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.",18.0
4309,EML4::ALK Fusion AND ALK S1206Y,,6.0
4310,ALK S1206Y AND v::ALK Fusion,,0.0
4311,ALK G1269A AND v::ALK Fusion,,10.0
4312,EML4::ALK Fusion AND ALK G1269A,The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.,17.5
4313,ERBB4 E715K,,0.0
4314,ERBB4 R687K,,0.0
4315,ERBB4 K935I,,0.0
4316,BRCA1 S1841N,,0.0
4317,BRCA1 S1841R,,0.0
4318,BRCA1 Y1853C,,0.0
4319,BRCA1 V1838E,,0.0
4320,BRCA1 R1699Q,,0.0
4321,BRCA1 T1700A,,0.0
4322,BRCA1 V1713A,,0.0
4323,BRCA1 M1775R,,0.0
4324,BRCA1 M1775K,,0.0
4325,CDH1 A298T,,0.0
4326,CDH1 W409R,,0.0
4327,CDH1 R732Q,,0.0
4328,EML4::ALK Fusion AND ALK I1171N AND ALK L1196M,,17.5
4329,EML4::ALK Fusion AND ALK G1202R AND ALK I1171N AND ALK L1196M,,7.5
4330,NPM1::ALK Fusion AND ALK I1171N,,0.0
4331,HIP1::ALK Fusion,,0.0
4332,ALK I1171N AND HIP1::ALK Fusion,,5.0
4333,v::ALK Fusion AND ALK I1171N,,0.0
4335,EGFR FGFR1,,0.0
4336,EGFR S645C,,3.0
4337,EGFR K754E,,3.0
4338,ARAF S214F,,3.0
4339,ARAF V145L,,3.0
4340,GNA11 R183C,,3.0
4341,GNA11 Q209L,,3.0
4342,EZH2 A692V,,0.0
4343,EZH2 A682G,,0.0
4344,EZH2 Y646S OR EZH2 Y646F OR EZH2 Y646H OR EZH2 Y646C OR EZH2 Y646N OR EZH2 A692V OR EZH2 A682G,"The cobas EZH2 Mutation Test is an FDA-companion, qualitative real-time PCR test currently used to identify specific EZH2 mutations to help determine whether patients with follicular lymphoma should be considered for treatment with Tazverik (Tazemetostat). Those mutations can be any of five present in exon 16 (Y646N, Y646F, or Y646X = Y646H, Y646S, Y646C), or two located in exon 18 (A682G and A692V). The Y646X is reported in this manner due to the used master mix in the assay that contains one fluorescent dye to report any of the three variants in the X group.",20.0
4345,EGFR EGFRVIII AND EGFR::SEPTIN14 Fusion,,0.0
4346,EGFR Amplification AND EGFR EGFRVIII AND EGFR::SEPTIN14 Fusion,,0.0
4347,EZH2 expression,,5.0
4348,ALK G1269A AND EML4::ALK e6::e19 AND ALK Amplification,,0.0
4349,FBXO11::ALK Fusion,,0.0
4350,EML6::ALK Fusion AND FBXO11::ALK Fusion,,0.0
4351,EML4::ALK Fusion AND ALK V1180L,,13.0
4352,EGFR::YAP1 Fusion,,0.0
4353,NOT KIT D816V,,5.0
4354,KIT D816F,,0.0
4355,NOT KIT D816V AND ( KIT V560G OR KIT D816Y OR KIT D816F ),,0.0
4356,EML4::ALK Fusion AND ALK G1202del,,0.0
4357,EML4::ALK Fusion AND ALK I1171S,,5.0
4358,HBB E6V,,0.0
4359,TBX2 Expression,,0.0
4360,TBXT Expression,,0.0
4361,TBXT Amplification,,0.0
4362,TBXT Gain,,0.0
4363,SMARCB1 Single nucleotide variant,,0.0
4364,SMARCB1 Deletion AND SMARCB1 Single nucleotide variant,,0.0
4365,KHDRBS1::NTRK3 Fusion,,0.0
4366,MET Amplification AND MET Splice Site (c.3028G>A),,7.5
4367,MTOR E2419K,,0.0
4368,MTOR E2014K AND MTOR E2419K,,5.0
4369,MYC Translocation,,0.0
4370,BCL2 Translocation,,0.0
4371,BCL6 Translocation,,0.0
4372,MYC Translocation AND ( BCL2 Translocation OR BCL6 Translocation ),,0.0
4373,BCR::ABL1 Fusion AND ABL1 T315I,,174.0
4374,BCR::ABL1 Fusion AND ABL1 F311I,,5.0
4375,EGFR Mutation AND v::RET Fusion,,0.0
4376,BCR::ABL1 Fusion AND ABL1 F317L,"BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.",96.5
4380,BCR::ABL1 Fusion AND ( ABL1 F317L OR ABL1 F317V ),,0.0
4381,BCR::ABL1 Fusion AND ABL1 F317V,,13.0
4382,SNCAIP Tandem duplication,,0.0
4383,IDH1 R132Q,,0.0
4385,BAP1 Q267fs,,0.0
4386,CHEK2 mutation,,30.0
4387,PPP2R2A Mutation,,10.0
4388,RAD54L Mutation,,30.0
4389,BRIP1 Mutation,,20.0
4390,BARD1 Mutation,,20.0
4391,CHEK1 Mutation,,20.0
4392,FANCL Mutation,,0.0
4393,RAD51B Mutation,,20.0
4394,RAD51C Mutation,,0.0
4395,RAD51D Mutation,,20.0
4396,CDKN1A rs1801270 AND CDKN1A rs1059234,,0.0
4397,NEAT1 Overexpression,,0.0
4398,EGFR::ZNF880 Fusion,,0.0
4399,EZH2 Y646S AND EZH2 Y646F AND EZH2 Y646H AND EZH2 Y646C AND EZH2 Y646N AND EZH2 A692V AND EZH2 A682G,,0.0
4401,EGFR S768I AND EGFR G719A AND EGFR L861Q,,0.0
4402,ERBB2 L15F,,0.0
4404,MECP2 c.771_814del,,0.0
4405,MECP2 c.21delC,,0.0
4406,EGFR L858R AND EGFR Exon 19 Deletion,,0.0
4407,TP53 Loss,,3.0
4408,BRCA1 Mutation AND BRCA2 Mutation,,0.0
4409,BRCA1 Mutation OR BRCA2 Mutation,,40.0
4410,FGFR3 S249C AND FGFR3 R248C AND FGFR3 Y373C AND FGFR3 G370C,,0.0
4411,FLT3 D385,,0.0
4412,FLT3 internal tandem duplication,,0.0
4413,FLT3 D835 AND FLT3 I836 AND FLT3 internal tandem duplication,,0.0
4414,FLT3 ITD AND FLT3 D835 AND FLT3 I836,,0.0
4415,IDH2 R140G,,0.0
4416,IDH2 R140L,,0.0
4417,IDH2 R140Q,,0.0
4418,IDH2 R140W,,0.0
4419,IDH2 R172G,,0.0
4420,IDH2 R172M,,0.0
4421,IDH2 R172S,,0.0
4422,IDH2 R172W,,0.0
4423,IDH2 R172K AND IDH2 R140G AND IDH2 R140L AND IDH2 R140Q AND IDH2 R140W AND IDH2 R172G AND IDH2 R172M AND IDH2 R172S AND IDH2 R172W,,0.0
4424,v::RET Fusion OR RET Mutation,,0.0
4425,TSC1 mutation,,0.0
4426,TSC2 mutation,,0.0
4427,TSC1 mutation OR TSC2 mutation,,0.0
4428,NRAS Wildtype,,0.0
4429,PIK3CA E542K AND PIK3CA E545K AND PIK3CA H1047R AND PIK3CA E545A AND PIK3CA E545G AND PIK3CA Q546E AND PIK3CA Q546R AND PIK3CA C420R AND PIK3CA E545D AND PIK3CA H1047Y AND PIK3CA H1047L,,0.0
4431,BCR::ABL1 Fusion AND ABL1 E255K,,83.0
4432,EGFR L858R OR EGFR Exon 19 Deletion,,410.0
4433,TERT c.-124C.T,,0.0
4434,ETV6::NTRK2 Fusion AND TERT c.-124C.T,,0.0
4435,ERBB2 Amplification OR ERBB2 Overexpression,,0.0
4438,FN1::ALK Fusion,,0.0
4439,TPM4::ALK Fusion,,0.0
4440,ERBB2 G776V,,0.0
4441,ARAF Mutation,,0.0
4442,ARAF S225V,,0.0
4443,ARAF P216A,,0.0
4444,ARAF Mutation AND ARAF S225V AND ARAF P216A,,0.0
4445,BRAF N486_P490 ,,0.0
4446,MAP2K1 K57_G61del,,0.0
4447,RET M918T AND RET V804M,,0.0
4448,BRAF V600R AND BRAF Non-V600,,0.0
4449,TET2 E796K,,0.0
4450,BAX L76R,,0.0
4451,AXIN2 P455K,,0.0
4452,BRAF V600E AND CDKN2A Deletion AND CDKN2B Deletion AND TET2 E796K AND BAX L76R AND AXIN2 P455K,,0.0
4453,BRAF V600E OR KIAA1549::BRAF Fusion,,0.0
4454,BRCA1 Mutation OR BRCA2 Mutation OR PALB2 Mutation,,0.0
4455,BRCA2 Deletion,,0.0
4456,TP53 Deletion,,0.0
4457,PTEN Deletion AND BRCA2 Deletion AND TP53 Deletion,,0.0
4458,EGFR Exon 19 insertion,,0.0
4459,EGFR A763_Y764insFQEA OR EGFR Exon 19 insertion,,0.0
4460,ERBB2 A775_G776insYVMA,,0.0
4461,ERBB2 A775_G776insYVMA,,0.0
4462,ERBB2 A775_G776insIVMA,,0.0
4463,ERBB2 A775_G776ins YVMA,,0.0
4464,ERBB2 G778_P780dup,,0.0
4465,ERBB2 G778-779 insCPG,,0.0
4466,ERBB2 G776_V777>VCV,,0.0
4467,ERBB2 G776delinsVC,,0.0
4468,ERBB2 L755P,,0.0
4469,ERBB2 V659E,,0.0
4470,ERBB2 S310F,,5.0
4471,ERBB2 S335C,,0.0
4472,ERBB2 Amplification OR ERBB2 A775_G776insYVMA OR ERBB2 A775_G776insIVMA OR ERBB2 A775_G776ins YVMA OR ERBB2 G778_P780dup OR ERBB2 G778-779 insCPG OR ERBB2 G776_V777>VCV OR ERBB2 G776delinsVC OR ERBB2 L755P OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 S335C,,0.0
4473,ERBB2 Mutation OR ERBB2 Exon 20 Insertion,,0.0
4474,ERBB2 G776S,,0.0
4475,ERBB2 D769H OR ERBB2 L755S OR ERBB2 V777L OR ERBB2 S310Y OR ERBB2 L755P OR ERBB2 Exon 20 Insertion OR ERBB2 S310F OR ERBB2 G776S,,0.0
4476,DCTN1::ALK Fusion,,0.0
4477,ZMYM2::FGFR1 Fusion,,0.0
4478,BCR::FGFR1 Fusion,,0.0
4479,CEP43::FGFR1 Fusion,,0.0
4480,TRIM24::FGFR1 Fusion,,0.0
4481,FGFR1 Translocation,,0.0
4482,ZMYM2::FGFR1 Fusion OR BCR::FGFR1 Fusion OR CEP43::FGFR1 Fusion OR TRIM24::FGFR1 Fusion OR FGFR1 Translocation,,0.0
4483,PCM1::JAK2 Fusion OR ETV6::ABL1 Fusion OR BCR::JAK2 Fusion,,0.0
4484,PCM1::JAK2 Fusion OR BCR::JAK2 Fusion,,0.0
4485,KIT Exon 11 Mutation OR KIT Exon 9 Mutation OR PDGFRA Exon 18 Mutation,,0.0
4486,KIT Exon 11 577-582insPYD,,0.0
4487,KIT Exon 11 557_560delWKVVE,,0.0
4488,KIT L576P OR KIT Amplification OR KIT W557R OR KIT V559A OR KIT V560D OR KIT K642E OR KIT D820Y OR KIT Exon 11 577-582insPYD OR KIT Exon 11 557_560delWKVVE,,0.0
4489,RAF1 Mutation,,0.0
4490,MAP2K1 Mutation,,0.0
4491,MAP2K2 Mutation,,0.0
4492,NRAS Mutation OR KRAS Mutation OR RAF1 Mutation OR MAP2K1 Mutation OR MAP2K2 Mutation,,0.0
4493,GATA3 Mutation,,0.0
4494,GNAS Mutation,,0.0
4495,KRAS G12R AND GATA3 Mutation AND GNAS Mutation,,0.0
4496,ABL1 TKD Mutation OR ABL1 P-Loop Mutation OR ABL1 Non-P-Loop Mutation,,0.0
4499,EGFR S768I OR EGFR G719A OR EGFR L861Q,,50.0
4500,GAB1::ABL1 Fusion,,0.0
4501,ERBB2 V777L AND PIK3CA H1047R,,0.0
4502,CCNE1 Amplification AND ERBB2 Overexpression,,0.0
4503,LMNA::NTRK1 Fusion AND NTRK1 G595R,,6.0
4504,NTRK1 F589L,,0.0
4505,LMNA::NTRK1 Fusion AND NTRK1 F589L,,6.0
4507,LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 F589L,,3.0
4508,NTRK1 G667C ,,0.0
4509,LMNA::NTRK1 Fusion AND NTRK1 G667C ,,0.0
4510,ERBB2 R143Q,,0.0
4511,ERBB2 D277H,,0.0
4512,NOT KIT D816V AND v::PDGFRB Fusion,,0.0
4513,KIT F522C,,0.0
4514,NOT KIT D816V AND KIT F522C,,0.0
4515,MET R988C,,0.0
4516,MET T1010I,,0.0
4517,MET R988C AND MET T1010I,,0.0
4518,MET Amplification OR ERBB2 Amplification,,0.0
4519,RIT1 Mutation OR NF1 Mutation,,0.0
4520,MDM2 Amplification AND MET D1010H,,0.0
4521,MET Amplification AND MET Exon 14 Skipping Mutation,,0.0
4522,PIK3CA E545K AND MET Exon 14 Skipping Mutation,,0.0
4523,NOT MET Amplification AND MET Exon 14 Skipping Mutation,,0.0
4524,MET Exon 14 Skipping Mutation AND MET Overexpression,,0.0
4526,ROS1 Amplification,,0.0
4527,MET Amplification OR ALK Amplification OR ROS1 Amplification,,0.0
4528,MET Amplification OR MET Exon 14 Skipping Mutation,,0.0
4529,HRAS Overexpression,,0.0
4530,MET Y1230C,,0.0
4531,MET Exon 14 Skipping Mutation AND MET Y1230C,,0.0
4532,MET Y1230H,,0.0
4533,MET Exon 14 Skipping Mutation AND MET Y1230H,,0.0
4534,MET Splice Site (c.3025_3028+5del),,0.0
4535,EGFR Exon 19 Deletion AND MET Exon 14 Skipping Mutation,,0.0
4536,CD274 Overexpression,,0.0
4537,MET Exon 14 Skipping Mutation AND CD274 Overexpression,,0.0
4538,MET Y1003S,,0.0
4539,MET Exon 14 Skipping Mutation AND MET D1228N,,0.0
4541,EGFR L858R AND MET Amplification,,0.0
4542,MET Y1003N,,0.0
4543,EGFR Exon 19 Deletion AND MET Y1003N,,0.0
4544,MET Amplification AND MYC Amplification,,0.0
4545,MET Exon 14 Skipping Mutation OR MET Overexpression,,0.0
4546,EGFR ITD ,,0.0
4547,BCOR ITD ,,165.0
4548,ZFTA::RELA Fusion,,103.0
4549,ABL1 Y253H,,0.0
4550,BCR::ABL1 Fusion AND ABL1 Y253H,,82.0
4551,ABL1 Mutation,,0.0
4552,BCR::ABL1 Fusion AND ABL1 Mutation,,0.0
4553,BCR::ABL1 Fusion AND ABL1 D276G,,18.0
4554,RUNX1 R135T,,0.0
4555,BCR::ABL1 Fusion AND ABL1 G250E,,67.0
4556,BCR::ABL1 Fusion AND ABL1 M351T,,65.5
4557,BCR::ABL1 Fusion AND ABL1 A365V,,0.0
4558,BCR::ABL1 Fusion AND ABL1 A366G,,0.0
4559,MET Exon 14 Skipping Mutation AND ( MET D1228N OR MET Y1230H ),,0.0
4560,ZFTA::NCOA1 Fusion,,5.0
4561,ZFTA::NCOA2 Fusion,,5.0
4562,ZFTA::MAML2 Fusion,,5.0
4563,MN1::ZFTA Fusion,,2.5
4564,QKI::NTRK2 Fusion,,12.5
4565,CDKN2A Deletion AND ZFTA::RELA Fusion,,0.0
4566,ZFTA::v Fusion,,0.0
4567,EGFR Amplification OR MET Amplification,,0.0
4569,EGFR Mutation AND ( MET Amplification OR MET Overexpression ),,0.0
4570,MET Splice Site (c.2888_3028del),,0.0
4571,KRAS G12D AND MET Splice Site (c.2888_3028del),,0.0
4572,MET Splice Site (c.2888_2919del),,0.0
4573,MET Amplification AND MET Splice Site (c.2888_2919del),,0.0
4574,MET Splice Site (c.2888-21_2888-20delinsGC),,0.0
4575,EGFR G719A AND MET Splice Site (c.2888-21_2888-20delinsGC),,0.0
4576,ERBB2 S653C,,0.0
4577,DICER1 RNase IIIb Mutation,,0.0
4578,DICER1 Loss-of-function,,0.0
4579,DICER1 RNase IIIb Mutation AND DICER1 Loss-of-function,,0.0
4580,MET Splice Site (c.3028+3A>G),,0.0
4581,EGFR L858R AND EGFR T790M AND MET Exon 14 Skipping Mutation,,0.0
4584,NTRK1 ATRX,,0.0
4585,PTEN A121E AND NTRK1 ATRX,,0.0
4586,ERBB2 T306M,,0.0
4587,ERBB2 S310F AND NOT ERBB2 T306M,,0.0
4588,ERBB2 R678L,,0.0
4589,ERBB2 V777M,,0.0
4590,ERCC2 D257N,,0.0
4591,ERCC2 T484M,,0.0
4592,ETV6::NTRK3 Fusion AND NTRK3 G623E,,0.0
4593,ESR1::CCDC170 Fusion,,0.0
4594,EGFR E14,,0.0
4596,NTRK3 G623R AND EML4::NTRK3 Fusion,,5.0
4597,SETD2 Loss,,0.0
4598,EPCAM c.556‚Äê490_*8438del,,0.0
4600,FGFR3 P449S,,0.0
4603,FGFR3 V57M,,0.0
4604,FGFR3 G65R,,0.0
4605,FGFR3 T450M,,0.0
4606,FGFR3 A717T,,0.0
4607,FGFR3 G52S,,0.0
4608,FGFR3 R238Q,,0.0
4609,FGFR3 G44S,,0.0
4610,FGFR3 P799L,,0.0
4611,FGFR3 L164V,,0.0
4612,FGFR3 T242M,,0.0
4613,FGFR3 D758N,,0.0
4614,FGFR3 K517R,,0.0
4615,FLT3 TKD MUTATION AND FLT3 D835Y,,0.0
4616,FLT3 ITD AND FLT3 D835Y,,0.0
4617,FLT3 ITD AND FLT3 D835H,,0.0
4618,JMJD1C::FOXR2 Fusion,,0.0
4620,FOXR2 Rearrangement,,40.0
4622,YAP1::TFE3 Fusion,,40.0
4623,NM nm0,,0.0
4624,v::NTRK1 Fusion AND NTRK1 G595R,,0.0
4625,v::NTRK3 Fusion AND NTRK3 G623R,,0.0
4626,v::NTRK1 Fusion AND NTRK1 F589L,,0.0
4627,v::NTRK1 Fusion AND NTRK1 G667S,,0.0
4628,NTRK3 G696A,,0.0
4629,v::NTRK3 Fusion AND NTRK3 G696A,,0.0
4630,ND1 p.Ile657Met,,0.0
4631,ND1 c.1971T>G,,0.0
4632,KRAS G12D AND ERBB2 S310F,,0.0
4633,ERBB2 S423R,,0.0
4634,KRAS G12D AND ERBB2 S423R,,0.0
4635,ERBB2 R678Q AND KRAS G12D,,0.0
4637,ERBB2 Q679L,,0.0
4638,KRAS G12D AND ERBB2 Q679L,,0.0
4639,ERBB2 E717D,,0.0
4640,KRAS G12D AND ERBB2 E717D,,0.0
4641,ERBB2 L755S AND KRAS G12D,,0.0
4642,ERBB2 V777L AND KRAS G12D,,0.0
4643,ERBB2 V842I AND KRAS G12D,,0.0
4644,MTAP Deletion,,0.0
4645,VGLL2::v Fusion,,0.0
4646,v::NCOA2 Fusion,,0.0
4647,ERBB2 V842I ,,0.0
4648,ERBB2 V777L AND KRAS G12C,,0.0
4649,ERBB2 E401G,,0.0
4650,KRAS G12C AND ERBB2 V842I ,,0.0
4651,ERBB2 E410G,,0.0
4652,GK rs12069019 Gg,,0.0
4653,MET Overexpression AND EWSR1::ATF1 Fusion,,0.0
4655,CRTC1::MAML2 Fusion,,0.0
4656,CRTC3::MAML2 Fusion,,0.0
4657,FOS Rearrangement,,0.0
4658,FOSB Rearrangement,,0.0
4659,EGFR T790M AND EGFR Exon 19 Deletion,,0.0
4660,EGFR L858R AND EGFR T790M,,0.0
4661,ABL1 M244V,,0.0
4662,BCR::ABL1 Fusion AND ABL1 M244V,,0.0
4663,ABL1 F359V,,0.0
4664,BCR::ABL1 Fusion AND ABL1 F359V,,0.0
4665,ERBB2 R34Q,,0.0
4666,FUS::ERG Fusion,,40.0
4667,FUS::FEV Fusion,,0.0
4668,EWSR1::ERG Fusion,,32.5
4669,EWSR1::NFATC2 Fusion,,0.0
4670,FUS::NFATC2 Fusion,,0.0
4671,ARHGAP26 Overexpression,,0.0
4672,ABL1 E255V,,0.0
4673,BCR::ABL1 Fusion AND ABL1 E255V,,54.5
4674,ABL1 F359I,,0.0
4675,BCR::ABL1 Fusion AND ABL1 F359I,,0.0
4676,PTCH1 Loss-of-function,,0.0
4677,ABL1 E355G,,0.0
4678,BCR::ABL1 Fusion AND ABL1 E355G,,0.0
4679,ABL1 F359C,,0.0
4680,BCR::ABL1 Fusion AND ABL1 F359C,,0.0
4681,BCR::ABL1 Fusion AND ARAF S214C,,0.0
4682,ABL1 H396R,,0.0
4683,BCR::ABL1 Fusion AND ABL1 H396R,,0.0
4684,FGFR2::? Fusion,,0.0
4685,FGFR2::v Fusion OR FGFR2::? Fusion,,75.0
4686,FGFR2::KIAA1217 Fusion,,0.0
4687,TNIP1::PDGFRB Fusion,,0.0
4688,FGFR2::POC1B Fusion,,0.0
4689,FGFR2::DBP Fusion,,0.0
4690,FGFR2::FILIP1 Fusion,,0.0
4691,FGFR2 C383R,,0.0
4692,FGFR1::TACC1 Fusion,,0.0
4693,FGFR1 M563T,,0.0
4694,FGFR1::PLAG1 Fusion,,0.0
4695,FGFR2::NRAP Fusion,,0.0
4696,FGFR2 Amplification AND FGFR2::? Fusion,,0.0
4697,FGFR2::WAC Fusion,,0.0
4698,FGFR2::TNS1 Fusion,,0.0
4699,FGFR2::TTC28 Fusion,,0.0
4700,FGFR2::CCDC6 Fusion,,0.0
4702,SLC4A4::ROS1 Fusion,,0.0
4703,RET D378_G685>E,,0.0
4704,ERBB3 Mutation,,0.0
4705,ERBB2 Amplification OR ERBB2 Mutation OR ERBB3 Mutation,,0.0
4706,ERBB2 Mutation OR ERBB3 Mutation,,0.0
4707,BRAF V600E OR BRAF K601E,,15.0
4709,CCND1 Amplification OR CCND2 Amplification OR CCND3 Amplification,,0.0
4710,FGFR1 K656E,,0.0
4711,FGFR1 Amplification OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion OR FGFR2 FGFR2 mutations,,0.0
4712,FGFR1 Amplification OR FGFR2 Mutation OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion,,0.0
4713,ABL1 L248V,,0.0
4714,BCR::ABL1 Fusion AND ABL1 L248V,,0.0
4715,BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Mutation,,0.0
4716,CDKN2A Loss OR CDKN2A Mutation,,15.0
4718,ABL1 Q252H,,0.0
4719,BCR::ABL1 Fusion AND ABL1 Q252H,,31.0
4720,ABL1 F486S,,0.0
4721,BCR::ABL1 Fusion AND ABL1 F486S,,0.0
4722,ABL1 A397P,,0.0
4723,BCR::ABL1 Fusion AND ABL1 A397P,,0.0
4724,ABL1 D363G,,0.0
4725,BCR::ABL1 Fusion AND ABL1 D363G,,0.0
4726,ABL1 D421G,,0.0
4727,BCR::ABL1 Fusion AND ABL1 D421G,,0.0
4728,ABL1 V299L,,0.0
4729,BCR::ABL1 Fusion AND ABL1 E255K AND ABL1 V299L,,0.0
4730,BCR::ABL1 Fusion AND ABL1 V299L,,22.0
4731,MAP2K4 Amplification,,0.0
4732,MLH1 Loss,,0.0
4733,MSH2 Loss OR MLH1 Loss,,0.0
4734,EZH2 Mutation OR SMARCA4 Loss OR SMARCB1 Loss,,0.0
4735,MET Splice Site (c.3027_3028+21delAGGTATATTTCAGTTTATTGTTC,,0.0
4736,EGFR T790M AND EGFR Exon 19 Deletion AND MET Splice Site (c.3027_3028+21delAGGTATATTTCAGTTTATTGTTC,,0.0
4737,NF1 Inactivating Mutation,,0.0
4738,BRAF Inactivating Mutation,,0.0
4739,NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating Mutation OR BRAF Inactivating Mutation,,0.0
4740,NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR BRAF Mutation OR NF1 Inactivating Mutation,,0.0
4741,ABL1 T315A,,0.0
4742,BCR::ABL1 Fusion AND ABL1 T315A,,0.0
4743,BCR::ABL1 Fusion AND ABL1 E279K,,0.0
4744,BCR::ABL1 Fusion AND ABL1 E292L,,0.0
4745,BCR::ABL1 Fusion AND ABL1 E292V,,0.0
4746,BCR::ABL1 Fusion AND ABL1 E450Q,,0.0
4747,v::TFEB Fusion,,20.0
4748,BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating Mutation,,0.0
4749,RB1 Wildtype,,0.0
4750,RB1 Wildtype AND ( CDKN2A Loss OR CDKN2A Mutation ),,0.0
4751,TFEB Amplification,,0.0
4752,UFD1::NTRK2 Fusion,,0.0
4754,RALGPS2::NTRK3 Fusion,,0.0
4756,IDH2 Mutation OR IDH1 Mutation,,0.0
4757,KRAS Alteration,,0.0
4758,CDKN2A alteration,,0.0
4759,SMAD4 Alteration,,0.0
4760,TP53 ALTERATION OR KRAS Alteration OR CDKN2A alteration OR SMAD4 Alteration,,0.0
4761,TP53 R267W,,0.0
4762,KRAS G12D AND KRAS G12R AND CDKN2A Loss AND CDKN2B Loss AND SMAD4 Deletion AND TP53 R267W,,0.0
4763,KRAS G12D AND KRAS G12R AND CDKN2A Loss AND CDKN2B Loss AND TP53 R267W,,0.0
4764,TP53 V218E,,0.0
4765,BRAF V600E AND ERBB2 Amplification AND SMAD4 LOSS AND TP53 V218E,,0.0
4766,ERBB2 E321G,,0.0
4767,CDKN2A p16 R80*,,0.0
4768,KRAS G12D AND CDKN2A p16 R80*,,0.0
4769,ERBB2 E265K,,0.0
4770,ERBB2 G279E,,0.0
4771,ERBB2 G309E,,0.0
4772,ERBB2 G292R,,0.0
4773,ERBB2 G660D,,0.0
4774,NF1 D1976fs,,0.0
4775,KRAS G12D AND GNAS R201C AND NF1 D1976fs,,0.0
4776,ERBB2 R678W,,0.0
4777,ERBB2 L726F,,0.0
4778,ERBB2 L726I,,0.0
4779,ERBB2 T733I,,0.0
4780,ERBB2 L755A,,0.0
4781,ERBB2 L755R,,0.0
4782,ERBB2 L755F,,0.0
4783,ERBB2 L755M,,0.0
4784,ERBB2 L755V,,0.0
4785,ERBB2 D769V,,0.0
4786,ERBB2 D769N,,0.0
4787,ERBB2 L785P,,0.0
4788,ERBB2 G776C,,0.0
4789,ERBB2 G776D,,0.0
4790,ERBB2 V777A,,0.0
4791,ERBB2 P780L,,0.0
4792,ERBB2 V794M,,0.0
4793,ERBB2 D808N,,0.0
4794,ERBB2 D821N,,0.0
4795,ERBB2 T862I,,0.0
4796,ERBB2 E914K,,0.0
4797,ERBB2 R896H,,0.0
4798,ERBB2 Y537N,,0.0
4799,ERBB2 D538G,,0.0
4800,TCF3::PBX1 Fusion,,90.0
4803,KRAS G13E,,0.0
4804,XRCC3 Mutation,,0.0
4805,ORC1 Mutation,,0.0
4806,XRCC3 Mutation OR ORC1 Mutation,,0.0
4807,RET TKD Mutation,,0.0
4808,RET CLD1 Mutation,,0.0
4809,FGFR1 FUS,,0.0
4810,KIF5B::FGFR1 e15::e11,,0.0
4811,TP53 ALTERATION AND VEGFA Overexpression,,0.0
4812,TP53 Mutation AND VEGFA Overexpression,,0.0
4813,MUS81 Mutation,,0.0
4814,NBN Mutation,,0.0
4815,ATM Mutation OR BRCA2 Mutation OR RAD51B Mutation OR MUS81 Mutation OR NBN Mutation,,0.0
4816,MUS81 Loss,,0.0
4817,RAD51B Loss,,0.0
4818,BRCA2 Loss,,0.0
4819,NBN Loss OR ATM Loss OR MUS81 Loss OR RAD51B Loss OR BRCA2 Loss,,0.0
4820,BCR::ABL1 Fusion AND ( ABL1 T315I OR ABL1 E255K ),,0.0
4821,KRAS G12W,,0.0
4822,KRAS G12F,,0.0
4823,KRAS G12N,,0.0
4824,KRAS A59G,,0.0
4825,NRAS G13E,,0.0
4826,NRAS G12W,,0.0
4827,NRAS G12A,,0.0
4828,BCR::ABL1 Fusion AND ABL1 E450V,,0.0
4829,BCR::ABL1 Fusion AND ABL1 E453A,,0.0
4830,BCR::ABL1 Fusion AND ABL1 E453K,,0.0
4831,EMILIN2::PDGFD Fusion,,0.0
4832,BCR::ABL1 Fusion AND ABL1 E453Q,,0.0
4833,BCR::ABL1 Fusion AND ABL1 E459K,,0.0
4834,BCR::ABL1 Fusion AND ABL1 E98G,,0.0
4835,BCR::ABL1 Fusion AND ABL1 F311L,,0.0
4836,BCR::ABL1 Fusion AND ABL1 F317C,,0.0
4837,BCR::ABL1 Fusion AND ABL1 F317I,,0.0
4838,BCR::ABL1 Fusion AND ABL1 F317R,,0.0
4839,BCR::ABL1 Fusion AND ABL1 F317S,,0.0
4840,NRAS G12F,,0.0
4841,NRAS G12N,,0.0
4842,NRAS G12R,,0.0
4843,NRAS Q61E,,0.0
4844,NRAS A59G,,0.0
4845,BAP1 Deficient,,0.0
4846,BRCA1 Deficient,,0.0
4847,BAP1 Deficient OR BRCA1 Deficient,,0.0
4848,SETD2 Mutation,,0.0
4849,BAP1 Mutation OR NF2 Mutation OR SETD2 Mutation,,0.0
4850,NTRK3 SPECC1L,,0.0
4851,SPECC1L::NTRK3 Fusion,,0.0
4852,ERBB2 A775_G776insTVMA,,0.0
4853,ERBB2 A775_G776insV,,0.0
4854,ERBB2 A775_G776insVVMA,,0.0
4855,ERBB2 G776_V777delinsVCD,,0.0
4856,ERBB2 G776delinsCV,,0.0
4857,ERBB2 G776delinsLC,,0.0
4858,ERBB2 G778_S779insLPS,,0.0
4859,MCL1 Amplification,,0.0
4860,NRAS A59T,,0.0
4861,NRAS A146V,,0.0
4862,NRAS A146T,,0.0
4863,NRAS A146P,,0.0
4864,NRAS K117N,,0.0
4865,RET C609S,,0.0
4866,RET C609R,,0.0
4867,RET C609G,,0.0
4868,RET C609F,,0.0
4869,RET C609W,,0.0
4870,RET C611S,,0.0
4871,RET C611R,,0.0
4872,BCR::ABL1 Fusion AND ABL1 G398R,,0.0
4873,BCR::ABL1 Fusion AND ABL1 H396P,,0.0
4874,BCR::ABL1 Fusion AND ABL1 I432T,,0.0
4875,BCR::ABL1 Fusion AND ABL1 L248R,,0.0
4876,BCR::ABL1 Fusion AND ABL1 L248R AND ABL1 F359I,,0.0
4877,BCR::ABL1 Fusion AND ABL1 L364I,,0.0
4878,MYBL1 Rearrangement,,40.0
4880,SERPINE1::FOSB Fusion,,0.0
4881,ARID1A Wildtype,,0.0
4882,ARID1A Loss OR ARID1A Wildtype,,0.0
4883,EGFR P753L,,0.0
4884,BCR::ABL1 Fusion AND ABL1 L364P,,0.0
4885,BCR::ABL1 Fusion AND ABL1 L384M,,0.0
4886,BCR::ABL1 Fusion AND ABL1 L387F,,0.0
4887,BCR::ABL1 Fusion AND ABL1 L387M,,0.0
4888,BCR::ABL1 Fusion AND ABL1 L364I AND ABL1 M244V,,0.0
4889,BCR::ABL1 Fusion AND ABL1 M343T,,0.0
4890,BCR::ABL1 Fusion AND ABL1 M388L,,0.0
4891,BCR::ABL1 Fusion AND ABL1 N146S,,0.0
4892,PRKCB Mutation,,0.0
4893,PLCG1 S345F,,0.0
4894,RALGPS2::NTRK3 e1::e4,,0.0
4895,TP53 Mutation AND TP53 Overexpression,,0.0
4896,GATAD2A::LYN Fusion,,0.0
4897,BCR::ABL1 Fusion AND ABL1 N331S,,0.0
4898,BCR::ABL1 Fusion AND ABL1 N336S,,0.0
4899,BCR::ABL1 Fusion AND ABL1 P480A,,0.0
4900,BCR::ABL1 Fusion AND ABL1 Q252R,,0.0
4901,BCR::ABL1 Fusion AND ABL1 Q300R,,0.0
4902,BCR::ABL1 Fusion AND ABL1 S417Y,,0.0
4903,BCR::ABL1 Fusion AND ABL1 S438C,,0.0
4904,MYC Translocation AND BCL2 Translocation,,0.0
4905,DDX3X D347G,,0.0
4906,ARID1A Q185*,,0.0
4907,CCND3 mutation,,0.0
4908,BCL7A mutation,,0.0
4909,CHD8 mutation,,0.0
4910,FBXO11 mutation,,0.0
4911,FOXO1 mutation,,0.0
4912,GNA13 mutation,,0.0
4913,WNK1 mutation,,0.0
4914,USP7 mutation,,0.0
4915,TFAP4 mutation,,0.0
4916,TCF3 mutation,,0.0
4917,SIN3A mutation,,0.0
4918,RFX7 mutation,,0.0
4919,PCBP1 mutation,,0.0
4920,P2RY8 mutation,,0.0
4921,KMT2D mutation,,0.0
4922,BMP7 mutation,,0.0
4923,EIF4A1 mutation,,0.0
4924,GNAI2 mutation,,0.0
4925,HNRNPU mutation,,0.0
4926,ID3 mutation,,0.0
4927,BIRC3 mutation,,0.0
4928,DAZAP1 mutation,,0.0
4929,EWSR1 mutation,,0.0
4930,HNRNPH1 non-coding mutations,,0.0
4931,EEF1G::ROS1 Fusion,,0.0
4932,EML1::NTRK2 Fusion,,0.0
4933,RET T930P,,0.0
4934,RET T930K,,0.0
4935,RET D898_E901del,,0.0
4936,RET T930M,,0.0
4937,MEF2B mutation,,0.0
4938,RET E632_L633del,,0.0
4939,RET C618R,,0.0
4940,RET C611G,,0.0
4941,RET C611Y,,0.0
4942,RET C618S,,0.0
4943,RET C618Y,,0.0
4944,RET C618F,,0.0
4945,RET C618W,,0.0
4946,RET C620R,,0.0
4947,FGFR1 Amplification OR FGFR2 Amplification,,0.0
4948,FGFR1 Alteration,,0.0
4949,FGFR2 Alteration,,0.0
4950,FGFR1 Alteration OR FGFR2 Alteration,,0.0
4951,BCR::ABL1 Fusion AND ABL1 T315V,,0.0
4952,YAP1::MAMLD1 Fusion,,0.0
4953,YAP1::FAM118B Fusion,,0.0
4954,YAP1::v Fusion,,0.0
4955,UBR5 Mutation,,0.0
4956,NSD2 Mutation,,0.0
4957,SP140 Mutation,,0.0
4958,NOTCH2 Mutation,,0.0
4959,S1PR1 Mutation,,0.0
4960,NFKBIE Mutation,,0.0
4961,ACTB Mutation,,0.0
4962,ARID1A Mutation,,0.0
4963,TNFRSF14 Mutation,,0.0
4964,SGK1 Mutation,,0.0
4965,BCL10 Mutation,,0.0
4966,BTG2 Mutation,,0.0
4967,BCL6 Mutation,,0.0
4968,CIITA Mutation,,0.0
4969,FAS Mutation,,0.0
4970,BTG1 Mutation,,0.0
4971,IRF8 Mutation,,0.0
4972,TMEM30A Mutation,,0.0
4973,TMEM30A loss-of-function mutation,,0.0
4974,CD58 Mutation,,0.0
4975,KLHL6 Mutation,,0.0
4976,CD70 Mutation,,0.0
4977,CREBBP Mutation,,0.0
4978,EP300 Mutation,,0.0
4979,H1-2 Mutation,,0.0
4980,ETS1 Mutation,,0.0
4981,IRF4 Mutation,,0.0
4982,BCL11A Mutation,,0.0
4983,CXCR4 Mutation,,0.0
4984,DDX3X Mutation,,0.0
4985,DTX1 Mutation,,0.0
4986,DUSP2 Mutation,,0.0
4987,EBF1 Mutation,,0.0
4988,GRHPR Mutation,,0.0
4989,H1-5 Mutation,,0.0
4990,H1-3 Mutation,,0.0
4991,H2AC6 Mutation,,0.0
4992,H2AC17 Mutation,,0.0
4993,H2BC5 Mutation,,0.0
4994,H2BC12 Mutation,,0.0
4995,HLA-A Mutation,,0.0
4996,HLA-B Mutation,,0.0
4997,HLA-C Mutation,,0.0
4998,HVCN1 Mutation,,0.0
4999,IL4R Mutation,,0.0
5000,ITPKB Mutation,,0.0
5001,KLF2 Mutation,,0.0
5002,KLHL14 Mutation,,0.0
5003,LTB Mutation,,0.0
5004,LYN Mutation,,0.0
5005,MEF2C Mutation,,0.0
5006,MGA Mutation,,0.0
5007,MPEG1 Mutation,,0.0
5008,NFKBIA Mutation,,0.0
5009,NFKBIZ 3-prime UTR mutation,,0.0
5010,NOL9 Mutation,,0.0
5011,OSBPL10 Mutation,,0.0
5012,PIM1 Mutation,,0.0
5013,PIM2 Mutation,,0.0
5014,POU2AF1 Mutation,,0.0
5015,POU2F2 Mutation,,0.0
5016,PRKDC Mutation,,0.0
5017,S1PR2 Mutation,,0.0
5018,SETD1B Mutation,,0.0
5019,SOCS1 Mutation,,0.0
5020,SPEN Mutation,,0.0
5021,STAT3 Mutation,,0.0
5022,STAT5B Mutation,,0.0
5023,STAT6 Mutation,,0.0
5024,TBL1XR1 Mutation,,0.0
5025,TNFAIP3 Mutation,,0.0
5026,TOX Mutation,,0.0
5027,UBE2A Mutation,,0.0
5028,WEE1 Mutation,,0.0
5029,XPO1 Mutation,,0.0
5030,ZFP36L1 Mutation,,0.0
5031,TMSB4X Mutation,,0.0
5032,BIRC6 Mutation,,0.0
5033,CD83 Mutation,,0.0
5034,ZNF292 Mutation,,0.0
5035,S100B Expression,,0.0
5036,LMNA::NTRK1 Fusion AND NOT S100B Expression,,0.0
5037,LMNA::NTRK1 Fusion AND S100B Expression,,0.0
5038,UFD1::NTRK2 e6::e7,,0.0
5039,VPS18::NTRK3 e4::e1,,0.0
5040,MYB Truncation,,0.0
5041,RET C620S,,0.0
5042,RET C620G,,0.0
5043,RET C620Y,,0.0
5044,RET C620F,,0.0
5045,RET P628_L633del,,0.0
5046,RET C630S,,0.0
5047,RET C630R,,0.0
5048,RET C630G,,0.0
5049,RET C630Y,,0.0
5050,RET C630F,,0.0
5051,RET D631del,,0.0
5052,RET D631Y,,0.0
5053,RET D631_L633delinsE,,0.0
5054,RET E632_A639delinsHR,,0.0
5055,BRAF Alteration,,0.0
5056,RET E632_T636delinsSS,,0.0
5057,RET E632_C634delinsG,,0.0
5058,RET E632_L633delinsV,,0.0
5059,RET C634S,,0.0
5060,RET C634G,,0.0
5061,RET C634Y,,0.0
5062,RET C634F,,0.0
5063,RET C634L,,0.0
5064,AKT1 Mutation,,0.0
5065,PIK3CA Mutation OR PTEN Mutation OR AKT1 Mutation,,0.0
5066,ROS1 G2032R AND v::ROS1 Fusion,,0.0
5067,FGFR1 Amplification OR FGFR2 Amplification OR FGFR3 Amplification OR FGFR4 Amplification,,0.0
5068,APC Mutation OR CTNNB1 Activating Mutation,,0.0
5069,ERBB2 T790M,,0.0
5070,ERBB2 Activating Mutation OR ERBB2 T790M,,0.0
5071,NF1 Mutation OR GNA11 Q209L,,0.0
5072,CD74::ROS1 Fusion,,0.0
5073,ROS1 L2026M AND CD74::ROS1 Fusion,,0.0
5074,FIP1L1::PDGFRA Fusion AND PDGFRA T674I,,0.0
5075,ROS1 G2032R AND CD74::ROS1 Fusion,"The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.",0.0
5076,ROS1 G2032R AND SLC4A4::ROS1 Fusion,,0.0
5077,BRAF V600 OR v::BRAF Fusion,,0.0
5078,NR4A3 reg_e@[SCPP]::NR4A3,,0.0
5079,RET A640G,,0.0
5080,RET V642I,,0.0
5081,RET S649L,,0.0
5082,RET E768Q,,0.0
5083,RET E768G,,0.0
5084,RET E768D,,0.0
5085,RET R770Q,,0.0
5086,RET N777S,,0.0
5087,RET V778I,,0.0
5088,RET Q781R,,0.0
5089,RET L881V,,0.0
5090,RET A883F,,0.0
5091,RET A883S,,0.0
5092,RET A883T,,0.0
5093,RET A883V,,0.0
5094,RET E884V,,0.0
5095,RET R886W,,0.0
5096,RET S891A,,0.0
5097,RET S904C,,0.0
5098,RET S904F,,0.0
5099,RET G911D,,0.0
5100,RET R912W,,0.0
5101,RET R912P,,0.0
5102,RET R912L,,0.0
5103,RET M918V,,0.0
5104,RET S922P,,0.0
5105,KMT2A Mutation,,0.0
5106,KMT2C Mutation OR KMT2A Mutation,,0.0
5107,ERBB2 G746S,,0.0
5108,AKT1 Alterations,,0.0
5109,PTEN Inactivating alteration,,0.0
5110,PIK3CA Mutation OR AKT1 Alterations OR PTEN Inactivating alteration,,0.0
5111,ROS1 G2101A AND CD74::ROS1 Fusion,,0.0
5113,BCR::NTRK2 Fusion,,2.5
5114,ABL1 Y253F,,0.0
5115,BCR::ABL1 Fusion AND ABL1 Y253F,,0.0
5117,TMB High,Tumors with a high mutational burden (TMB-High) are reported to have increased sensitivity to immunotherapy. High Tumor Mutation Burden is defined as 10 or more mutations per MB of DNA in an FDA approved companion diagnostic test based on next generation sequencing.,0.0
5118,MSI High,"High microsatellite instability will often arise in cases where mismatch repair is deficient (dMMR). In tumors with MSI, marker length at microsatellite sequences will differ from that in normal tissue. Determination of MSI-High will usually include criteria such as tumor DNA showing additional microsatellite alleles of different lengths in multiple microsatellite markers, or greater than one third of all microsatellite markers examined.  MSI-H has been associated to better prognosis in colorectal cancer, and also reported to be associated with sensitivity to checkpoint inhibition therapy in some instances.",0.0
5119,Kataegis Positive,"Tumors postitive for kataegis show areas of the genome with increased rates of mutation including C>T and C>G, where average intermutation distances may be less than 1kb apart in the enriched areas.",0.0
5120,CK High,High complex karyotype (CK) is defined as having greater than or equal to 5 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA),0.0
5121,Chromothripsis Positive,,0.0
5122,RB1 Mutation OR ESR1 Mutation,,0.0
5123,ERBB2 P780_Y791insGSP,,0.0
5125,ROS1 L2155S AND CD74::ROS1 Fusion,,0.0
5126,ERBB2 V777_S779dup,,0.0
5127,ERBB2 G776_V777insL,,0.0
5128,ERBB2 V777_G778insCG,,0.0
5129,ERBB2 G776_V777insVGC,,0.0
5130,ERBB2 G778dup,,0.0
5131,ERBB2 G778_S779insCPG,,0.0
5132,ERBB2 S779_P780insVGS,,0.0
5133,ERBB2 I767F,,0.0
5134,RET C618T,,0.0
5135,RET L629_E632del,,0.0
5136,RET E632_C634delinsDVA,,0.0
5137,RET D631_L633delinsV,,0.0
5138,RET L629_I638delinsCD,,0.0
5139,RET L629_A640delinsVRP,,0.0
5140,RET A883Y,,0.0
5141,RET D898_E902del,,0.0
5142,RET D903_S904delinsEP,,0.0
5144,EGFR Alteration,,0.0
5145,EGFR Amplification OR EGFR Alteration,,0.0
5146,TP53 R72P,,0.0
5147,ERBB2 G776_V777delinsCVCG,,0.0
5148,ERBB2 G776_V777insVC,,0.0
5149,PIK3CA Mutation OR RB1 Mutation OR ESR1 Mutation,,0.0
5150,CD274 Amplification,,0.0
5151,v::NUTM1 Fusion,,85.0
5152,BRD4::NUTM1 Fusion,,45.5
5153,U2AF1 Q157P/R OR U2AF1 S34Y/F,,0.0
5154,EWSR1::CREB3L1 Fusion,,22.5
5155,FUS::CREB3L2 Fusion,,35.0
5156,MET Splice Site (c.2929_3028),,0.0
5157,MET D963E,,0.0
5158,MET Splice Site (c.2888-5_2890delinsA),,0.0
5159,OVOL2 Overexpression,,0.0
5160,AXIN2 rs143348853,,0.0
5161,ETV6::NTRK3 Fusion AND NTRK3 G623R,,10.0
5162,KRAS G12 OR KRAS G13,,0.0
5163,v::NTRK1 Fusion OR v::NTRK3 Fusion OR v::NTRK2 Fusion,,0.0
5164,MET Amplification AND MET Splice Site (c.3028+3A>G),,0.0
5165,MET H1094Y,,0.0
5166,MET Splice Site (c.3028+2T>G) AND MET Splice Site (c.2888-5_2890delinsA) AND MET H1094Y,,0.0
5167,PIK3CA E542K AND TP53 R337L AND MET Splice Site (c.3028+1G>A),,0.0
5168,MET D1010H AND MET Y1230C,,0.0
5169,MET Splice Site (c.2929_3028+212del),,0.0
5170,NOT MET Amplification AND MET Splice Site (c.2929_3028+212del),,0.0
5171,MET Splice Site (c.3020_3028+17del),,0.0
5172,MET Y1230H AND MET Splice Site (c.3020_3028+17del),,0.0
5173,MET Splice Site (c.3028+3_3028+6del),,0.0
5174,MSI Low,Low grade microsatellite instability (MSI-L) is not generally distinguished from microsatellite stable (MSS) or mismatch repair (MMR) competent tumors. In some cases MSS tumors have been reported to lack response to immune checkpoint inhibition.,0.0
5175,BRAF V600E AND MSI Low,"in colon carcinoma, patients with BRAF V600E tumors that are microsatellite stable (MSS) have shown worse prognosis than MSS tumors with no BRAF or KRAS mutation. This prognostic effect of BRAF V600E was not seen in MSI High tumors.",0.0
5176,KRAS Exon 2 Mutation AND MSI Low,"In colon carcinoma, patients with KRAS Exon 2 mutant tumors that are microsatellite stable (MSS) have shown worse prognosis than MSS tumors with no BRAF or KRAS mutation. This prognostic effect of KRAS Exon 2 mutation was not seen in MSI High tumors.",0.0
5177,Aneuploidy Hyperdiploid,A chromosomal abnormality in which the chromosomal number is greater than the normal diploid number.  Hyperdiploid B lymphoblastic leukemia/lymphoma is the largest genetic entity B-cell precursor acute lymphoblastic leukemia in children which contain more than 50 and usually less than 66 chromosomes and associated with a favorable clinical outcome.,0.0
5178,MTOR Alteration,,0.0
5180,PTEN Alterations,,0.0
5181,AKT2 Mutation,,0.0
5183,MET D1010H AND CD274 Overexpression,,0.0
5184,MET Splice Site (c.3027_3028+14del),,0.0
5185,MET D1228N AND MET Splice Site (c.3027_3028+14del),,0.0
5186,MET Splice Site (c.2888-1G>C),,0.0
5187,MN1 Rearrangement,,40.0
5188,BCR::ABL1 Fusion AND ABL1 TKD Mutation,,0.0
5189,MALAT1::GLI1 Fusion,,0.0
5190,LPP::HMGA2 Fusion OR HMGA2::LPP Fusion,,0.0
5191,MN1::BEND2 Fusion,,0.0
5192,Methylation signature CpG island hypermethylation,,0.0
5193,HPV Type 18,,0.0
5194,HPV Type 16,,0.0
5195,MNX1::ETV6 Fusion,,30.0
5196,YES1 Amplification,,0.0
5197,EGFR Mutation AND YES1 Amplification,,0.0
5198,ERBB2 Amplification AND YES1 Amplification,,0.0
5201,FGFR2 Mutation OR FGFR2::v Fusion OR FGFR2::? Fusion,,0.0
5202,CD274 Overexpression AND MET Splice Site (c.3028+3A>G),,0.0
5203,MET Splice Site (c.3028+1_3028+3delinsTT),,0.0
5204,MET D1228N AND MET Splice Site (c.3028+1_3028+3delinsTT),,0.0
5205,MET Splice Site (c.2888‚Äì47_2888-24del),,0.0
5206,PML::RARA Fusion AND PML S214L,,0.0
5207,PML::RARA Fusion AND PML A216T,,0.0
5209,HLA-A *02:01P,,0.0
5210,HLA-A *02:02P,,0.0
5211,HLA-A *02:03P,,0.0
5212,HLA-A *02:06P,,0.0
5213,MAGEA4 Expression,,0.0
5214,HLA-A *02:01P OR HLA-A *02:02P OR HLA-A *02:03P OR HLA-A *02:06P OR MAGEA4 Expression,,0.0
5215,MAGEA4 Expression AND ( HLA-A *02:01P OR HLA-A *02:02P OR HLA-A *02:03P OR HLA-A *02:06P ),,0.0
5216,KIF5B::RET Fusion AND RET V804L,,0.0
5217,DEK::NUP214 Fusion,,0.0
5218,NPM1::MLF1 Fusion,,0.0
5219,KIF5B::RET Fusion AND RET G810A,,0.0
5220,CD72::ROS1 Fusion,,0.0
5221,SDC4::ROS1 Fusion,,0.0
5222,v::ALK Fusion OR v::ROS1 Fusion,,0.0
5223,MET Amplification OR MET Exon 14 Skipping Mutation OR v::ALK Fusion OR v::ROS1 Fusion,,0.0
5224,MAP3K1 Mutation,,0.0
5225,MAP2K4 loss-of-function Mutation,,0.0
5226,MAP3K1 Loss-of-Function Mutation,,0.0
5227,MAP2K4 loss-of-function Mutation OR MAP3K1 Loss-of-Function Mutation,,0.0
5228,IFNGR1 Knockdown,,0.0
5229,NFASC::NTRK1 Fusion,,0.0
5230,LMNA::NTRK1 Fusion OR TPM3::NTRK1 Fusion,,0.0
5231,ETV6::FGFR3 Fusion,,0.0
5232,FGFR3::TACC3 Fusion AND FGFR2::CCDC6 Fusion,,0.0
5233,IFNGR1 Loss,,0.0
5238,BCR::ABL1 Fusion AND ABL1 V379I,,0.0
5239,PML::RARA Fusion AND PML A216V,,0.0
5240,PML::RARA Fusion AND PML L218P,,0.0
5241,BCR::ABL1 Fusion AND ABL1 V289I,,0.0
5242,PDGFRB C843G,,0.0
5243,AGGF1::PDGFRB Fusion AND PDGFRB C843G,,0.0
5244,LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 G667C ,,0.0
5245,EGFR::FGFR1 e24::e10,,0.0
5246,CLIP2::EGFR e10::e18,,0.0
5247,Chromothripsis Positive AND CLIP2::EGFR e10::e18,,0.0
5248,v::DUX4 Fusion,,0.0
5249,DUX4::v Fusion OR v::DUX4 Fusion,,0.0
5250,GOLGA4::RAF1 Fusion,,0.0
5251,ANO10::RAF1 Fusion,,0.0
5252,TP53 Rearrangement,,0.0
5253,SLC4A4::RASGRF1 Fusion,,0.0
5254,IQGAP1::RASGRF1 Fusion,,0.0
5255,BCOR::MAML3 Fusion,,0.0
5256,BCOR::CCNB3 Fusion OR BCOR::MAML3 Fusion,,0.0
5257,v::MITF Fusion,,0.0
5258,EMSY Amplification,,0.0
5259,EMSY Overexpression,,0.0
5260,JAK1 Mutation,,0.0
5261,JAK2 Mutation,,0.0
5262,B2M Mutation AND MSI High AND ( JAK1 Mutation OR JAK2 Mutation ),,0.0
5263,MSI High AND ( B2M Mutation OR JAK1 Mutation OR JAK2 Mutation ),,0.0
5264,B2M Mutation AND MSI High,,0.0
5265,B2M High Expression,,0.0
5266,B2M Loss,,0.0
5267,KAT6A::CREBBP Fusion,,35.0
5268,PIK3CA Q75E,,0.0
5269,PIK3CA N345K OR PIK3CA M1043V OR PIK3CA Q75E,,0.0
5270,VHL P86S (c.256C>T) AND VHL Splice Region (c.340+5G>C),,0.0
5271,VHL E70K (c.208G>A) AND VHL Splice Region (c.340+5G>C),,0.0
5272,VHL R200W (c.598C>T) AND VHL V130I (c.388G>A),,0.0
5273,VHL R200W (c.598C>T) AND VHL R161Q (c.482G>A),,0.0
5274,VHL S139C (c.416C>G),,0.0
5275,VHL R167Q (c.500G>A) AND VHL T105M (c.314C>T),,0.0
5276,VHL R167Q (c.500G>A) AND VHL P81S (c.241C>T),,0.0
5277,VHL Exon 3 Deletion AND VHL S139C (c.416C>G),,0.0
5278,VHL S183L (c.548C>T) AND VHL D126N (c.376G>A),,0.0
5279,VCP::TFE3 Fusion,,0.0
5280,YWHAE::NUTM2A Fusion,,0.0
5281,YWHAE::NUTM2B Fusion,,0.0
5282,YWHAE::NUTM2E Fusion,,0.0
5283,YWHAE::NUTM2A Fusion OR YWHAE::NUTM2B Fusion OR YWHAE::NUTM2E Fusion,,0.0
5284,Methylation signature ST-EPN-ZFTA,"The Supratentorial Ependymoma ZFTA Fusion-Positive Methylation Signature (ST-EPN-ZFTA, formerly ST-EPN-RELA) methylation based signature (Heidelberg Brain Tumor Methylation Classifier; DKFZ Classifier) found almost exclusively among supratentorial ependymomas with ZFTA-RELA (or other ZFTA) fusions, used commonly as a diagnostic tool for identifying ""Supratentorial ependymoma, ZFTA fusion-positive"" subtype as defined by the WHO Classification of Tumors of the Central Nervous (2021) even in the absence of DNA or RNA testing or evidence for these fusions.",0.0
5285,ZEB1 Increased Expression,,0.0
5286,MYB::NFIB Fusion,,0.0
5287,MTOR Mutation OR PIK3CA Mutation OR PTEN Mutation OR AKT1 Mutation OR AKT2 Mutation,,0.0
5288,PIK3CA H1047R OR PIK3CA H1047Y OR PIK3CA H1047L,,0.0
5291,MEF2D::? Fusion,,0.0
5292,MEF2D::v Fusion,,35.0
5293,UBTF UBTF-TD,,0.0
5294,LINC01969::UFSP1 Fusion,,0.0
5295,MEF2D::BCL9 Fusion,,0.0
5296,PIK3CA E545K OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545D,,0.0
5297,IDH2 R172K OR IDH2 R172G OR IDH2 R172W,,0.0
5298,IDH1 R132C OR IDH1 R132H OR IDH1 R132L OR IDH1 R132G OR IDH1 R132S,,0.0
5299,PIK3CA Q546E OR PIK3CA Q546R,,0.0
5300,SDHA Loss,,0.0
5301,SDHB Loss,,0.0
5302,SDHC Loss,,0.0
5303,SDHD Loss,,0.0
5304,SDHA Loss OR SDHB Loss OR SDHC Loss OR SDHD Loss,,0.0
5305,VPS18::NTRK3 e4::e18,,0.0
5306,EGFR L858R OR EGFR T790M,,0.0
5307,ZNF217 Overexpression,,0.0
5308,FAAP20 loss,,0.0
5309,KMT2A Translocation,,0.0
5310,CLDN18 positive,,0.0
5311,ATR Loss-of-function,,0.0
5312,ESR1 Y537D,,0.0
5313,ESR1 L469V,,0.0
5314,ESR1 L536H,,0.0
5315,ESR1 L536P,,0.0
5316,IDH2 R172M OR IDH2 R172S,,0.0
5317,PIK3CA Exon 21 Mutation AND PIK3CA Exon 10 Mutation,,0.0
5318,PIK3CA Exon 21 Mutation OR PIK3CA Exon 10 Mutation,,0.0
5319,PIK3CA H1047R OR PIK3CA H1047L,,0.0
5322,DUX4L1::IGH Fusion,,0.0
5323,DUX4L1::v Fusion,,0.0
5324,NRG1 Fusion,,0.0
5325,LRP1B alterations,,0.0
5326,v::IRF4 Fusion,,35.0
5327,FAT1 Loss,,0.0
5328,LRP1B Loss-of-function,,0.0
5329,EGFR G719A AND EGFR E709K,,0.0
5330,EGFR G719C AND EGFR E709A,,0.0
5331,MAP2K1 G128D,,0.0
5332,MAP2K1 C121S AND MAP2K1 G128D,,0.0
5333,EGFR L718Q AND EGFR L718V,,0.0
5334,TCF3::HLF Fusion,,0.0
5335,IGH::IL3 Fusion,,0.0
5336,TACSTD2 T256R,,0.0
5337,TOP1 E418K,,0.0
5338,TOP1 -122fs,,0.0
5339,TOP1 E418K OR TOP1 -122fs,,0.0
5340,TOP1 E418K AND TOP1 -122fs,,0.0
5341,Methylation signature PA. ,,0.0
5342,Methylation signature PA-NF1,,0.0
5343,NF1 Mutation AND Methylation signature PA-NF1,,0.0
5344,NF1 Splice Site (c.205-1G>C),,0.0
5345,NF1 Splice Site (c.1845+1G>A),,0.0
5346,NF1 D1644H,,0.0
5347,NF1 Y489C,,0.0
5348,NF1 Splice Site (c.654+2T>A),,0.0
5349,NF1 Y794fs*27,,0.0
5350,NF1 Q514fs*43,,0.0
5351,NF1 p.H2393fs*3,,0.0
5352,NF1 Y1783*,,0.0
5353,NF1 Y333*,,0.0
5354,NF1 R1276*,,0.0
5355,NF1 G1219E,,0.0
5356,NF1 p.W426*,,0.0
5357,NF1 p.R1276*,,0.0
5358,CREBBP HAT mutation,,0.0
5359,CREBBP R1446C,,0.0
5360,IGH::DUX4 Fusion,,0.0
5361,EGFR D770_P772dup,,0.0
5362,ATP7B Expression,,0.0
5363,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 G250E,,0.0
5364,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 Q252H,,0.0
5365,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 Y253H,,0.0
5366,ABL1 T315L,,0.0
5367,BCR::ABL1 Fusion AND ABL1 T315L,,0.0
5368,ABL1 T315M,,0.0
5369,BCR::ABL1 Fusion AND ABL1 T315M,,0.0
5370,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 E255V,,0.0
5371,BCR::ABL1 Fusion AND ABL1 Y253H AND ABL1 E255V,,0.0
5372,BCR::ABL1 Fusion AND ABL1 E255V AND ABL1 V299L,,0.0
5373,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 M244V,,0.0
5374,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 F359V,,0.0
5375,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 H396R,,0.0
5376,BCR::ABL1 Fusion AND ABL1 M351T AND ABL1 V299L,,0.0
5377,BCR::ABL1 Fusion AND ABL1 F359V AND ABL1 V299L,,0.0
5378,BCR::ABL1 Fusion AND ABL1 F317L AND ABL1 F359V,,0.0
5379,BRAF V600E AND NF1 Loss,,0.0
5380,DICER1 G1809R,,0.0
5381,TFCP2 EWSR1::TFCP2,,0.0
5382,v::TFCP2 Fusion,,15.0
5383,FUS::TFCP2 Fusion,,10.0
5384,v::NR4A3 Fusion,,15.0
5385,FLT3 ITD AND FLT3 F691L,,0.0
5386,KEAP1 Mutation,,0.0
5387,STK11 Mutation AND KEAP1 Mutation,,0.0
5388,EGFR A123B,,0.0
5389,BAP1 Loss-of-function,,0.0
5390,BRCA1 Loss-of-function OR BAP1 Loss-of-function,,15.0
5391,ERCC6 Overexpression,,0.0
5392,NF1 Q1189*,,0.0
5393,NF1 D1644H AND NF1 Q1189*,,0.0
5394,NF1 L1221R,,0.0
5395,NF1 L2118fs*33,,0.0
5396,NF1 Splice Site (c.2850+1G>A),,0.0
5397,NF1 spliceSplice Site (c.3871-1G>C),,0.0
5398,NF1 Splice Site (c.3871-1G>C),,0.0
5399,NF1 Splice Site (c.4110+1G>T),,0.0
5400,NF1 I1445R,,0.0
5401,NF1 W9*,,0.0
5402,NF1 R1509H,,0.0
5403,NF1 L1243R,,0.0
5404,NF1 N412S,,0.0
5405,NF1 Splice Site (c.3113+1G>A),,0.0
5406,NF1 R1306*,,0.0
5407,NF1 R304*,,0.0
5408,NF1 6818A>T,,0.0
5409,NF1 G629R,,0.0
5410,NF1 Splice Site (c.205-1G>C) AND NF1 G629R,,0.0
5411,BRAF V600 AND BRAF Amplification,,0.0
5412,EGFR::RAD1 Fusion,,0.0
5413,EGFR::SHC1 Fusion,,0.0
